Novel AAV receptors and methods for identifying those

A CRISPRa screen with a high-density guide RNA library identifies cell-surface proteins enhancing AAV transduction efficiency, addressing limitations in current receptor identification methods and improving transduction across diverse cell types.

WO2026241180A1PCT designated stage Publication Date: 2026-11-19GENENTECH INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027643
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-11
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current methods for identifying adeno-associated virus (AAV) receptors are limited in their ability to uncover receptors for AAV serotypes that cannot transduce wild-type cells, lack sensitivity, and are not applicable to all cell types, and CRISPRa libraries face challenges in gene coverage and activation efficiency.

Method used

A CRISPR-mediated transcriptional activation (CRISPRa) screen using a high-density guide RNA library to identify cell-surface proteins that enhance AAV transduction efficiency, applicable to any cell type, by overexpressing or knocking out specific proteins and analyzing transduction efficiency.

Benefits of technology

Unbiased and sensitive identification of novel AAV receptors, enabling improved transduction efficiency of AAV particles across various cell types, including those previously non-transducible by standard AAV serotypes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000001_0001
    Figure IMGF000001_0001
  • Figure IMGF000030_0001
    Figure IMGF000030_0001
  • Figure IMGF000089_0001
    Figure IMGF000089_0001
Patent Text Reader

Abstract

Herein is reported a method for increasing the transduction efficiency of AAV particles or of a preparation comprising AAV particles of a cell comprising the steps of overexpressing at least one protein selected from the group of proteins consisting of LPAR5, BRS3, FUT1, CH25H, PUM1, SLC5A8, SLC7A11, HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B in the cell.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] P60067-WQ

[0002] Novel AAV receptors and methods for identifying those

[0003] Field of the Invention

[0004] The current invention is in the field of cell line engineering. More specifically, herein is reported a method for the identification of novel cell-surface and secreted human proteins whose overexpression increases the transduction efficiency of AAV preparations or AAV particles as well as cells overexpressing said cell-surface proteins and uses thereof.

[0005] The current invention provides for high-density Clustered Regularly Interspaced Short Palindromic Repeats activation (CRISPRa) guide RNA libraries and their use in various applications, including whole-genome screening for identification of tumor essential genes, cancer therapy resistance genes, and cancer driving genes.

[0006]

[0007] Adeno-associated viruses (AAVs) are widely used in research and clinical settings for targeted gene delivery. However, cellular receptors and entry mechanisms for most natural and engineered AAVs remain unknown. This hampers the choice and design of efficient and tissue-specific AAV capsids, as well as the generation of cell lines for potency assays required in gene therapy.

[0008] AAV receptors have been discovered, e.g., by genome-wide knock-out screens for AAV2 using insertional mutagenesis in haploid human cells (Pillay et al., 2016) and genome-wide CRISPRKO screens for rAAV2.5T or AAVrh32.33 in HeLa cells or Huh7-AAVR KO cells (Dudek et al., 2020; Hao et al., 2023). These methods have been limited to screen only capsids that can transduce cells used to perform the screen, but they cannot identify receptors or helper proteins for AAVs that cannot infect those cells since they will not be expressed and therefore cannot be knocked out. This hampers the development of cell-based potency assays for AAV capsids like AAVrh74 or AAV9-derived capsids, which cannot transduce wild-type HEK293 cells.

[0009] To tackle these limitations and identify AAV9 receptors in an unbiased and high-throughput manner, the Retrogenix assay was recently applied for this purpose (see, e.g., Shay et al., 2024). This assay consists of Retrogenix cell microarrays (Freeth and Soden, 2019) with cDNAs encoding membrane and secreted proteins that can reverse-transfect HEK293 cells that are grown on the slides. AAV capsids are then biotinylated, added to the slides and detected with fluorescently labelled streptavidin on fixed spots in the slides corresponding to the cDNA positions of candidate AAV-binding proteins (Shay et al., 2024). Limitations of this method include the selection of a single isoform for these screenings, eventually missing other isoforms that could be relevant, the lack of application to alternative cell types that cannot grow on the slides or be reverse transfected efficiently and the lack of sensitivity and lack of the quantitative nature of the resulting blot images.

[0010] In addition, this assay can identify AAV binding to the cells, but not necessarily AAV entry or transduction.

[0011] Thus, there is a need for methods for identifying novel AAV receptors.

[0012] One of the strengths of canonical Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology has been the ability to conduct large-scale genetic screens with relative ease. However, CRISPR activation (CRISPRa) screening is less straightforward than traditional CRISPR knock-out screening, as precise targeting of transcriptional start sites (TSSs) for each target gene is necessary to achieve target gene activation. Accurately identifying a gene TSS can be difficult, and is an ongoing process for many genes, making design of effective single guide RNAs (sgRNAs) much more difficult than for CRISPR knock-out modalities. In addition, unlike CRISPR knock-out which requires only a single instance of gene editing to induce a permanent mutation, CRISPRa requires constitutive and high levels of all elements of the CRISPRa system, including dead Cas9 (dCas9), transcriptional activation domains (TADs), and sgRNAs, to initiate and maintain gene activation.

[0013] Several whole-genome CRISPRa sgRNA libraries have been designed and are publicly available, each with their own advantages and disadvantages. Unfortunately, currently-available libraries are less than ideal in terms of gene coverage and activation efficiency, owing at least in part to inadequate methods of defining TSSs for protein-coding genes, inadequate (e.g., overly restrictive / stringent) methods of designing sgRNA to target promoter regions upstream of said TSSs, and / or inadequate library size.

[0014] Thus, there is a need in the art for improved CRISPRa guide RNA libraries capable of providing better coverage for genes of interest, including for identifying novel AAV receptors or whole genome screening.

[0015] Summary

[0016] Herein are reported CRISPRa guide RNA (e.g., sgRNA) libraries, in particular human CRISPRa guide RNA libraries, and methods of making and using such libraries, including methods for identifying receptors mediating AAV uptake into mammalian cells. The method of identifying receptors mediating AAV uptake according to the current inventions employs in certain embodiments a CRISPR-mediated transcriptional activation (CRISPRa) screen using multiple gRNAs to induce different isoforms of genes encoding cell-surface proteins.

[0017] An exemplary method according to the current invention is an unbiased and sensitive method with which it is possible to identify novel AAV receptors or helper proteins that enable transduction by AAV particles and that can be applied to any cell type of interest.

[0018] Thus, the current invention is based, at least in part, on the finding that with a CRISPR-mediated transcriptional activation it is possible to identify in an unbiased way genes and pathways, including those that increase AAV entry into cells. Without being bound by this theory, it is assumed that this is especially suitable for AAV serotypes that could not transduce the wild-type version of cells. Any CRISPR-suitable library can be used (see, e.g., Sanson, K. R., et al., Nat. Commun. 9 (2018) 5416, for an exemplary library for a CRISPR-KO screen)

[0019] Even though the method according to the current invention is exemplified using HEK293 cells and AAV, the method according to the current invention is applicable to any cell type that can be transduced with AAV or lentiviruses, including stem-cell derived or primary cell types.

[0020] One aspect of the invention is a method for identifying a cell-surface protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles comprising the steps of

[0021] - generating a library of cells wherein in each cell a different endogenous cell-surface or soluble protein is overexpressed,

[0022] - identifying and selecting cells of the library which show an increased transduction efficiency i) compared to cells not overexpressing said endogenous cell-surface or secreted protein, or ii) compared to the parent cells used for the generation of the library, or iii) compared to cells overexpressing a different endogenous cell-surface or secreted protein,- amplifying the nucleic acid sequence from the genome of the selected cells encoding the gRNA leading to overexpression of the cell-surface protein,

[0023] and thereby identifying a cell-surface protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles.

[0024] A further aspect of the invention is a method for identifying a cell-surface protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles comprising the steps of

[0025] - generating a library of cells wherein in each cell the expression of a different cell-surface protein is reduced / abolished / knocked-out,

[0026] - identifying and selecting cells of the library which show an increased transduction efficiency i) compared to cells not overexpressing said endogenous cell-surface or secreted protein, or ii) compared to the parent cells used for the generation of the library, or iii) compared to cells overexpressing a different endogenous cell-surface or secreted protein,

[0027] - amplifying the nucleic acid sequence from the genome of the selected cells encoding the gRNA that reduced / abolished / knocked-out expression of the cell surface protein,

[0028] and thereby identifying a cell-surface protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles.

[0029] Another aspect of the invention is a method for increasing the transduction efficiency of AAV particles or of a preparation comprising AAV particles of a cell comprising the steps of

[0030] - transfecting the cell with a nucleic acid encoding / overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2B11 in the cell; and / or

[0031] - transfecting the cell with a nucleic acid encoding / overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC,

[0032] TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B in the cell.

[0033] Also an aspect of the invention is a method for producing a polypeptide in a cell comprising the steps of

[0034] - cultivating a cell overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2B11 and containing the nucleic acid encoding the polypeptide under conditions suitable for the expression of the polypeptide, and / or

[0035] - cultivating a cell overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B and containing the nucleic acid encoding the polypeptide under conditions suitable for the expression of the polypeptide,

[0036] - recovering the polypeptide from the cell or the cultivation medium,

[0037] - optionally purifying the polypeptide,

[0038] and thereby producing the polypeptide.

[0039] A further aspect of the invention is an assay for determining the transduction efficiency of an AAV preparation or an AAV particle comprising the steps of

[0040] - incubating cells overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2B11 with the AAV preparation or particle, and / or

[0041] -incubating cells overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1,

[0042] MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B with the AAV preparation or particle,

[0043] - determining the fraction of the cells transduced by the AAV preparation or AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV preparation or particle),

[0044] and thereby determining the transduction efficiency of an AAV preparation or AAV particle.

[0045] An aspect of the invention is an assay for selecting an AAV particle comprising the steps of

[0046] - separately incubating cells overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2B11 with AAV particles differing in their capsid amino acid sequence, and / or

[0047] - separately incubating cells overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B with AAV particles differing in their capsid amino acid sequence,

[0048] - determining for each AAV particle the fraction of the cells transduced by the AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV particle) and thereby determining the transduction efficiency of each AAV particle differing in their capsid amino acid sequence,

[0049] - ranking the AAV particles differing in their capsid amino acid sequence according to their transduction efficiency,

[0050] and.

[0051] selecting one or more AAV particles.

[0052] Another aspect of the invention is the use of a protein selected from the list of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2B11 for increasing the transduction efficiency of an AAV preparation or AAV particle of a cell.

[0053] Another aspect of the invention is the use of a protein selected from the list of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B for increasing the transduction efficiency of an AAV preparation or AAV particle of a cell.

[0054] Another aspect of the invention is the use of a protein selected from the list of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B for increasing the transduction efficiency of an AAV preparation or AAV particle of a cell.

[0055] Another aspect of the invention is a human CRISPR-mediated transcriptional activation (CRISPRa) guide RNA library comprising

[0056] - a plurality of guide RNAs (sgRNAs), each sgRNA comprising (i) a DNA-targeting segment having a spacer sequence which targets a promoter region of a targeted gene, the promoter region comprising a genomic region surrounding a transcriptional start site (TSS); and (ii) a backbone capable of binding to a dCas fusion protein;

[0057] wherein the plurality of sgRNAs comprise 10 or more sgRNA per promoter region such that the plurality of sgRNAs comprise at least 10 sgRNA per targeted gene.

[0058] Another aspect of the invention is a system for CRISPR-mediated transcriptional activation (CRISPRa) comprising

[0059] - a human CRISPRa guide RNA library; and

[0060] - a CRISPRa system comprising a dCas fusion protein, the dCas fusion protein comprising a dCas effector protein and one or more transcriptional activation domains (TADs).

[0061] Another aspect of the invention method of generating a whole genome human CRISPRa guide RNA library, the method comprising

[0062] - identifying protein-coding isoforms for a human genome as targeted genes; and

[0063] - for each targeted gene identified in the previous step:

[0064] i. identifying a first transcriptional start site (TSS) of the targeted gene; ii. defining a promoter region of the targeted gene, the promoter region comprising a genomic region surrounding the TSS;

[0065] iii. identifying one or more possible spacer sequences within the promoter region;

[0066] iv. removing spacer sequences containing EcoRI or Kpnl restriction enzyme recognition sites from the possible spacer sequences;

[0067] v. removing spacer sequences comprises a GC content less than 20% or more than 80% from the possible spacer sequences;

[0068] vi. ranking the possible spacer sequences based on Azimuth on-target activity score;

[0069] vii. prioritizing the possible spacer sequences based on location relative to an activation window of -150bp to -75bp of the TSS;

[0070] viii. selecting 10 or more spacer sequences from the possible spacer sequences after completing steps i-vii for the first TSS of the targeted gene; and ix. designing 10 or more sgRNAs for the first TSS of the targeted gene, each sgRNA comprising one of the spacer sequences selected in step viii and a backbone capable of binding to a dCas effector protein.

[0071] In more detail, the current invention encompasses at least the following embodiments

[0072] 1. A method for identifying a cell-surface or secreted protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles comprising the steps of

[0073] - generating a library of cells wherein in each cell a different cell-surface or secreted protein is overexpressed,

[0074] - identifying and selecting cells of the library which show an increased transduction efficiency i) compared to cells not overexpressing said endogenous cell-surface or secreted protein, or ii) compared to the parent cells used for the generation of the library, or iii) compared to cells overexpressing a different endogenous cell-surface or secreted protein,

[0075] and thereby identifying a cell-surface or secreted protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles.

[0076] 2. A method for identifying a cell-surface or secreted protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles comprising the steps of

[0077] - generating a library of cells wherein in each cell the expression of a different cell-surface protein is reduced / abolished / knocked-out,

[0078] - identifying and selecting cells of the library which show an increased transduction efficiency i) compared to cells not overexpressing said endogenous cell-surface or secreted protein, or ii) compared to the parent cells used for the generation of the library, or iii) compared to cells overexpressing a different endogenous cell-surface or secreted protein,

[0079] and thereby identifying a cell-surface protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles.

[0080] 3. The method according to any one of embodiments 1 to 2, wherein the generation of the library uses CRISPR technology.

[0081] 4. The method according to any one of embodiments 1 and 3, wherein the generation of the library is by introducing a library of guide RNAs (gRNAs) directed to a standard effective window surrounding the transcription start sites (TSS) of genes encoding cell-surface or secreted proteins of the cell and the identifying is by CRISPR-mediated transcriptional activation (CRISPRa) screening.

[0082] 5. The method according to embodiment 4, wherein the standard effective window surrounding the transcription start sites (TSS) is about 50-150 bp upstream pf the TSS.

[0083] 6. The method according to any one of embodiments 4 to 5, wherein the library of gRNAs comprises about 10-15 gRNAs per TSS.

[0084] 7. The method according to any one of embodiments 4 to 6, wherein the library of gRNAs comprises about 10-15 gRNAs per TSS and a set of non-targeting controls.

[0085] 8. The method according to any one of embodiments 4 to 7, wherein the library is generated by the introduction of the gRNAs as lentiviral vectors.

[0086] 9. The method according to any one of embodiments 1 and 3 to 8, wherein the library is generated from a parent cell line which expresses the components of a CRISPRa system based on the Synergistic Activation Mediator (SAM) concept.

[0087] 10. The method according to any one of embodiments 2 to 3, wherein the generation of the library is by introducing a library of guide RNAs (gRNAs) directed to genes encoding cell-surface proteins of the cell and the identifying is by CRISPR knock-out (CRISPR KO) screening.

[0088] 11. The method according to embodiment 10, wherein the gRNAs are directed to the coding region of the genes.

[0089] 12. The method according to any one of embodiments 10 to 11, wherein the library of gRNAs comprises on average 4 gRNAs per gene.

[0090] 13. The method according to any one of embodiments 10 to 12, wherein the library of gRNAs comprises on average 4 gRNAs per gene and a set of non-targeting controls.

[0091] 14. The method according to any one of embodiments 1 to 13, wherein the generating of the library is by oligo synthesis, cloning into a pool of lentiviral plasmids with a selection marker and preparing a pool of lentiviruses containing an even distribution of all oligo nucleic acids.

[0092] 15. The method according to any one of embodiments 1 to 14, wherein the library is a gRNA library.

[0093] 16. The method according to any one of embodiments 1 to 15, wherein the generating of the library is by generating a pool of cells that have a single genetic perturbation induced by any of the gRNAs in the library by transducing the parent cells with a pooled lentiviral preparation at an MOI that results in about 30 % of the cells in the library being transduced.

[0094] 17. The method according to embodiment 16, wherein the MOI of the pooled lentiviral library is in the range of about 0.3 to about 0.5.

[0095] 18. The method according to any one of claims 1 to 17, wherein the method comprises before the identifying step the step of

[0096] - transducing the cells of the library with an adeno-associated virus (AAV) preparation or particle.

[0097] 19. The method according to any one of claims 1 to 18, wherein the method comprises before the identifying step the step of

[0098] - transducing the cells that express the pooled gRNA library with an adeno-associated virus (AAV) preparation or particle.

[0099] 20. The method according to any one of embodiments 1 and 3 to 19, wherein the transduction efficiency is below 10 %, preferably below 5 %.

[0100] 21. The method according to any one of embodiments 2 to 19, wherein the transduction efficiency is above 60 %, preferably above 75 %.

[0101] 22. The method according to any one of embodiments 19 to 21, wherein the AAV comprises a transgene encoding a fluorescent protein.

[0102] 23. The method according to any one of embodiments 19 to 22, wherein the AAV comprises a transgene encoding a fluorescence protein and a selection marker.

[0103] 24. The method according to any one of embodiments 4 to 23, wherein the library has as size so that about 500-1000 cells per gRNA are employed.

[0104] 25. The method according to any one of embodiments 19 to 24, wherein the method comprises after the transduction step and before the identifying step the step of

[0105] - cultivating the transduced cells.

[0106] 26. The method according to embodiment 25, wherein the cultivating is in the absence of a selection agent for the first two days and thereafter the selection agent is added to the cultivation medium.

[0107] 27. The method according to any one of embodiments 25 to 26, wherein the cultivation is for up to 8 days.

[0108] 28. The method according to any one of embodiments 25 to 27, wherein the cultivation is splitted after about 6 days, transduced with an AAV carrying a fluorescent reporter gene and later divided into a first fraction of unsorted cells (containing transduced and non-transduced cells) and a second fraction of transduced cells.

[0109] 29. The method according to embodiment 28, wherein the fraction of transduced cells is generated by subjecting the second fraction of cells to FACS sorting based on the expression of the fluorescent reporter protein.

[0110] 30. The method according to any one of embodiments 28 to 29, wherein the identifying and selecting comprises the following steps:

[0111] - obtaining about 500 reads per gRNA to obtain read counts for all gRNA sequences present in the pooled library in each of the cell fractions,

[0112] - determining enrichment and depletion of gRNAs in the transduced cell (CRISPRa screen) or nontransduced cell (CRISPR KO screen) fractions relative to the bulk fraction of unsorted cells,

[0113] - pairwise comparing sorted versus unsorted cells whereby non-targeting gRNAs serve as controls for generating the null distribution of RRA with gRNAs with less than 20 read counts in all samples being excluded from further analyses,

[0114] - selecting gRNAs with enrichment or depletion determined.

[0115] 31. The method according to embodiment 30, wherein gRNAs are selected with a false discovery rate (FDR) of 0.1 or less, preferably of 0.05 or less.

[0116] 32. The method according to any one of embodiments 19 to 31, wherein the AAV is of serotype 9 or rh.74.

[0117] 33. The method according to any one of embodiments 1 to 32, wherein the protein is a cell surface protein.

[0118] 34. The method according to any one of embodiments 1 to 33, wherein the protein is an endogenous protein.

[0119] 35. A method for increasing the transduction efficiency of AAV particles or of a preparation comprising AAV particles of a cell comprising the steps of

[0120] - transfecting the cell with a nucleic acid encoding / overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, and UGT2B11 in the cell.

[0121] 36. A method for producing a polypeptide in a cell comprising the steps of

[0122] - cultivating a cell overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, BCAR1, TMEM114, SLC35B2, SLC11A1, KDELR2, TAS2R40, FHDC1, LY6G5C, CLDN4, IFRD2, TMX2, STEAP3, CDKN1B, KCNK3, CWH43, OR5B21, MS4A8, KCNK2, ATP12A, PAM, GLB1L2, OPHN1, FADS2, SMIM17, RGR, HTR2A, LRTM2, POPDC2, CMTM6, GJB5, PQLC2, GPR4, COL1A2, NSG1, SIGMAR1, PTPRE, CD79A, TMEM72, PLXDC1, CLCN3, CYBRD1, KIAA0100, FKTN, LTB, ATP2C1, NCKIPSD, SLC2A7, SEMA6D, PLPP1, EFCAB14, ITPR2, WNT5B, PKD2L1, PAIP1, TLR2, STX6, CLPTM1, PRSS21, SLC5A2, KCNJ13, SLC35E1, UGT8, KCNE5, OR13C4, HEPHL1, TMEM45B, TMEM52B, SPTSSA, TGFA, LILRA4, ANTXR1, SRCAP, ESYT3, SMDT1 and FBXW 12 and containing the nucleic acid encoding the polypeptide under conditions suitable for the expression of the polypeptide,

[0123] - recovering the polypeptide from the cell or the cultivation medium,

[0124] - optionally purifying the polypeptide,

[0125] and thereby producing the polypeptide.

[0126] 37. An assay for determining the transduction efficiency of an AAV preparation or an AAV particle comprising the steps of

[0127] - incubating cells overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, BCAR1, TMEM114, SLC35B2, SLC11A1, KDELR2, TAS2R40, FHDC1, LY6G5C, CLDN4, IFRD2, TMX2, STEAP3, CDKN1B, KCNK3, CWH43, OR5B21, MS4A8, KCNK2, ATP12A, PAM, GLB1L2, OPHN1, FADS2, SMIM17,

[0128] RGR, HTR2A, LRTM2, POPDC2, CMTM6, GJB5, PQLC2, GPR4, COL1A2, NSG1, SIGMAR1, PTPRE, CD79A, TMEM72, PLXDC1, CLCN3, CYBRD1, KIAA0100, FKTN, LTB, ATP2C1, NCKIPSD, SLC2A7, SEMA6D, PLPP1, EFCAB14, ITPR2, WNT5B, PKD2L1, PAIP1, TLR2, STX6, CLPTM1, PRSS21, SLC5A2, KCNJ13, SLC35E1, UGT8, KCNE5, OR13C4, HEPHL1, TMEM45B, TMEM52B, SPTSSA, TGFA, LILRA4, ANTXR1, SRCAP, ESYT3, SMDT1 and FBXW12 with the AAV preparation or particle,

[0129] - determining the fraction of the cells transduced by the AAV preparation or AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV preparation or particle),

[0130] and thereby determining the transduction efficiency of an AAV preparation or AAV particle.

[0131] 38. The assay according to embodiment 37, wherein the assay is a cell-based potency assay.

[0132] 39. An assay for selecting an AAV particle comprising the steps of

[0133] - separately incubating cells overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, BCAR1, TMEM114, SLC35B2, SLC11A1, KDELR2, TAS2R40, FHDC1, LY6G5C, CLDN4, IFRD2, TMX2, STEAP3, CDKN1B, KCNK3, CWH43, OR5B21, MS4A8, KCNK2, ATP12A, PAM, GLB1L2, OPHN1, FADS2, SMIM17, RGR, HTR2A, LRTM2, POPDC2, CMTM6, GJB5, PQLC2, GPR4, COL1A2, NSG1, SIGMAR1, PTPRE, CD79A, TMEM72, PLXDC1, CLCN3, CYBRD1, KIAA0100, FKTN, LTB, ATP2C1, NCKIPSD, SLC2A7, SEMA6D, PLPP1, EFCAB14, ITPR2, WNT5B, PKD2L1, PAIP1, TLR2, STX6, CLPTM1, PRSS21, SLC5A2, KCNJ13, SLC35E1, UGT8, KCNE5, OR13C4, HEPHL1, TMEM45B, TMEM52B, SPTSSA, TGFA, LILRA4, ANTXR1, SRCAP, ESYT3, SMDT1 and FBXW12 with AAV particles differing in their capsid amino acid sequence,

[0134] - determining for each AAV particle the fraction of the cells transduced by the AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV particle) and thereby determining the transduction efficiency of each AAV particle differing in their capsid amino acid sequence,

[0135] - ranking the AAV particles differing in their capsid amino acid sequence according to their transduction efficiency,

[0136] and.

[0137] selecting one or more AAV particles.

[0138] 40. The method according to embodiment 39, wherein the AAV particles are of the same serotype.

[0139] 41. The method according to any one of embodiments 39 to 40, wherein the particles with the highest transduction efficiency are selected.

[0140] 42. Use of a protein selected from the list of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, BCAR1, TMEM114, SLC35B2, SLC11A1, KDELR2, TAS2R40, FHDC1, LY6G5C, CLDN4, IFRD2, TMX2, STEAP3, CDKN1B, KCNK3, CWH43, OR5B21, MS4A8, KCNK2, ATP12A, PAM, GLB1L2, OPHN1, FADS2, SMIM17, RGR, HTR2A, LRTM2, POPDC2, CMTM6, GJB5, PQLC2, GPR4, COL1A2, NSG1, SIGMAR1, PTPRE, CD79A, TMEM72, PLXDC1, CLCN3, CYBRD1, KIAA0100, FKTN, LTB, ATP2C1, NCKIPSD, SLC2A7, SEMA6D, PLPP1, EFCAB14, ITPR2, WNT5B, PKD2L1, PAIP1, TLR2, STX6, CLPTM1, PRSS21, SLC5A2, KCNJ13, SLC35E1, UGT8, KCNE5, OR13C4, HEPHL1, TMEM45B, TMEM52B, SPTSSA, TGFA, LILRA4, ANTXR1, SRCAP, ESYT3, SMDT1 and FBXW12 for increasing the transduction efficiency of an AAV preparation or AAV particle of a cell.

[0141] 43. The method or use according to any one of embodiments 1 to 42, wherein the cell is a mammalian cell.

[0142] 44. The method or use according to any one of embodiments 1 to 43, wherein the cell is a human cell.

[0143] 45. The method or use according to any one of embodiments 1 to 44, wherein the cell is a HEK cell.

[0144] 46. The method or use according to any one of embodiments 1 to 44, wherein the cell is a human liver cell.

[0145] 47. The method or use according to any one of embodiments 1 to 44, wherein the cell is a human neuronal cell.

[0146] 48. The method or use according to any one of embodiments 1 to 44, wherein the cell is a cell of the human eye.

[0147] 49. The method or use according to any one of embodiments 1 to 48, wherein the list of proteins consists of LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, BCAR1, TMEM114, SLC35B2, SLC11A1, KDELR2, TAS2R40, FHDC1, LY6G5C, CLDN4, IFRD2, TMX2, STEAP3, CDKN1B, KCNK3, CWH43, OR5B21, MS4A8, KCNK2, ATP12A, PAM, GLB1L2, OPHN1, FADS2, SMIM17, RGR, HTR2A, LRTM2, POPDC2, CMTM6, GJB5, PQLC2, GPR4, COL1A2, NSG1, SIGMAR1, PTPRE, CD79A, TMEM72, PLXDC1, CLCN3, CYBRD1, KIAA0100, FKTN, LTB, ATP2C1, NCKIPSD, SLC2A7, SEMA6D, PLPP1, EFCAB14, ITPR2, WNT5B, PKD2L1, PAIP1, TLR2, STX6, CLPTM1, PRSS21, SLC5A2, KCNJ13, SLC35E1, UGT8, KCNE5, OR13C4, HEPHL1, TMEM45B, TMEM52B, SPTSSA, TGFA, LILRA4, ANTXR1, SRCAP, ESYT3, SMDT1 and FBXW12.

[0148] 50. The method or use according to any one of embodiments 1 to 48, wherein the list of proteins consists of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2B11.

[0149] 51. The method or use according to any one of embodiments 1 to 48, wherein the list of proteins consists of LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2Bll.

[0150] 52. The method or use according to any one of embodiments 1 to 48, wherein the list of proteins consists of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13 and SLC5A8.

[0151] 53. The method or use according to any one of embodiments 1 to 48, wherein the list of proteins consists of LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13 and SLC5A8.

[0152] 54. The method or use according to any one of embodiments 1 to 48, wherein the list of proteins consists of DPP4, LPAR5, BRS3, FUT1, CH25H, PUM1, SLC5A8 and SLC7A11.

[0153] 55. The method or use according to any one of embodiments 1 to 48, wherein the list of proteins consists of LPAR5, BRS3, FUT1, CH25H, PUM1, SLC5A8 and SLC7A11.

[0154] 56. A method for increasing the transduction efficiency of AAV particles or of a preparation comprising AAV particles of a cell comprising the steps of

[0155] - transfecting the cell with a nucleic acid encoding / overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B in the cell.

[0156] 57. A method for increasing the transduction efficiency of AAV particles or of a preparation comprising AAV particles of a cell comprising the steps of

[0157] - transfecting the cell with a nucleic acid encoding / overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B in the cell.58. A method for producing a polypeptide in a cell comprising the steps of

[0158] - cultivating a cell overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B and containing

[0159] the nucleic acid encoding the polypeptide under conditions suitable for the expression of the polypeptide,

[0160] - recovering the polypeptide from the cell or the cultivation medium,

[0161] - optionally purifying the polypeptide,

[0162] and thereby producing the polypeptide.

[0163] 59. A method for producing a polypeptide in a cell comprising the steps of

[0164] - cultivating a cell overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B and containing the nucleic acid encoding the polypeptide under conditions suitable for the expression of the polypeptide,

[0165] - recovering the polypeptide from the cell or the cultivation medium,

[0166] - optionally purifying the polypeptide,

[0167] and thereby producing the polypeptide.

[0168] 60. An assay for determining the transduction efficiency of an AAV preparation or an AAV particle comprising the steps of

[0169] - incubating cells overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B with the AAV preparation or particle,

[0170] - determining the fraction of the cells transduced by the AAV preparation or AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV preparation or particle),

[0171] and thereby determining the transduction efficiency of an AAV preparation or AAV particle.

[0172] 61. An assay for determining the transduction efficiency of an AAV preparation or an AAV particle comprising the steps of

[0173] - incubating cells overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B with the AAV preparation or particle,

[0174] - determining the fraction of the cells transduced by the AAV preparation or AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV preparation or particle),

[0175] and thereby determining the transduction efficiency of an AAV preparation or AAV particle.

[0176] 62. An assay for selecting an AAV particle comprising the steps of

[0177] - separately incubating cells overexpressing at least one protein selected from the group of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B with AAV particles differing in their capsid amino acid sequence,

[0178] - determining for each AAV particle the fraction of the cells transduced by the AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV particle) and thereby determining the transduction efficiency of each AAV particle differing in their capsid amino acid sequence,

[0179] - ranking the AAV particles differing in their capsid amino acid sequence according to their transduction efficiency,

[0180] and,

[0181] selecting one or more AAV particles.

[0182] 63. An assay for selecting an AAV particle comprising the steps of

[0183] - separately incubating cells overexpressing at least one protein selected from the group of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B with AAV particles differing in their capsid amino acid sequence,

[0184] - determining for each AAV particle the fraction of the cells transduced by the AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV particle) and thereby determining the transduction efficiency of each AAV particle differing in their capsid amino acid sequence,

[0185] - ranking the AAV particles differing in their capsid amino acid sequence according to their transduction efficiency, and selecting one or more AAV particles.

[0186] 64. Use of a protein selected from the list of proteins consisting of HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21, GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B for increasing the transduction efficiency of an AAV preparation or AAV particle of a cell.

[0187] 65. Use of a protein selected from the list of proteins consisting of DPP4, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, DNAJC13, SLC5A8, KDELR3, CCR10, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11, UGT2B11, HTR2C, HTR7, ZC3HAV1, SLC7A5, STEAP3, MS4A8, HTR2A, P2RY1, MUC21,

[0188] GPR12, S1PR2, UGT3A1, HTR6, TNC, TMEM253, KCNIP3, GPR156, LPAR4, MFSD14B, GRM2, SLC2A3, TMEM135, GRM8, KCNJ9, TMEM263, SLC9A7, and YIF1B for increasing the transduction efficiency of an AAV preparation or AAV particle of a cell.

[0189] 66. A human CRISPR-mediated transcriptional activation (CRISPRa) guide RNA library comprising:

[0190] - a plurality of single guide RNAs (sgRNAs), each sgRNA comprising:

[0191] - a DNA-targeting segment having a spacer sequence which targets a promoter region of a targeted gene, the promoter region comprising a genomic region surrounding a transcriptional start site (TSS); and

[0192] - a backbone capable of binding to a dCas fusion protein;

[0193] wherein the plurality of sgRNAs comprise 10 or more sgRNA per promoter region such that the plurality of sgRNAs comprise at least 10 sgRNA per targeted gene.

[0194] 67. The CRISPRa guide RNA library of embodiment 66, wherein at least a subset of the plurality of sgRNAs targets two or more promoter regions per targeted gene, such that the plurality of sgRNAs comprise at least 20 sgRNA per targeted gene.

[0195] 68. The CRISPRa guide RNA library of embodiment 67, wherein the two or more promoter regions are at least Ikb apart.

[0196] 69. The CRISPRa guide RNA library of embodiment 67 or 68, wherein at least a subset of the plurality of sgRNAs targets three or more promoter regions per targeted gene, four or more promoter regions per targeted gene, five or more promoter regions per targeted gene, six or more promoter regions per targeted gene, or seven or more promoter regions per targeted gene.

[0197] 70. The CRISPRa guide RNA library of any one of embodiments 66-69, wherein the spacer sequences of the plurality of sgRNAs provide coverage of a whole genome comprising a plurality of targeted genes.

[0198] 71. The CRISPRa guide RNA library of any one of embodiments 66-70, wherein the plurality of sgRNAs comprises two or more non-overlapping sub-libraries which each provide coverage for a subset of the whole genome.

[0199] 72. The CRISPRa guide RNA library of any one of embodiments 66-69, wherein the spacer sequences of the plurality of sgRNAs provides coverage for a subset of a genome, the subset comprising a plurality of targeted genes.

[0200] 73. The CRISPRa guide RNA library of any one of embodiments 66-72, wherein the plurality of sgRNAs comprises spacer sequences which target promoter regions of at least 5,000 targeted genes, at least 10,000 targeted genes, at least 15,000 targeted genes, or at least 20,000 targeted genes.

[0201] 74. The CRISPRa guide RNA library of any one of embodiments 66-73, wherein the plurality of sgRNAs comprises spacer sequences which target promoter regions of of at least 5,000 TSSs, at least 10,000 TSSs, at least 15,000 TSSs, at least 20,000 TSSs, or at least 22,000 TSSs.

[0202] 75. The CRISPRa guide RNA library of any one of embodiments 66-74, wherein each of the TSSs targeted by the plurality of sgRNAs is located -500bp to +500bp of the start of their respective targeted gene.

[0203] 76. The CRISPRa guide RNA library of any one of embodiments 66-75, wherein the promoter region is located -175bp to -50bp of the TSS, -200bp to -25bp of the TSS, -250bp to Obp of the TSS, -300bp to Obp of the TSS, -350bp to Obp of the TSS, or -400bp to Obp of the TSS.

[0204] 77. The CRISPRa guide RNA library of any one of embodiments 66-76, wherein each spacer sequence does not comprise a restriction site for EcoRI or KpnI.

[0205] 78. The CRISPRa guide RNA library of any one of embodiments 66-77, wherein each sgRNA comprises a GC content of between 20% to 80%.

[0206] 79. The CRISPRa guide RNA library of any one of 66-78, wherein each spacer sequence does not comprise a PolyU / T termination signal.

[0207] 80. The CRISPRa guide RNA library of any one of embodiments 66-79, wherein each sgRNA has an MIT score of greater than 0.5, or between 0.25 to 0.5.

[0208] 81. The CRISPRa guide RNA library of any one of embodiments 66-80, wherein each sgRNA has an Azimuth score lower than 0.25.

[0209] 82. The CRISPRa guide RNA library of any one of embodiments 66-81, wherein the dCas fusion protein is a dCas9 fusion protein.

[0210] 83. The CRISPRa guide RNA library of any one of embodiments 66-82, wherein the backbone comprises a GNE-3 backbone.

[0211] 84. The CRISPRa guide RNA library of any one of embodiments 66-83, wherein the plurality of sgRNAs comprises at least 50,000, at least 100,000, or at least 200,000 sgRNA.

[0212] 85. The CRISPRa guide RNA library of any one of embodiments 66-84, further comprising at least 500 or at least 1000 non-targeting control (NTC) sgRNAs.

[0213] 86. A system for CRISPR-mediated transcriptional activation (CRISPRa) comprising:

[0214] the CRISPRa guide RNA library of any one of embodiments 66-85, and a CRISPRa system comprising a dCas fusion protein, the dCas fusion protein comprising a dCas effector protein and one or more transcriptional activation domains (TADs).

[0215] 87. The system of embodiment 86, wherein the CRISPRa system is a dCas9-Synergistic Activation Mediator (SAM) system, a dCas9-VPR system, a SunTag system, or a CRISPRa-sel system.

[0216] 88. The system of embodiment 86 or 87, wherein the dCas effector protein is a dead S. Pyogenes Cas9 (spCas9).

[0217] 89. A cell library comprising the system of any one of embodiments 86-88.

[0218] 90. The cell library of claim 89, wherein the cell library is generated using murine primary cells from a dCas9a-SAMKI / KImouse model which constitutively express the dCas9-SAM system.

[0219] 91. The cell library of claim 89 or 90, wherein the cell library has as size so that about 500-1000 cells per gRNA are employed.

[0220] 92. A method of generating a whole genome murine CRISPRa guide RNA library, the method comprising:

[0221] a. identifying protein-coding isoforms for a murine genome as targeted genes; and b. for each targeted gene identified in step a:

[0222] i. identifying a first transcriptional start site (TSS) of the targeted gene; ii. defining a promoter region of the targeted gene, the promoter region comprising a genomic region surrounding the TSS;

[0223] iii. identifying one or more possible spacer sequences within the promoter region;

[0224] iv. removing spacer sequences containing EcoRI or Kpnl restriction enzyme recognition sites from the possible spacer sequences;

[0225] v. removing spacer sequences comprises a GC content less than 20% or more than 80% from the possible spacer sequences;

[0226] vi. ranking the possible spacer sequences based on Azimuth on-target activity score;

[0227] vii. prioritizing the possible spacer sequences based on location relative to an activation window of -150bp to -75bp of the TSS;

[0228] viii. selecting 10 or more spacer sequences from the possible spacer sequences after completing steps i-vii for the first TSS of the targeted gene; and ix. designing 10 or more sgRNAs for the first TSS of the targeted gene, each sgRNA comprising one of the spacer sequences selected in step viii and a backbone capable of binding to a dCas effector protein.

[0229] 93. The method of embodiment 92, further comprising identifying a second TSS of the targeted gene and repeating steps i-xi for the second TSS of the targeted gene of step b.

[0230] 94. A method of using a human CRISPRa guide RNA library, the method comprising:

[0231] a. generating a library of cells wherein in each cell a different cell survival or cell proliferation protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of the CRISPRa guide RNA library of any one of embodiments 66-85 in each cell of the library of cells;

[0232] b. growing the cells of the library for said cells for a pre-determined amount of time; c. collecting genomic DNA from the library of cells before growing and after the pre-determined amount of time growing;

[0233] d. amplifying and sequencing the genomic DNA at the TSS of each targeted gene from before and after the pre-determined amount of time; and

[0234] e. comparing the amount of sgRNA for each targeted gene before and after the predetermined amount of time and determining which TSSs are enriched and which TSSs are depleted, wherein TSS enrichment is indicative of increased cell proliferation and TSS depletion is indicative of increased cell death; thereby identifying which proteins increase cell proliferation or cell death, respectively.

[0235] 95. A method of using a human CRISPRa guide RNA library, the method comprising:

[0236] a. generating a library of cells wherein in each cell a different protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of the CRISPRa guide RNA library of any one of embodiments 66-85 in each cell of the library of cells;

[0237] b. growing the cells of the library under pressure from an anti -cancer therapy for a pre-determined amount of time;

[0238] c. collecting genomic DNA from the library of cells before growing and after the pre-determined amount of time;

[0239] d. amplifying and sequencing the genomic DNA at the TSS of each targeted gene from before and after the pre-determined amount of time; and

[0240] e. comparing the amount of sgRNA for each targeted gene before and after the predetermined amount of time and determining which TSSs are enriched, wherein TSS enrichment is indicative of increased resistance to the anti-cancer therapy; thereby identifying which genes promote resistance to the anti-cancer therapy.

[0241] 96. A method of using a human CRISPRa guide RNA library, the method comprising:

[0242] - generating a library of tumor-generating cells wherein in each cell a different protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of the CRISPRa guide RNA library of any one of embodiments 66-85 in each cell of the library of cells;

[0243] - transplanting the tumor-generating cells into recipient mice;

[0244] - monitoring the recipient mice for tumor development after transplantation for a predetermined amount of time;

[0245] - collecting genomic DNA from the library of cells before transplanting and after the predetermined amount of time;

[0246] - amplifying and sequencing the genomic DNA at the TSS of each targeted gene from before and after the pre-determined amount of time; and

[0247] - comparing the amount of sgRNA for each targeted gene before and after the predetermined amount of time and determining which TSSs are enriched, wherein TSS enrichment is indicative of increased tumor growth in the presence of an overexpressed oncogene; thereby identifying oncogenes that promote tumor growth in the tumor-generating cells.

[0248] 97. A method of using a human CRISPRa guide RNA library, the method comprising:

[0249] - generating a library of tumor-generating cells wherein in each cell a different protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of the CRISPRa guide RNA library of any one of embodiments 66-85 in each cell of the library of cells;

[0250] - growing the cells of the library and the parental cells, separately, for a pre-determined amount of time;

[0251] - transducing the parental cells with an AAV to determine a parental MOI which results in a pre-determined transduction efficiency;

[0252] - transducing the cells of the library with the AAV at the parental MOI;

[0253] - splitting the cells of the library into an unsorted fraction and a sorted fraction;

[0254] - sorting the sorted fraction to generate an AAV transduced fraction;

[0255] - collecting genomic DNA from the unsorted fraction and the AAV transduced fraction;

[0256] - amplifying and sequencing the genomic DNA at the TSS of each targeted gene; and

[0257] - comparing the amount of sgRNA for each targeted gene in the unsorted fraction and the AAV transduced fraction and determining which TSSs are enriched,

[0258] wherein TSS enrichment is indicative of AAV transduction; thereby identifying which proteins act as AAV receptors and / or helper proteins that enable transduction of cells by the AAV used in the screen.

[0259] 98. The method of embodiment 97, wherein the genes that enhance AAV transduction include DPP4, AAVR, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2,

[0260] SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2B11.

[0261] 99. The method of any one of embodiments 94-98, wherein the cells are grown in vitro.

[0262] 100. The method of any one of embodiments 94-99, wherein the cells are human primary cells or human immortalized cells.

[0263] In addition to the various embodiments depicted and claimed, the disclosed subject matter is also directed to other embodiments having other combinations of the features disclosed or claimed herein. As such, the particular features presented herein can be combined with each other in other manners within the scope of the disclosed subject matter such that the disclosed subject matter includes any suitable combination of the features disclosed herein. The foregoing description of specific embodiments of the disclosed subject matter has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosed subject matter to those embodiments disclosed.

[0264] Description of the Figures

[0265] Figure 1 Exemplary titration of pooled lentiviral library. The percentage of transduced cells was calculated for each lentivirus dilution based on the number of positive transduced cells 96 hours post transduction. An MOI of about 0.4-0.5, equivalent to 30% of transduced cells, was selected and the amount of lentiviral library corresponding to that dilution was scaled up to perform the CRISPRa screen.

[0266] Figure 2 Exemplary titration curve of AAV9. The percentage of transduced HEK293A SAM cells was measured as the percentage of mGreenLantern-positive cells by flow cytometry and plotted against the corresponding MOI. An MOI of 25 000 was selected to perform the screen since it was at the inflection point of the titration curve.

[0267] Figure 3 Generic workflow of the method according to the invention. FACS sorting based on the expression of the fluorescent protein with subsequent amplification and sequencing of the gRNAs.

[0268] Figures 4A-4D Quality control metrics of the CRISPRa screen for the identification of AAV9 receptors.

[0269] Figure 4A: mapping ratio of the gRNAs in each population of the CRISPRa screen.

[0270] Figure 4B: proportion of gRNAs with zero counts in all cell fractions from the CRISPRa screen (missed sgRNAs).

[0271] Figure 4C: evenness of the distribution of reads for each gRNA across samples from three independent replicates of the CRISPRa screen.

[0272] Figure 4D: exemplary distribution of gRNA read counts in bulk fractions of cells (this is the bulk from the second replicate).

[0273] Figure 5 Volcano plot showing genes whose gRNAs were either enriched or depleted in the fluorescent protein positive fraction of AAV9-transduced cells from the CRISPRa screen. Top candidates enriched with a global FDR<0.05 are labelled.

[0274] Figure 6 Distribution of gRNAs targeting the 16 hits (FDR<0.05, as labelled in Figure 5) in AAV9-transduced cells (exemplary example from the first replicate). Most individual gRNAs were enriched compared to the bulk fraction of unsorted cells.

[0275] Figures 7A-7B Validation of top screen hits using an orthogonal method.

[0276] Figure 7A: HEK293 cells were transiently transfected with an individual cDNA encoding one of the screen hits and then transduced with an AAV9 preparation comprising the coding sequence of a fluorescent protein at the same MOI that was used in the screen. The percentage of transduced cells was quantified by flow cytometry.

[0277] Figure 7B: Representative images of validated hits showing fluorescence in transduced cells that overexpress a given protein identified in the screen.

[0278] Figures 8A-8C mGreenLantern fluorescence of HEK293 A cells. Representative plot showing histograms of mGreenLantern fluorescence in HEK293 A SAM cells transduced with the lentiviral gRNA library.

[0279] Figure 8A: cells non-transduced with AAV9 comprising a nucleic acid encoding a fluorescent protein (negative control).

[0280] Figure 8B: cells transduced with AAV9 comprising a nucleic acid encoding a fluorescent protein (P4 and P5 correspond to positive and negative sorted populations, respectively).

[0281] Figure 8C: cells transduced with AAV9 comprising a nucleic acid encoding a fluorescent protein and sorted (purity check of P4).

[0282] Figure 9 Exemplary titration curve of AAVrh74. The percentage of transduced HEK293 A SAM cells was measured as the percentage of mGreenLantern-positive cells by flow cytometry and plotted against the corresponding MOI. An MOI at the inflection point of the titration curve that transduced less than 5% of the cell was used to perform the screens.

[0283] Figures 10A-10D Quality control metrics of the CRISPRa screen for the identification of AAVrh74 receptors.

[0284] Figure 10A: mapping ratio of the gRNAs in each population of the CRISPRa screen.

[0285] Figure 10B: proportion of gRNAs with zero counts in all cell fractions from the CRISPRa screen (missed sgRNAs).

[0286] Figure 10C: evenness of the distribution of reads for each gRNA across samples from three independent replicates of the CRISPRa screen.

[0287] Figure 10D: exemplary distribution of gRNA read counts in bulk fractions of cells (this is the bulk from the first replicate).

[0288] Figure 11 Volcano plot showing genes whose gRNAs were either enriched or depleted in the fluorescent protein positive fraction of AAVrh74-transduced cells from the CRISPRa screen. Top candidates enriched with a global FDR<0.05 are labelled.

[0289] Figure 12 Distribution of the log fold-change in transduced cells compared to bulk unsorted cells of gRNAs (FDR<0.05) targeting top AAVrh74 screen hits in all screen replicates.

[0290] Figures 13A-13C Validation of top screen hits in cell lines that stably overexpress the most prevalent cDNA isoform of each hit. Figure 13 A: Flow cytometry data evaluating the percentage of AAV9-transduced cells at an MOI of 200 000 for each of the stable cell lines overexpressing top AAV9 screen hits. Figure 13B: Flow cytometry data evaluating the percentage of AAVrh74-transduced cells at an MOI of 200,000 for each of the stable cell lines overexpressing top AAVrh74 screen hits. Figure 13C: Representative images of cell lines that stably overexpress a given protein identified in both screens, showing AAV-driven fluorescence in transduced cells with either AAV9 (top panels) or AAVrh74 (bottom panels). Different usage of common AAV-receptors by different AAV capsids was observed.

[0291] Figure 14 Details about the creation of the Sonata library. Figure 14 presents a diagram showcasing the prioritization of sgRNA selection within the optimal activation window. Priority was given first to sgRNAs within the first region (Rl) of [-150 bp, -75 bp], and then in regions of decreasing priority (and increasing size): R2 = [-175 bp, -50 bp], R3 = [-200 bp, -25 bp], R4 = [-250 bp, 0 bp], R5 = [-300 bp, 0 bp], R6 = [-350 bp, 0 bp], and R7 = [-400 bp, 0 bp].

[0292] Detailed

[0293]

[0294] The current invention is based, at least in part, on the finding that with a CRISPR-mediated transcriptional activation screen it is possible to unbiasedly identify genes and pathways that can increase AAV entry into cells, especially into cells that are not amenable to AAV transduction as wild-type cells. Without being bound by this theory, it is assumed that this is especially suitable for AAV serotypes that could not transduce the wild-type version of those cells.

[0295] DEFINITIONS

[0296] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular, and cellular biology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art.

[0297] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth. As well, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably.

[0298] Unless otherwise defined herein the term “comprising of’ shall include the term “consisting of’.

[0299] By “consisting of’, it is meant the exclusion from the composition, method, or kit of any element, step, or ingredient not specified in the claim.

[0300] The term “about” as used herein in connection with a specific value (e.g. temperature, concentration, time and others) shall refer to a variation of + / - 1 % of the specific value that the term “about” refers to.

[0301] As used herein, the term “Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)” refers to sequences based on regularly spaced clustered short repeat palindromic sequences that, unlike RNA interference, control gene expression at the transcriptional level.

[0302] In general, “CRISPR system” refers collectively to elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas protein, a tracr (trans-activating CRISPR) sequence (e.g., tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a “direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a “spacer” in the context of an endogenous CRISPR system), and / or other sequences and transcripts from a CRISPR locus.

[0303] CRISPR / Cas systems or CRISPR-Cas systems can include a non-coding RNA molecule (guide) RNA, which sequence-specifically binds to DNA, and a Cas protein (e.g., Cas9), with nuclease functionality (e.g., two nuclease domains). One or more elements of a CRISPR system can be derived from a type I, type II, or type III CRISPR system, e.g., can be derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. CRISPR systems in accordance with embodiments of the invention are generally characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). In the context of formation of a CRISPR complex, “target sequence” refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell. In some embodiments, the target sequence may be within an organelle of a eukaryotic cell, for example, mitochondrion or chloroplast. A sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an “editing template” or “editing polynucleotide” or “editing sequence”. In aspects of the invention, an

[0304] exogenous template polynucleotide may be referred to as an editing template. In an aspect of the invention the recombination is homologous recombination.

[0305] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5 ’ with respect to (“upstream” of) or 3 ’ with respect to (“downstream” of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide RNA sequences. In some embodiments, the CRISPR enzyme and guide RNA sequence are operably linked to and expressed from the same promoter.

[0306] The term “CRISPR-associated protein” or “Cas protein” refers to a wild-type Cas protein, a fragment thereof, or a mutant or variant thereof. The term “Cas mutant” or “Cas variant” refers to a wild-type Cas protein, e.g., a protein or polypeptide derivative of a protein having one or more point mutations, insertions, deletions, truncations, fusion proteins, or combinations thereof. In certain embodiments, a “Cas mutant” or “Cas variant” substantially retains the nuclease activity of the Cas protein. In certain embodiments, a “Cas mutant” or “Cas variant” is mutated such that one or both nuclease domains are inactive. In certain embodiments, a “Cas mutant” or “Cas mutant” has nuclease activity. In certain embodiments, a “Cas mutant” or “Cas variant” lacks some or all of the nuclease activity of its wild-type counterpart.

[0307] A “Cas9” molecule or protein, as used herein, refers to a Cas9 polypeptide or a nucleic acid encoding a Cas9 polypeptide. A “Cas9 polypeptide” is a polypeptide that can interact with a gRNA molecule and, in concert with the gRNA molecule, localize to a site comprising a target domainand, in certain embodiments, a PAM sequence. Cas9 molecules include both naturally occurring Cas9 molecules and Cas9 molecules and engineered, altered, or modified Cas9 molecules or Cas9 polypeptides that differ, e.g., by at least one amino acid residue, from a reference sequence, e.g., the most similar naturally occurring Cas9 molecule. The terms “altered”, “engineered” or “modified”, as used in this context, refer merely to a difference from a reference or naturally occurring sequence, and impose no specific process or origin limitations. A Cas9 molecule may be a nuclease (an enzyme that cleaves both strands of a double-stranded nucleic acid), a nickase (an enzyme that cleaves one strand of a double-stranded nucleic acid), or an enzymatically inactive (or dead) Cas9 molecule.

[0308] The term “fusion protein”, as used herein, refers to a single protein created by joining two or more proteins, protein domains, or protein fragments that are not naturally found together in a single protein. For example, a fusion protein may contain a first domain from one Cas protein and a second domain from a different Cas protein or may contain a first domain from a transcriptional activation protein and a second domain from a Cas protein. Modification to include such domains in fusion proteins may confer additional activity on the modified polypeptides. Such activities may include nuclease activity, methyltransferase activity, demethylase activity, DNA or RNA repair activity, DNA or RNA damage activity, deamination activity, dismutase activity, alkylation activity, scavenging activity, oxidation, pyrimidine dimer formation activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity, glycosylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylation activity, desSUMOylation activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity, or any combination thereof, that modifies a polypeptide associated with the target sequence nucleic acid. A fusion protein may also comprise epitope tags (e.g., histidine tags, FLAG® tags (Sigma Aldrich, St. Louis, MO), Myc tags), reporter protein sequences (e.g., glutathione- S-transferase, betagalactosidase, luciferase, green fluorescent protein, cyan fluorescent protein, yellow fluorescent protein) and / or nucleic acid binding domains (e.g., a DNA binding domain, an RNA binding domain). A fusion protein may also comprise activator domains (e.g., heat shock transcription factors, NFKB activators) or repressor domains (e.g., a KRAB domain). Exemplary transcriptional activation domains (TADs) include VP16, VP64, VP28, TALE, p65, Rta, AD2, CR3, EKLF1, GATA4, PRVIE, p53, SP1, MYOD, MEF2C, TAX, PPARy, or the like. In some embodiments,

[0309] linker nucleic acid sequences are used to join the two or more proteins, protein domains, or protein fragments.

[0310] As used herein, the term “gRNA molecule” or “gRNA” refers to a guide RNA which is capable of targeting a Cas molecule to a target nucleic acid. In certain embodiments, a guide RNA comprises, or consists essentially of, a direct repeat sequence fused or linked to a guide sequence or spacer sequence. In one embodiment, the term “gRNA molecule” refers to a guide ribonucleic acid. In another embodiment, the term “gRNA molecule” refers to a nucleic acid encoding a gRNA. In one embodiment, a gRNA molecule is non-naturally occurring. In one embodiment, a gRNA molecule is a synthetic gRNA molecule.

[0311] As used herein, the term “single guide RNA” or “sgRNA” refers to a single RNA molecule that combines a custom-designed short crRNA sequence with a scaffold or backbone tracrRNA sequence, as frequently used in connection with CRISPR-Cas systems.

[0312] The term "nucleotide," in addition to referring to the naturally occurring ribonucleotide or deoxyribonucleotide monomers, shall herein be understood to refer to related structural variants thereof, including derivatives and analogs, that are functionally equivalent with respect to the particular context in which the nucleotide is being used (e.g., hybridization to a complementary base), unless the context clearly indicates otherwise.

[0313] The term “nucleic acid” or “polynucleotide” refers to a polymeric form of two or more nucleotides of any length, either deoxyribonucleotides or ribonucleotides (or both), or analogs thereof. This includes polymers of nucleotides such as RNA and DNA, as well as synthetic forms, modified (e.g, chemically or biochemically modified) forms thereof, and mixed polymers (e.g, including both RNA and DNA subunits). Polynucleotides according to the present disclosure may have any three dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, selection markers, regulatory elements, and primers. A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. Exemplary modifications include methylation, substitution of one or more of the naturallyoccurring nucleotides with an analog, intemucleotide modifications such as uncharged linkages (e.g, methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, and the like), pendent moi eties (e.g, polypeptides), intercalators (e.g., acridine, psoralen, and the like), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids and the like). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Typically, the nucleotide monomers are linked via phosphodiester bonds, although synthetic forms of nucleic acids can comprise other linkages (e.g., peptide nucleic acids as described in Nielsen et al. (Science 254:1497-1500, 1991). A nucleic acid can be, e.g., single-stranded, double-stranded, or triplestranded and is not limited to any particular length. Unless otherwise indicated, a particular nucleic acid sequence comprises or encodes complementary sequences, in addition to any sequence explicitly indicated.

[0314] The term "oligonucleotide" refers to a nucleic acid that includes at least two nucleic acid monomer units (e.g., nucleotides). An oligonucleotide typically includes from about six to about 175 nucleic acid monomer units, more typically from about eight to about 100 nucleic acid monomer units, and still more typically from about 10 to about 50 nucleic acid monomer units (e.g., about 15, about 20, about 25, about 30, about 35, or more nucleic acid monomer units). The exact size of an oligonucleotide will depend on many factors, including the ultimate function or use of the oligonucleotide. Oligonucleotides are optionally prepared by any suitable method, including, but not limited to, isolation of an existing or natural sequence, DNA replication or amplification, reverse transcription, cloning and restriction digestion of appropriate sequences, or direct chemical synthesis by a method such as the phosphotriester method of Narang etal. (Meth. EnzymoL 68:90-99, 1979); the phosphodiester method of Brown et al. (Meth. Enzymol. 68:109-151, 1979); the diethylphosphoramidite method of Beaucage et al. (Tetrahedron Lett. 22:1859-1862, 1981); the triester method ofMatteucci etal. (J. Am. Chem. Soc. 103:3185-3191, 1981); automated synthesis methods; or the solid support method of U. S. Pat. No. 4,458,066, or other methods known to those skilled in the art.

[0315] The term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that aresingle-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g., circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g., retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adenoassociated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

[0316] Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell).

[0317] “Recombinant,” as used herein, refers to an amino acid sequence or a nucleotide sequence that has been intentionally modified by recombinant methods. By the term "recombinant nucleic acid" herein is meant a nucleic acid, originally formed in vitro, in general, by the manipulation of a nucleic acid by endonucleases, in a form not normally found in nature. Thus an isolated, mutant DNA polymerase nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell, it will replicate non-recombinantly, i.e., using the in vivo cellular machinery of the hostcell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. A "recombinant protein" is a protein made using recombinant techniques, / .<., through the expression of a recombinant nucleic acid as depicted above.

[0318] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

[0319] The term "primer" as used herein refers to a polynucleotide capable of acting as a point of initiation of template-directed nucleic acid synthesis when placed under conditions in which polynucleotide extension is initiated (e.g., under conditions comprising the presence of requisite nucleoside triphosphates (as dictated by the template that is copied) and a polymerase in an appropriate buffer and at a suitable temperature or cycle(s) of temperatures (e.g., as in a polymerase chain reaction)). To further illustrate, primers can also be used in a variety of other oligonuceotide-mediated synthesis processes, including as initiators of de novo RNA synthesis and in vitro transcription-related processes (e.g., nucleic acid sequence-based amplification (NASBA), transcription mediated amplification (TMA), etc.). A primer is typically a single- stranded oligonucleotide (e.g., oligodeoxyribonucleotide). The appropriate length of a primer depends on the intended use of the primer but typically ranges from 6 to 40 nucleotides, more typically from 15 to 35 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template but must be sufficiently complementary to hybridize with a template for primer elongation to occur. In certain embodiments, the term "primer pair" means a set of primers including a 5' sense primer (sometimes called “forward”) that hybridizes with the complement of the 5' end of the nucleic acid sequence to be amplified and a 3' antisense primer (sometimes called “reverse”) that hybridizes with the 3' end of the sequence to be amplified (e.g., if the target sequence is expressed as RNA or is an RNA). A primer can be labeled, if desired, by incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include32P, fluorescent dyes, electron-dense reagents, enzymes (as commonly used in ELISA assays), biotin, or haptens and proteins for which antisera or monoclonal antibodies are available.

[0320] " Complementarity" of nucleic acids means that a nucleotide sequence in one strand of nucleic acid, due to orientation of its nucleobase groups, forms hydrogen bonds with another sequence on an opposing nucleic acid strand. The complementary bases in DNA are typically A with T and C with G. In RNA, they are typically C with G and U with A. Complementarity can be perfect or substantial / sufficient. Perfect complementarity between two nucleic acids means that the two nucleic acids can form a duplex in which every base in the duplex is bonded to a complementary base by Watson-Crick pairing. " Substantial" or "sufficient" complementary means that a sequence in one strand is not completely and / or perfectly complementary to a sequence in an opposing strand, but that sufficient bonding occurs between bases on the two strands to form a stable hybrid complex in set of hybridization conditions (e.g., salt concentration and temperature). Such conditions can be predicted by using the sequences and standard mathematical calculations to predict the Tm (melting temperature) of hybridized strands, or by empirical determination of Tm by using routine methods. Tm includes the temperature at which a population of hybridization complexes formed between two nucleic acid strands are 50% denatured (i.e., a population of double-stranded nucleic acid molecules becomes half dissociated into single strands). At a temperature below the Tm, formation of a hybridization complex is favored, whereas at a temperature above the Tm, melting or separation of the strands in the hybridization complex is favored. Tm may be estimated for a nucleic acid having a known G+C content in an aqueous 1 M NaCl solution by using, e.g., Tm=81.5+0.41(% G+C), although other known Tm computations consider nucleic acid structural characteristics.

[0321] A “promoter” is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter region includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. The promoter region comprises a genomic region surrounding a transcriptional start site (TSS). A promoter region also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.

[0322] DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

[0323] CRISPRa gRNA Library Generation Overview

[0324] Provided herein are CRISPRa guide RNA (e.g., sgRNA) libraries, in particular human CRISPRa guide RNA libraries, and methods of making and using such libraries. In some embodiments, the CRISPRa guide RNA libraries comprise sgRNAs targeting more than one TSS per targeted gene. In some embodiments, the CRISPRa guide RNA libraries comprise sgRNAs that target the TSSs of a whole genome (e.g., the whole human genome). In some embodiments, the CRISPRa guide RNA libraries comprise sub-libraries of a whole-genome library. In some embodiments, the CRISPRa guide RNA libraries are capable of being used in CRISPRa systems including a Cas effector protein and one or more transcription activation domains. In some embodiments, the CRISPRa guide RNA libraries are capable of being used in CRISPRa system such as a dCas9-Synergistic Activation Mediator (SAM) system, a dCas9-VPR system, or a SunTag system. In some embodiments, the CRISPRa guide RNA libraries are used for whole-genome screening. In some embodiments, one or more sub-libraries is used for selected screening (e.g., identification of novel cell-surface proteins whose overexpression increases the transduction efficiency of AAV preparations or AAV particles of mammalian cells). In some embodiments, the CRISPRa guide RNA libraries are used for identifying one or more genes of interest (e.g., genes encoding secreted proteins, genes encoding cell surface proteins, genes encoding membrane proteins, tumor essential genes, therapy resistance genes, cancer driving genes, etc.).

[0325] The CRISPRa guide RNA libraries according to the invention encompass the following features:

[0326] - a plurality of single guide RNAs (sgRNAs), each sgRNA comprising: i. a DNA-targeting segment having a spacer sequence which targets a promoter region of a targeted gene, the promoter region comprising a genomic region surrounding a transcriptional start site (TSS); and

[0327] - a backbone capable of binding to a dCas fusion protein.

[0328] The plurality of sgRNAs comprise 10 or more sgRNA per promoter region such that the plurality of sgRNAs comprise at least 10 sgRNA per targeted gene.

[0329] While sgRNA targeting schemes for CRISPRa have advanced in recent years, the ability to predict a function for each guide remains low compared to gene knock-out / suppression methods. Propertargeting of the transcriptional start site (TSS) is key to achieving robust gene upregulation. Provided herein are methods of generating and using high-density CRISPRa guide RNA libraries.

[0330] In an exemplary embodiment, a human CRISPRa whole genome sgRNA library is provided which was generated using some of the most up-to-date TSS information available at the time of filing. This new human CRISPRa whole-genome sgRNA platform - Sonata - was designed to be compatible with the dCas9-SAM system. To increase the probability of target gene activation, the library contains 10 sgRNAs per gene. Additionally, many previous methods of CRISPRa sgRNA library construction have exclusively directed the dCas9 activator to a single TSS per gene, which could potentially limit observations to phenotypes derived from isoform (TSS)-specific expression. To account for this, an sgRNA targeting scheme was established using a new methodology informed by multiple datasets across various cell types of high-quality human TSS annotations, offering the potential for activating up to seven distinct promoters per gene. This resulted in a library with >220,000 sgRNAs covering >22,000 TSSs for 19,153 genes, with accompanying non-targeting control (NTC) sgRNAs. Finally, the library backbone contained both puromycin resistance and BFP fluorescence selection markers for ease of use, along with a previously optimized sgRNA scaffold, to increase overall library functionality.

[0331] To facilitate diverse screening applications, the Sonata whole-genome library can be separated into sub-libraries, e.g., 1) DNA repair, epigenetics, GPCRs, kinases, phosphatases, proteases, ubiquitination; 2) ion channel, drug targets, secretome (part 1); 3) secretome (part 2); 4) others (part 1); and 5) others (part 2). Alternative or additional sub-libraries can also be generated - e.g., a sub-library comprising only those sgRNAs targeting transcriptional modifiers and / or a membrane proteome sub-library comprising cell-surface and secreted proteins.

[0332] In another exemplary embodiment, a human CRISPRa membrane proteome sgRNA library is provided which was generated using some of the most up-to-date TSS information available at the time of filing. This new human CRISPRa membrane proteome sgRNA platform - Transylvania -was designed to be compatible with the dCas9-SAM system. To increase the probability of target gene activation, the library contains 10 sgRNAs per gene. Additionally, many previous methods of CRISPRa sgRNA library construction have exclusively directed the dCas9 activator to a single TSS per gene, which could potentially limit observations to phenotypes derived from isoform (TSS)-specific expression. To account for this, an sgRNA targeting scheme was established using a new methodology informed by multiple datasets across various cell types of high-quality human TSS annotations, offering the potential for activating up to seven distinct promoters per gene. Thisresulted in a library with >90,000 sgRNAs covering >7,000 TSSs for 6,538 genes, with accompanying non-targeting control (NTC) sgRNAs. Finally, the library backbone contained both puromycin resistance and BFP fluorescence selection markers for ease of use, along with a previously optimized sgRNA scaffold, to increase overall library functionality.

[0333] To facilitate diverse screening applications and ease of use, the Transylvania gRNA library can be separated into sub-libraries, e.g., 1) GPCR genes, STM (single-pass transmembrane) genes, and other genes encoding tyrosine-kinase, cytokine and neuropeptide receptors and adhesion molecules; and 2) genes encoding non-overlapping GPCRs and other ion channels, amino acid transporters, and olfactory receptors. Alternative or additional sub-libraries can also be generated.

[0334] The libraries of the present invention may be broadly useful tools for the scientific community, enabling the study and discovery of new gene functions, disease biology, and therapies. One such application is described herein as an exemplary embodiment - identification of novel AAV receptors using a membrane proteome sub-library comprising cell-surface and secreted proteins.

[0335] CRISPR activation

[0336] Clustered regularly interspaced short palindromic repeat activation (CRISPRa) is an adaptation of CRISPR technology that enables target-specific gene expression. Canonical CRISPR technology uses a Cas nuclease protein (e.g., a Cas9 effector protein) to generate DNA double-stranded breaks, as directed by a single guide RNA (sgRNA) to a locus of interest. CRISPRa differs as it employs a nuclease-dead Cas protein (e.g., a dCas9 effector protein) engineered with or capable of recruiting transcriptional activation domains (TADs). When coupled with sgRNAs that direct the nuclease-dead Cas protein to the “promoter” regions upstream of the transcriptional start site (TSS), gene induction is enabled.

[0337] A variety of CRISPRa modalities have been developed, such as dCas9-SAM (see, e.g., S. Konermann, et al., Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 (2015)), dCas9-VPR (see, e.g., M. E. Tanenbaum, etal., A proteintagging system for signal amplification in gene expression and fluorescence imaging. Cell 159, 635-646 (2014)), or SunTag (see, e.g., K. J. Wangensteen, et al., Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform. Hepatology 68, 663-676 (2018)), which differ in aspects like the TADs used and sgRNA scaffold designs. A number of mouse models for CRISPRa have also been generated, including some using the SunTag (see, e.g., K. J. Wangensteen, et al., supra, and H. Zhou, et al., In vivo simultaneous transcriptional

[0338] activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. Nat Neurosci 21, 440-446 (2018)) and dCas9-Synergistic Activation Mediator (SAM) systems (see, e.g., Y. Deng, et al., Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Nat Commun 13, 4739 (2022); C. Hunt, et al., Tissue-specific activation of gene expression by the Synergistic Activation Mediator (SAM) CRISPRa system in mice. Nat Commun 12, 2770 (2021); and F. I. Thege, et al., A Programmable In Vivo CRISPR Activation Model Elucidates the Oncogenic and Immunosuppressive Functions of MYC in Lung Adenocarcinoma. Cancer Res 82, 2761-2776 (2022)). These models have greatly increased the utility of CRISPRa technology in vitro and in vivo, as they permit the bypassing of complicated construct delivery into primary eukaryotic (e.g., human, mouse) cells.

[0339] Deactivated (Dead) Cas Enzymes

[0340] Deactivated Cas enzymes can be used for CRISPR activation (CRISPRa) techniques, in accordance with the present disclosure.

[0341] Deactivated Cas enzymes include variants of Cas proteins that have been engineered to lose their DNA-cleaving activity. This is achieved by introducing mutations in the catalytic domains responsible for cutting DNA. For example, in Cas9, mutations in the RuvC and HNH nuclease domains render the protein catalytically inactive. As a result, dCas enzymes retain their ability to bind to specific DNA sequences, guided by a complementary guide RNA, but cannot introduce DNA strand breaks.

[0342] Cas proteins contemplated for use with the provided disclosure include, but are not limited to, deactivated variants of Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), Casl2, Casl3, CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, CsxlS, Csfl, Csf2, Csf3, Csf4, Casl2a, Casl2a2, Casl2g, Casl 3, Cas 14, CasPhi, spCas9, nCas9, dCas9 and include sequence targeting-functional variants and derivatives thereof.

[0343] An exemplary Cas protein is a Cas9 protein or a protein derived from a Cas9 protein. Cas9 proteins are from a type II CRISPR / Cas system and typically share four key motifs with a conserved architecture. Motifs 1, 2, and 4 are RuvC-like motifs, and motif 3 is an HNH motif Exemplary Cas9 proteins are from Streptococcus pyogenes, Streptococcus therm ophilus, Streptococcus sp.,Staphylococcus aureus, Nocardiopsis dassonvillei, Streptomyces pristinaespiralis, Streptomyces viridochromogenes, Streptomyces viridochromogenes, Streptosporangium roseum, Streptosporangium roseum, Alicyclobacillus acidocaldarius, Bacillus pseudomycoides, Bacillus selenitireducens, Exiguobacterium sibiricum, Lactobacillus delbrueckii, Lactobacillus salivarius, Microscilla marina, Burkholderiales bacterium, Polaromonas naphthalenivorans, Polaromonas sp., Crocosphaera watsonii, Cyanothece sp., Microcystis aeruginosa, Synechococcus sp., Acetohalobium arabaticum, Ammonifex degensii, Caldicelulosiruptor becscii, Candidatus Desulforudis, Clostridium botulinum, Clostridium difficile, Finegoldia magna, Natranaerobius thermophilus, Pelotomaculum thermopropionicum, Acidithiobacillus caldus, Acidithiobacillus ferrooxidans, Allochromatium vinosum, Marinobacter sp., Nitrosococcus halophilus, Nitrosococcus watsoni, Pseudoalteromonas haloplanktis, Ktedonobacter racemifer, Methanohalobium evestigatum, Anabaena variabilis, Nodularia spumigena, Nostoc sp., Arthrospira maxima, Arthrospira platensis, Arthrospira sp., Lyngbya sp., Microcoleus chthonoplastes, Oscillatoria sp., Petrotoga mobilis, Thermosipho africanus, Acaryochloris marina, Neisseria meningitidis, or Campylobacter jejuni. In a preferred embodiment, the dCas protein is a dead S. Pyogenes Cas9 (spCas9).

[0344] Fusion Proteins

[0345] Cas fusion proteins are also contemplated for use with the present disclosure. In particular, suitable Cas fusion proteins include, but are not limited to, those that are transcriptional effectors (e.g., activating domains such as VP64 and VPR). Transcriptional activation domains include regions of a naturally occurring transcription factor which, in conjunction with a DNA-binding domain (e.g., a catalytically inactive Cas protein complexed with a guide RNA), can activate transcription from a promoter by contacting transcriptional machinery either directly or through other proteins such as coactivators. Transcriptional activation domains also include functional fragments or variants of such regions of a transcription factor and engineered transcriptional activation domains that are derived from a native, naturally occurring transcriptional activation domain or that are artificially created or synthesized to activate transcription of a target gene. Afunctional fragment is a fragment that is capable of activating transcription of a target gene when operably linked to a suitable DNA-binding domain. A functional variant is a variant that is capable of activating transcription of a target gene when operably linked to a suitable DNA-binding domain. Exemplary transcriptional activation domains (TADs) include VP16, VP64, VP28, TALE, p65, Rta, AD2, CR3, EKLF1, GATA4, PRVIE, p53, SP1, MYOD, MEF2C, TAX, PPARy, or the like.

[0346] In some embodiments, a dCas enzyme can be fused to a transcriptional activator to enhance the expression of target genes. In some embodiments, a dCas enzyme (e.g., dCas9 or dCasl2a enzyme) is linked to a transcription activation domain, optionally selected from VP64, p65, Rta (Replication and Transcription Activator), VPR (VP64-p65-Rta), SunTag, HSF1 (Heat Shock Factor 1), P300 Core, SAM (Synergistic Activation Mediator), and ET1 (Epstein-Barr Virus EBNA-LP Transactivation Domain).

[0347] Other examples of transcriptional activation domains include herpes simplex virus VP 16 transactivation domain, VP64 (quadruple tandem repeat of the herpes simplex virus VP 16), a NF-KB p65 (NF-KB trans-activating subunit p65) activation domain, a MyoDl transactivation domain, an HSF1 transactivation domain (transactivation domain from human heat-shock factor 1), RTA (Epstein Barr virus R transactivator activation domain), a SETT / 9 transactivation domain, a p53 activation domain 1, a p53 activation domain 2, a CREB (cAMP response element binding protein) activation domain, an E2A activation domain, an NF AT (nuclear factor of activated T-cells) activation domain, and functional fragments and variants thereof. Other examples of transcriptional activation domains include Gcn4, MLL, Rtg3, Gln3, Oafl, Pip2, Pdrl, Pdr3, Pho4, Leu3, and functional fragments and variants thereof. Yet other examples of transcriptional activation domains include Spl, Vax, GATA4, and functional fragments and variants thereof. Other examples include activation domains from Octi, Oct-2A, AP-2, CTF1, P300, CBP, PCAF, SRC1, PvALF, ERF-2, OsGAI, HALF-1, Cl, API, ARF-5, ARF-6, ARF-7, ARF-8, CPRF1, CPRF4, MYC-RP / GP, and TRAB1PC4, and functional fragments and variants thereof.

[0348] Guide RNA

[0349] Guide RNA are also contemplated for use with the present disclosure. A guide RNA is capable of targeting a Cas molecule to a target nucleic acid. As used herein, the term guide RNA refers to a guide ribonucleic acid or a nucleic acid encoding a guide RNA, as dictated by the context of the disclosure. In some embodiments, a guide RNA molecule is non-naturally occurring. In some embodiments, a guide RNA molecule is a synthetic gRNA molecule. In some embodiments, the guide RNA is a single guide RNA or sgRNA. A single guide RNA is a single RNA molecule that combines a custom-designed short crRNA or spacer sequence with a scaffold or backbone tracrRNA sequence for use in connection with a CRISPR-Cas system, such as a CRISPRa system.

[0350] The DNA-targeting segment of a given guide RNA comprises a nucleotide sequence or spacer sequence that is complementary to a sequence on the complementary strand of the target DNA. Inthis manner, the spacer sequence (or guide sequence) can be said to “target” a specific region ( / .<., the region comprising the sequence on the complementary strand) of the target DNA. The DNA-targeting segment of a guide RNA interacts with the target DNA in a sequence-specific manner via hybridization (i.e., base pairing). As such, the nucleotide sequence (also referred to herein as a spacer sequence or a guide sequence) of the DNA-targeting segment may vary and determines the location within the target DNA with which the guide RNA and the target DNA will interact. The DNA-targeting segment of a subject guide RNA can be modified to hybridize to any desired sequence within a target DNA. Scaffolds are portions of a guide RNA (e.g., a tracrRNA or backbone of a sgRNA) that provide binding capability to a Cas protein. In some embodiments, the guide RNA scaffold comprises all the regions of the guide RNA (e.g., 5' hairpin region, intervening region, 3' hairpin, and termination sequence) except for the DNA-targeting region / segment. Thus, in some embodiments (e.g., in a sgRNA), the guide RNA scaffold comprises all the constant regions of the guide RNA.

[0351] The DNA-targeting segment can have, for example, a length of at least about 12, 15, 17, 18, 19, 20, 25, 30, 35, or 40 nucleotides. Such DNA-targeting segments can have, for example, a length from about 12 to about 100, from about 12 to about 80, from about 12 to about 50, from about 12 to about 40, from about 12 to about 30, from about 12 to about 25, or from about 12 to about 20 nucleotides. For example, the DNA targeting segment can be from about 15 to about 25 nucleotides (e.g., from about 17 to about 20 nucleotides, or about 17, 18, 19, or 20 nucleotides). For example, for a Cas9 from S. pyogenes, a typical DNA-targeting segment is between 16 and 20 nucleotides in length or between 17 and 20 nucleotides in length. For Cas9 from S. aureus, a typical DNA-targeting segment is between 21 and 23 nucleotides in length. For Cas 12a, a typical DNA-targeting segment is at least 16 nucleotides in length or at least 18 nucleotides in length.

[0352] In some embodiments, the DNA-targeting segment can be about 20 nucleotides in length. However, shorter and longer sequences can also be used for the targeting segment (e.g., 15-25 nucleotides in length, such as 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length). The degree of identity between the DNA-targeting segment and the corresponding guide RNA target sequence (or degree of complementarity between the DNA-targeting segment and the other strand of the guide RNA target sequence) can be, for example, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%. The DNA-targeting segment and the corresponding guide RNA target sequence can contain one or more mismatches. For example, the DNA-targeting segment of the guide RNA and the correspondingguide RNA target sequence can contain 1-4, 1-3, 1-2, 1, 2, 3, or 4 mismatches (e.g., where the total length of the guide RNA target sequence is at least 17, at least 18, at least 19, or at least 20 or more nucleotides). For example, the DNA-targeting segment of the guide RNA and the corresponding guide RNA target sequence can contain 1-4, 1-3, 1-2, 1, 2, 3, or 4 mismatches where the total length of the guide RNA target sequence 20 nucleotides.

[0353] Single-guide RNAs can comprise a DNA-targeting segment and a scaffold sequence (i.e., the protein-binding or Cas-binding sequence of the guide RNA). For example, such guide RNAs can have a 5' DNA-targeting segment joined to a 3' scaffold sequence.

[0354] Guide RNAs targeting any of the guide RNA target sequences disclosed herein can include, for example, a DNA-targeting segment on the 5' end of the guide RNA fused to a guide RNA scaffold sequence developed for CRISPRa on the 3' end of the guide RNA. That is, any of the DNA-targeting segments disclosed herein can be joined to the 5' end of any CRISPRa scaffold sequences to form a single guide RNA.

[0355] In some guide RNAs (e.g., single guide RNAs), at least one loop (e.g., two loops) of the guide RNA is modified by insertion of a distinct RNA sequence that binds to one or more adaptors (i.e., adaptor proteins or domains). Such adaptor proteins can be used to further recruit one or more heterologous functional domains, such as transcriptional activation domains.

[0356] Target DNAs for guide RNAs include nucleic acid sequences present in a DNA to which a DNA-targeting segment of a gRNA will bind, provided sufficient conditions for binding exist. Suitable DNA / RNA binding conditions include physiological conditions normally present in a cell. The strand of the target DNA that is complementary to and hybridizes with the gRNA can be called the "complementary strand," and the strand of the target DNA that is complementary to the "complementary strand" (and is therefore not complementary to the Cas protein or gRNA) can be called "noncomplementary strand" or "template strand."

[0357] The target DNA includes both the sequence on the complementary strand to which the guide RNA hybridizes and the corresponding sequence on the non-complementary strand (e.g., adjacent to the protospacer adjacent motif (PAM)). For Type II CRISPR / Cas system, the term "guide RNA target sequence" as used herein refers specifically to the sequence on the non-complementary strand corresponding to (i.e., the reverse complement of) the sequence to which the guide RNAhybridizes on the complementary strand. That is, the guide RNA target sequence refers to the sequence on the non- complementary strand adjacent to the PAM (e.g., upstream or 5' of the PAM in the case ofCas9). A guide RNA target sequence is equivalent to the DNA-targeting segment of a guide RNA, but with thymines instead of uracils. As one example, a guide RNA target sequence for an SpCas9 enzyme can refer to the sequence upstream of the 5 -NGG-3' PAM on the non-complementary strand. A guide RNA is designed to have complementarity to the complementary strand of a target DNA, where hybridization between the DNA-targeting segment of the guide RNA and the complementary strand of the target DNA promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided that there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex. If a guide RNA is referred to herein as targeting a guide RNA target sequence, what is meant is that the guide RNA hybridizes to the complementary strand sequence of the target DNA that is the reverse complement of the guide RNA target sequence on the non-complementary strand.

[0358] As described herein, the target sequence is adjacent to the transcription start site (TSS) of a gene (e.g., a target sequence in a promoter region). For example, the target sequence can be within 1000, 900, 800, 700, 600, 500, 400, 300, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, or 1 base pair of the transcription start site, within 1000, 900, 800, 700, 600, 500, 400, 300, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, or 1 base pair upstream of the transcription start site, or within 1000, 900, 800, 700, 600, 500, 400, 300, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, or 1 base pair downstream of the transcription start site. Optionally, the target sequence is within the region 200 base pairs upstream of the transcription start site and 1 base pair downstream of the transcription start site (-200 to +1).

[0359] The target sequence can be within any gene desired to be targeted for transcriptional activation. Targeted genes can include genes expressed in particular organs or tissues, such as the liver or bone marrow. Target genes can include disease-associated genes. A disease-associated gene refers to any gene that yields transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non-disease control. Exemplary target genes can include those encoding secreted proteins, cell surface proteins, and / or membrane proteins in a mammalian cell e.g., genes that increase the transduction efficiency of adeno-associated viral particles).

[0360] An example of a guide RNA target sequence is a 20-nucleotide DNA sequence immediately preceding an NGG motif recognized by an SpCas9 protein.

[0361] CRISPRa guide RNA Libraries

[0362] Aspects of the present disclosure include a CRISPR-mediated transcriptional activation (CRISPRa) guide RNA library comprising a plurality of guide RNAs. In some embodiments, the plurality of guide RNAs comprise single guide RNAs (sgRNAs). Each sgRNA of the plurality of sgRNAs may comprise a spacer sequence which targets a promoter region of a targeted gene, the promoter region comprising a genomic region surrounding a transcriptional start site (TSS) and a backbone or scaffold capable of binding to a dCas fusion protein. The plurality of sgRNAs may comprise 10 or more sgRNA per promoter region such that the plurality of sgRNAs comprise at least 10 sgRNA per targeted gene or about 10-15 sgRNA per targeted gene.

[0363] In some embodiments, at least a subset of the plurality of sgRNAs target two or more promoter regions per targeted gene, such that the plurality of sgRNAs comprise at least 20 sgRNA per targeted gene. In at least some instances it may be preferred to avoid overlap between sgRNA and / or steric hinderance caused by recruitment of CRISPRa systems to multiple locations surround the targeted gene, thus in some embodiments the two or more promoter regions are at least Ikb apart. In some embodiments, at least a subset of the plurality of sgRNAs target three or more promoter regions per targeted gene, four or more promoter regions per targeted gene, five or more promoter regions per targeted gene, six or more promoter regions per targeted gene, or seven or more promoter regions per targeted gene. In some embodiments, the plurality of sgRNAs target an average of four promoter regions per targeted gene.

[0364] In some embodiments, the guide RNA library comprises at least 50,000, at least 100,000, or at least 200,000 sgRNA. In some embodiments, the guide RNA library comprises at least 500 or at least 1000 non-targeting control (NTC) sgRNAs.

[0365] In some embodiments, the spacer sequences of the plurality of sgRNAs provides coverage for a subset of a genome, the subset comprising a plurality of targeted genes. That is, the sgRNAs target a plurality of targeted genes making up a subset of a whole genome of interest ( / .<., less than the entire genome of interest).

[0366] In some embodiments, the spacer sequences of the plurality of sgRNAs provide coverage of a whole genome comprising a plurality of targeted genes. That is, the sgRNAs target a plurality of targeted genes making up an entire genome of interest ( / .<., all coding genes of a species of interest).

[0367] In some embodiments, the plurality of sgRNAs making up the guide RNA library comprises spacer sequences targeting promoter regions of at least 5,000 targeted genes, at least 10,000 targeted genes, at least 15,000 targeted genes, or at least 20,000 targeted genes. In some cases, the majority of the targeted genes are targeted with about 5, about 10, about 20, about 30, about 40, about 50, about 60, or about 70 guide RNAs

[0368] In some embodiments, the plurality of sgRNAs making up the guide RNA library comprises spacer sequences targeting promoter regions of at least 5,000 TSSs, at least 10,000 TSSs, at least 15,000 TSSs, at least 20,000 TSSs, or at least 22,000 TSSs. In some embodiments, each of the TSSs targeted by the plurality of sgRNAs is located -500bp to +500bp of the start of their respective targeted gene. In some embodiments, the promoter region is located -175bp to -50bp of the TSS, -200bp to -25bp of the TSS, -250bp to Obp of the TSS, -300bp to Obp of the TSS, -350bp to Obp of the TSS, or -400bp to Obp of the TSS.

[0369] In some embodiments, the library contains a plurality of sgRNAs, wherein the plurality of sgRNAs comprise binding regions that are designed according to one or more of the following criteria: designed to target a promoter region between, or between about, 0 and about 400 bp upstream of the transcription start site (TSS), or wherein a majority, substantial majority, or at least 90% (e.g., at least 90, 95, or 99%) of the sgRNAs are targeted to a region between, or between about 50 and about 175 bp, about 200 to about 25 bp, 250 to about 0 bp, 300 to about 0 bp, 350 to about 0 bp, or about 400 to about 0 bp upstream of the TSS of a gene; designed to target regions upstream of the TSS as annotated by RefTSS; designed such that no spacer sequence comprises a restriction site for EcoRI or Kpnl; designed such that each sgRNA comprises a GC content of between 20% to 80%; designed such that no spacer sequence comprises a PolyU / T termination signal; designed such that each sgRNA has an MIT score of greater than 0.5, or between 0.25 to 0.5. designed such that each sgRNA has an Azimuth score lower than 0.25. In some embodiments, the backbone comprises a GNE-3 backbone.

[0370] In some cases, the majority of sgRNAs do not contain three or more or four or more repeated nucleotides, or do not contain three or more or four or more repeated U's, A's, G's, C's, or a combination thereof, excluding the 3' transcription termination sequence

[0371] In some embodiments, the plurality of sgRNAs comprises two or more non-overlapping sublibraries which each provide coverage for a subset of the whole genome. In some embodiments, the plurality of sgRNAs comprises three or more non-overlapping sub-libraries which each providecoverage for a subset of the whole genome. In some embodiments, the plurality of sgRNAs comprises four or more non-overlapping sub-libraries which each provide coverage for a subset of the whole genome. In some embodiments, the plurality of sgRNAs comprises five or more nonoverlapping sub-libraries which each provide coverage for a subset of the whole genome.

[0372] In some embodiments, the guide RNA library, (e.g., an sgRNA library) comprises a plurality of guide RNA molecules, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more guide RNA molecules per TSS, including, but not limited, to a genome-scale CRISPR Synergistic Activating Mediator (SAM) library targeting 19,153 genes with 222,225 unique guide sequences for genome-wide transcriptional activation of every gene in the human genome. In some embodiments, the library is designed as one or more sub-libraries, e.g., 5 sub-libraries (also referred to herein as “pools”).

[0373] In some embodiments, the guide RNA library, (e.g., an sgRNA library) comprises a plurality of guide RNA molecules, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more guide RNA molecules per TSS, including, but not limited, to a membrane proteome CRISPR Synergistic Activating Mediator (SAM) library targeting 6,538 genes with 90,483 unique guide sequences for targeted transcriptional activation of human genes encoding cell-surface and secreted proteins. In some embodiments, the library is designed as two sub-libraries (also referred to herein as “pools”).

[0374] CRISPRa Systems

[0375] In some embodiments, provided herein are systems for use with the CRISPRa guide RNA libraries described herein. Such systems may comprise a CRISPRa guide RNA library generated as described herein and a CRISPRa system comprising a dCas fusion protein. In some embodiments, CRISPRa systems comprise a dCas fusion protein comprising a dCas effector protein and one or more transcriptional activation domains (TADs). For example, the wherein the CRISPRa system may be a dCas9-Synergistic Activation Mediator (SAM) system, a dCas9-VPR system, a SunTag system, or a CRISPRa-sel system in some embodiments. It will be understood by a person of ordinary skill in the art that the backbone of the guide RNA of the CRISPRa guide RNA library will be different depending on the CRISPRa system with which it is to be paired.

[0376] CRISPRa systems contemplated for use with the provided disclosure include, but are not limited to, Cas proteins or derivatives thereof with reduced or eliminated nuclease activity fused to adaptor proteins, and guide RNAs as described elsewhere herein to activate transcription of targeted genes. In some embodiments, the methods and compositions disclosed herein employ the CRISPRa systems (e.g., CRISPR SAM complexes) that are stably expressed in the cell lines to

[0377] induce transcriptional activation of a targeted gene transduced using a viral vector such as an AAV virus, adenovirus or lentivirus.

[0378] Library Generation Methods

[0379] Aspects of the disclosure include methods of generating a CRISPRa guide RNA library. In some embodiments, the CRISPRa guide RNA library is a whole genome human CRISPRa guide RNA library. In some embodiments, the CRISPRa guide RNA library is a membrane proteome library targeting genes which encode cell-surface and secreted proteins.

[0380] An exemplary method includes the steps of

[0381] a. identifying protein-coding isoforms for a genome of interest (e.g., a human genome) as targeted genes; and

[0382] b. for each targeted gene identified in step a:

[0383] i. identifying a first transcriptional start site (TSS) of the targeted gene; ii. defining a promoter region of the targeted gene, the promoter region comprising a genomic region surrounding the TSS;

[0384] iii. identifying one or more possible spacer sequences within the promoter region;

[0385] iv. removing spacer sequences containing EcoRI or Kpnl restriction enzyme recognition sites from the possible spacer sequences;

[0386] v. removing spacer sequences comprises a GC content less than 20% or more than 80% from the possible spacer sequences;

[0387] vi. ranking the possible spacer sequences based on Azimuth on-target activity score;

[0388] vii. prioritizing the possible spacer sequences based on location relative to an activation window of -150bp to -75bp of the TSS;

[0389] viii. selecting 10 or more spacer sequences from the possible spacer sequences after completing steps i-vii for the first TSS of the targeted gene; and ix. designing 10 or more sgRNAs for the first TSS of the targeted gene, each sgRNA comprising one of the spacer sequences selected in step viii and a backbone capable of binding to a dCas effector protein.

[0390] Steps i-iii are performed sequentially. Steps iv - vii may be performed in any order. Steps viii and ix may be performed sequentially or simultaneously.

[0391] In some embodiments, the method may further comprise identifying at least a second TSS (e.g, a second, a third, a fourth, a fifth, a sixth, and / or a seventh TSS) of the targeted gene and repeating steps i-xi for the second TSS (and / or third, fourth, fifth, sixth, and seventh TSS) of the targeted gene of step b.

[0392] Delivery Methods

[0393] Methods of the disclosure, in some aspects, initially include delivering a pooled vector library encoding the guide RNAs of the CRISPRa guide RNA library to an initial population of cells, wherein cells of the initial population comprise a CRISPRa system comprising a dCas effector protein and one or more transcriptional activation domains (TADs). In some embodiments, delivering of the vector comprises transducing cells of the population with the pooled vector library such that single cells of the initial population receive a single guide RNA of the CRISPRa guide RNA library. In some embodiments, this means transducing a population of cells large enough to employ about 500 to about 1000 cells per guide RNA of the CRISPR guide RNA library.

[0394] In some embodiments, an initial population of cells is cultured to effect transcriptional activation, thereby producing a population of cells engineered to overexpress proteins driven by promoter regions targeted by the guide RNA of the CRISPRa guide RNA library. Cell culture, in some embodiments, involves various techniques in which cells are grown in an artificial, controlled environment. The artificial, controlled environment generally involves exposing the cells to growth medium and, optionally, various forms of growth factors, antibiotics, or antimycotics, the combination of which is changed periodically by manual or automatic manipulation. Culturing cells in this way allows for normal biological activity to be maintained ex-vivo, thereby mimicking how cells may behave within a living organism. Normal biological activity can include, for example, maintenance of cell proliferation, cell differentiation, signal transduction, and enzymatic activity. In some embodiments this includes overexpression of targeted genes (and resulting proteins) within each cell of the initial population by the CRISPRa system, as guided by the guide RNA of the CRISPRa guide RNA library. This can result in a population of cells (e.g., a cell library) which overexpress the targeted genes of the CRISPRa guide RNA library.

[0395] Delivery Vehicles

[0396] Vectors include delivery vehicles used to introduce an agent (e.g., genetic material) into target cells, for example through transfection or transduction. In some embodiments, a vector is a viral vector (e.g., engineered virus or viral genome). Non-limiting examples of viral vectors includelentiviral vectors, adenoviral vectors, adeno-associated viral (AAV) vectors, retroviral vectors, herpes simplex virus (HSV) vectors, sendai virus (SeV) vectors, and baculovirus vectors.

[0397] A vector, in some aspects, encodes a single sgRNA of a CRISPRa guide RNA library. It should be understood that the phrase “vector encoding” includes a “vector comprising a nucleic acid encoding.”

[0398] An aspect of the present disclosure provides a library of vectors, each vector comprising an sgRNA of the CRISPRa guide RNA library, such that the library of vectors can deliver the sgRNA of the CRISPRa guide RNA library to host cells in order to generate a cell library as described herein.

[0399] In some embodiments, a vector is lentiviral vector. The core components of a lentiviral vector system typically include a transfer vector, packaging plasmid, and envelope plasmid. A transfer vector, referred to herein as a “lentiviral vector,” includes a nucleic acid encoding a sgRNA, which is driven by a promoter, such as U6 or EFla, for example. A lentiviral vector can also contain long terminal repeats (LTRs) at the 5’ and 3’ ends, which are for viral replication and / or integration. Other elements within the lentiviral vector can include a psi (T) packaging signal, which enables RNA genome recognition and incorporation into viral particles, and regulatory elements such as the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) to enhance transgene stability and expression, along with a polyadenylation (polyA) signal for efficient transcription termination. A packaging plasmid encodes the structural and enzymatic components for viral particle assembly and function. This includes, for example, the gag gene, which provides structural proteins such as capsid and matrix proteins; the pol gene, which encodes enzymes such as reverse transcriptase and integrase for genome replication and integration; and, in some embodiments, the rev gene, which facilitates the export of unspliced viral RNA from the nucleus to the cytoplasm. An envelope plasmid provides the viral envelope protein, which determines the vector’s tropism, or cell type specificity. A commonly used envelope protein is vesicular stomatitis virus G (VSV-G), for example. Alternative envelope proteins can also be used. In some embodiments, lentiviral vectors are produced by co-transfecting HEK293 cells (e.g., HEK293T or HEK293F cells), Vero cells, HT1080 cells, or other cells with the plasmid components. The cells package the lentiviral vector RNA into viral particles, which can then be collected for use as described herein.

[0400] In other embodiments, a vector is a non-viral vector. Non-limiting examples of non-viral vectors include plasmid DNA, minicircle DNA, transposons, and artificial chromosomes.

[0401] Incubation and Activation

[0402] Methods of the disclosure, in some aspects, include culturing an initial population of cells to effect CRISPR-mediated transcriptional activation, thereby producing a population of engineered to overexpress proteins driven by promoter regions targeted by the guide RNA of the CRISPRa guide RNA library. In some embodiments, methods herein comprise delivering a pooled vector library to an initial population of cells, each vector of the vector library encoding a different sgRNA of the CRISPRa guide RNA library. An initial population of cells is simply a population of (e.g., two to more) cells (e.g., primary or cell line) into which a vector encoding a sgRNA (or pooled vector library encoding a plurality of sgRNA of a CRISPRa guide RNA library) is delivered (e.g., transfected or transduced). An initial population of cells should not be limited by the number of cells in the population. An initial population of cells (or any population of cells herein) can comprise tens, hundreds, thousands, or millions of cells, or more. For example, a population of cells can comprise 10 to 10,000,000 cells. In some embodiments, a population of cells comprises 10 to 1,000,000; 10 to 100,000; 10 to 10,000; 10 to 1000; 100 to 10,000,000; 100 to 1,000,000; 100 to 100,000; 100 to 10,000; 100 to 1000; 1000 to 10,000,000; 1000 to 1,000,000; 1000 to 100,000; 1000 to 10,000; 10,000 to 10,000,000; 10,000 to 1,000,000; or 10,000 to 100,000 cells. In some embodiments, a population of cells (e.g., an initial population of cells) comprises at least 100, at least 1000, at least 10,000, at least 100,000, at least 1,000,000, or at least 10,000,000 cells.

[0403] In the context of the present disclosure, activation includes upregulation of a targeted gene and overexpression of a protein in a cell. Targeted gene activation using a pooled library of CRISPRa guide RNA can be used to assess gene function in a variety of unique gain-of-function settings in vitro and in vivo. For example, targeted gene induction can be used in passive growth screens to recapitulate phenotypes associated with locus amplification / aneuploidy, resulting in so-called “STOP” and “GO” effects. In another example, targeted gene induction can be used to assess resistance factors to various therapies, such as anti-cancer therapies. In another example, targeted gene induction can be used to uncover oncogenic drivers of cell growth in in vivo mouse models. In another example, targeted gene induction can be used to uncover novel cell-surface receptors mediating AAV uptake.

[0404] Following the cell culture period during which gene activation takes effect, the cells may be used in further methods of use (e.g., incubation with one or more agents or under one or more stress conditions or transplantation into mice or incubation with AAVs) and / or collected for analysis of target protein levels, sgRNA levels, etc.

[0405] Described herein are methods of screening for one or more genetic elements that modulate a phenotype. The method can be performed by contacting a plurality of cells with a library of structurally distinct single guide RNAs (sgRNAs) that target a plurality of targeted genes, such as any of the sgRNA or sgRNA libraries described herein. Contacting the plurality of cells with a plurality of sgRNAs can thereby generate a cell library, each cell of the cell library comprising: an sgRNA and a CRISPRa system comprising a dCas fusion protein, the dCas fusion protein comprising a dCas effector protein and one or more transcriptional activation domains (TADs). The method includes selecting the cells on the basis of the phenotype and quantitating the frequency of the sgRNAs within the population of selected cells. The frequency of sgRNAs in the cells of the cell library, before and / or after exposure to an agent or condition, can be quantitated by next generation sequencing. sgRNAs that target promoter regions that modulate the phenotype can be overrepresented or underrepresented in the selected cells. In some cases, the cells are also contacted with a plurality (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 50, 75, 100, 150, 200, 250, 300, 350, 400, 500, 750, 1000 or more) of control sgRNAs. For example, the control sgRNAs can have binding regions that do not bind to any genomic region or transcript (also referred to herein as NTCs). Alternatively, the control sgRNAs can bind to a genomic region that is known to not produce or affect the phenotype of interest. As yet another alternative the control sgRNAs can affect an alternate control phenotype.

[0406] The phenotype can be cell growth, survival, or proliferation in vitro or in vivo. In some cases, the phenotype is cell growth, survival, or proliferation in vitro in the presence of an agent, such as a cytotoxic agent, an oncogene, a tumor suppressor, a transcription factor, a kinase (e.g., a receptor tyrosine kinase), a gene (e.g., an exogenous gene) under the control of a promoter (e.g., a heterologous promoter), a checkpoint gene or cell cycle regulator, a growth factor, a hormone, a DNA damaging agent, a drug, or a chemotherapeutic. In some cases, the phenotype is cell growth, survival, or proliferation in vivo in a disease model.

[0407] The phenotype can also be protein expression, RNA expression, protein activity, or cell motility, migration, or invasiveness in vitro or in vivo. In some cases, the phenotype is protein expression, RNA expression, protein activity, or cell motility, migration, or invasiveness in vitro in the presence of an agent, such as a cytotoxic agent, an oncogene, a tumor suppressor, a transcription factor, a kinase (e.g., a receptor tyrosine kinase), a gene (e.g., an exogenous gene) under the control of a promoter (e.g., a heterologous promoter), a checkpoint gene or cell cycle regulator, a growth factor, a hormone, a DNA damaging agent, a drug, a chemotherapeutic, or a delivery vehicle (e.g.,AAV). In some cases, the phenotype is protein expression, RNA expression, protein activity, or cell motility, migration, or invasiveness in vivo in a disease model.

[0408] Overrepresentation and underrepresentation can be relative to their frequency in the library that was contacted with the cells, relative to the frequency of the sgRNAs in the cells (or a subpopulation of the cells) prior to selection (or early in the selection period), or relative to a frequency in control cells that are not subject to the selection or subject to an alternative selection. The target genetic elements of such overrepresented or underrepresented sgRNAs can thereby be identified as genetic elements that modulate the phenotype.

[0409] Identifying Tumor-Essential Genes

[0410] Methods of the disclosure, in some aspects, include use of a human CRISPRa guide RNA library, the method comprising: (a) generating a library of cells wherein in each cell a different cell survival or cell proliferation protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of a human CRISPRa guide RNA library generated as described herein into each cell of the library of cells; (b) growing the cells of the library for said cells for a pre-determined amount of time; (c) collecting genomic DNA from the library of cells before growing and after the pre-determined amount of time growing; (d) amplifying and sequencing the genomic DNA at the TSS of each targeted gene from before and after the pre-determined amount of time; and (e) comparing the amount of sgRNA for each targeted gene before and after the predetermined amount of time and determining which TSSs are enriched and which TSSs are depleted, wherein TSS enrichment is indicative of increased cell proliferation and TSS depletion is indicative of increased cell death; thereby identifying which proteins increase cell proliferation or cell death, respectively. In some embodiments, the cells are grown in vitro as described herein. In some embodiments, the cells are human primary cells or human immortalized cells.

[0411] Identifying therapy resistance genes

[0412] Methods of the disclosure, in some aspects, include use of a human CRISPRa guide RNA library, the method comprising: (a) generating a library of cells wherein in each cell a different protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of a human CRISPRa guide RNA library generated as described herein into each cell of the library of cells; (b) growing the cells of the library under pressure from an anti-cancer therapy for a pre-determined amount of time; (c) collecting genomic DNA from the library of cells before growing and after the pre-determined amount of time; (d) amplifying and sequencing the genomic DNA at the TSS ofeach targeted gene from before and after the pre-determined amount of time; and (e) comparing the amount of sgRNA for each targeted gene before and after the pre-determined amount of time and determining which TSSs are enriched, wherein TSS enrichment is indicative of increased resistance to the anti-cancer therapy; thereby identifying which genes promote resistance to the anti-cancer therapy.

[0413] Identifying cancer driving genes

[0414] Methods of the disclosure, in some aspects, include use of a human CRISPRa guide RNA library, the method comprising: (a) generating a library of tumor-generating cells wherein in each cell a different protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of a human CRISPRa guide RNA library generated as described herein into each cell of the library of cells; (b) transplanting the tumor-generating cells into recipient mice; (c) monitoring the recipient mice for tumor development after transplantation for a pre-determined amount of time; (d) collecting genomic DNA from the library of cells before transplanting and after the predetermined amount of time; (e) amplifying and sequencing the genomic DNA at the TSS of each targeted gene from before and after the pre-determined amount of time; and (f) comparing the amount of sgRNA for each targeted gene before and after the pre-determined amount of time and determining which TSSs are enriched, wherein TSS enrichment is indicative of increased tumor growth in the presence of an overexpressed oncogene; thereby identifying oncogenes that promote tumor growth in the tumor-generating cells.

[0415] Identifying Novel AAV Receptors

[0416] Methods of the disclosure, in some aspects, include use of a human CRISPRa guide RNA library, the method comprising: (a) generating a library of cells from a parental cell line, wherein in each cell a different cell membrane or secreted protein is overexpressed, wherein the library of cells is generated by introducing a single sgRNA of a human CRISPRa guide RNA library generated as described herein into each cell of the library of cells; (b) growing the cells of the library and the parental cells, separately, for a pre-determined amount of time; (c) transducing the parental cells with an AAV to determine a parental MOI which results in a pre-determined transduction efficiency; (d) transducing the cells of the library with the AAV at the parental MOI; (e) splitting the cells of the library into an unsorted fraction and a sorted fraction; (f) sorting the sorted fraction to generate an AAV transduced fraction; (f) collecting genomic DNA from the unsorted fraction and the AAV transduced fraction; (g) amplifying and sequencing the genomic DNA at the TSS ofeach targeted gene; and (h) comparing the amount of sgRNA for each targeted gene in the unsorted fraction and the AAV transduced fraction and determining which TSSs are enriched, wherein TSS enrichment is indicative of AAV transduction; thereby identifying which proteins act as AAV receptors and / or helper proteins that enable transduction of cells by the AAV used in the screen. In some embodiments, the cells are grown in vitro as described herein. In some embodiments, the cells are human primary cells or human immortalized cells. In some embodiments, the genes that enhance AAV transduction include DPP4, AAVR, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2Bll

[0417] Compositions

[0418] Also provided herein are compositions comprising a library comprising a plurality of delivery vehicles, each delivery vehicle comprising a nucleic acid encoding a CRISPRa guide RNA (e.g., sgRNA). In some embodiments, a composition comprises a library comprising a plurality of vectors (e.g., lentiviral vectors), each vector encoding a CRISPRa guide RNA (e.g., sgRNA). In some embodiments, the composition comprises multiple vectors (e.g, hundreds or thousands of vectors), each encoding a CRISPRa guide RNA (e.g, sgRNA).

[0419] Further provided herein are cells comprising a vector encoding a CRISPRa guide RNA (e.g., sgRNA), wherein the cell expresses a CRISPRa system comprising a dCas fusion protein, the dCas fusion protein comprising a dCas effector protein and one or more transcriptional activation domains (TADs). In some embodiments, the dCas effector protein is a dCas9.

[0420] Exemplary Identification of Novel AA V Receptors

[0421] Herein is reported a method for the identification of novel cell-surface proteins whose overexpression increases the transduction efficiency of AAV preparations or AAV particles of mammalian cells.

[0422] The method according to the invention encompasses the following general steps:

[0423] - generating a CRISPR guide RNA (gRNA) library, wherein the gRNAs target secreted proteins or cell-surface proteins, i.e. membrane proteins / proteins comprising a transmembrane domain, of a cell, preferably of a mammalian cell, most preferably of endogenous proteins,

[0424] - generating a variant of the cell comprising all elements of a CRISPRa machinery in case a screen for cell-surface proteins that allow at all or increase the transduction efficiency upon their overexpression shall be performed,

[0425] - generating a variant of the cell with Cas9 expression in case a CRISPR-based KO screen shall be performed, i.e. a screen for cell-surface proteins that reduce or abolish the transduction efficiency upon their suppression / knock-out

[0426] - inserting the gRNA library under conditions that only one / a single gRNA is inserted per cell into the respective variant of the cell, e.g. in case the gRNA library is transferred to lentivirus, i.e. as a lentiviral gRNA library, a low MOI is used to have mostly only a single gRNA per cell, i.e. MOI of -0.4-0.5 equivalent to 30% of transduced cells, to generate a cellular library (Figure 1),

[0427] - selecting cells that have received at least one gRNA, this can be achieved, e.g., by cultivation in the presence of a selection agent in case the respective selection marker has been introduced concomitantly with / linked to the gRNA, thereby eliminating cells not comprising a gRNA,

[0428] - splitting the cells,

[0429] - determining with a first aliquot of the parental cells not receiving the lentiviral library the AAV MOI resulting in the transduction of the desired fraction of the selected cells, e.g. in case of an AAV particle of the serotype 9 encapsidating a transgene encoding a fluorescent protein, such as, e.g., mGreenLantern, an MOI of 25000 was determined for obtaining less than 5% of transduced parental cells (see Figure 2); in case of a CRISPR KO screen, the MOI should be determined to achieve a transduction efficiency above 60 %,

[0430] - transducing the cells that have received the lentiviral gRNA library with the same AAV at the determined MOI,

[0431] - in case of a CRISPRa screen, splitting the cells after transduction into a first fraction of unsorted cells and a second fraction of transduced cells, that is, e.g., a second fraction of cells that is subjected to FACS sorting based on the expression of the fluorescent protein (Figure 3),

[0432] - in case of a CRISPR KO screen, splitting the cells after transduction into a first fraction of unsorted cells and a second fraction of non-transduced cells or lowly-transduced cells, that is, e.g., a second fraction of cells that is subjected to FACS sorting based on the expression of the fluorescent protein,

[0433] - amplifying and sequencing the gRNAs in each cell fraction (Figure 3) by PCR, e.g., using primers with sequencing adapters, a barcode in the reverse primer and a stagger in the forward primer,

[0434] - determining the enrichment of gRNAs in the sorted cell population of interest (transduced cells in case of a CRISPRa screen, and non-transduced cells in case of a CRISPR KO screen) over the fraction of unsorted cells containing an even distribution of the original gRNA library to identify the genes targeted by the enriched gRNAs, which encode AAV receptors or helper proteins that enhance the transduction of cells by the AAV used in the screen.

[0435] In more detail, in the example provided herein to show the working of the method according to the current invention, raw fastq files with -500 reads per gRNA were used as input for the MAGeCK algorithm (version = 0.5.9.5) (see, e.g., Li, W., et al., Genom. Biol. 15 (2014) 554) to obtain read counts for all gRNA sequences present in the pooled library in each of the cell fractions. Enrichment and depletion of gRNAs in the transduced cell (CRISPRa screen) was or nontransduced cell (CRISPR KO screen) fractions is calculated relative to the bulk fraction of unsorted cells using the robust rank aggregation (RRA) statistical method from the MAGeCK algorithm (0.5.9.5). Pairwise comparisons of sorted versus unsorted cells in each replicate were performed, and non-targeting gRNAs were used as controls for generating the null distribution of RRA. gRNAs with less than 20 read counts in all samples were excluded from further analyses to increase robustness. False discovery rate (FDR) was used for gRNA-level p-value adjustment. The genelevel log fold changes (LFC) to assess gRNA enrichment were calculated as the mean LFC of gRNAs with an FDR<0.25.

[0436] The entire workflow of a method according to the invention using a CRISPRa screen is schematically shown in Figure 3.

[0437] CRISPRa (CRISPR activation) is an approach employing a modified CRISPR-Cas9 system. With this method it is possible to enhance gene expression without altering the underlying DNA sequence. It uses a catalytically inactive Cas9 protein (dCas9) that is fused to a transcriptional activator, and is guided by a guide RNA (gRNA) to a target sequence, e.g. a transcription start site (TSS). Therefore, this increases the expression of the gene that is driven by the targeted TSS.

[0438] CRISPR KO (CRISPR knockout) is an approach employing the CRISPR-Cas9 system. In this method specific target sites are disrupted and thereby inactivated. It involves the use of single guide RNAs (sgRNAs) to target the coding exons of a given gene to recruit a catalytically active Cas9 protein that generates a double-strand break, and often leads to small insertions or deletions of nucleotides at the target site. This usually disrupts the expression of the targeted gene.

[0439] The current invention is exemplified in the following using HEK293 cells and AAV. This shall not be construed as a limitation but as an exemplification of the working of the current invention. The method according to the current invention is applicable to any cell type that can be transduced with lentiviruses, including stem-cell derived or primary cell types.

[0440] Individual different membrane proteins or receptors were overexpressed in each of the cells of a clonal HEK293 adherent cell line engineered with CRISPR-mediated transcriptional activation (CRISPRa) components. This was achieved by transducing a pooled lentiviral library of gRNAs. Thereafter, these cells were transduced with AAV9-mGreenLantern or AAVrh74-mGreenLantern at a low multiplicity of infection (MOI) that cannot transduce wild-type HEK293 cells. Finally, fluorescence-activated cell sorting (FACS) was performed to separate mGreenLantern positive cells. The gRNAs present in this cell fraction were sequenced, and so were the gRNAs present in a bulk fraction of unsorted cells. Without being bound by this theory, it is assumed that gRNAs that target receptors or proteins that supported internalization of the above AAVs into cells are enriched in the AAV transduced cells (mGreenLantern-positive cells) compared to the bulk cell fraction.

[0441] Computational analysis of the screening results showed a good mapping ratio (>91.5%) in all samples, with a few missed gRNAs (~1% of total gRNA library size) and an even distribution of all gRNAs in bulk samples (Gini index=0.10, with 300-400 reads per gRNA for most gRNAs) (Figures 4A-4D).

[0442] Twenty -five hits were identified with a false discovery rate threshold of less than 0.05 (FDR<0.05). These included two previously published AAV9 receptors (Shay 2024; Pillay 2016), KIAA0319L (AAVR) and DPP4, which showed the working of the method according to the current invention (inherent positive controls), and twenty-four novel proteins enhancing AAV9 transduction were identified (Figure 5):

[0443] DPP4, AAVR, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2Bll.

[0444] The hits were supported by multiple targeting gRNAs that were significantly enriched in transduced (mGreenLantern-positive) cells (Figure 6).

[0445] All 14 top-ranked hits increased in the percentage of AAV9-transduced cells compared to the control construct as shown by overexpressing them individually in HEK293 adherent cells after transient transfection of the most abundant isoform (Figures 7A-7B).

[0446] Overall, the method according to the current invention provides a priori knowledge on putative target and off-target tissues of any AAV capsid with high accuracy, thereby, amongst other things, speeding up AAV capsid selection and engineering.

[0447] In more detail, CRISPR-mediated transcriptional activation (CRISPRa) was used to selectively overexpress different genes, i.e. activate different transcription start sites (TSS). In this screen a gRNA library was used. The library comprised two separate gRNA pools. The first pool encompassed 2079 genes with a total of 2517 TSS with 15 gRNAs per TSS on average. Targeted genes included 400 GPCR genes (458 TSS), 1679 STM genes (2059 TSS) and other genes encoding tyrosine-kinase, cytokine and neuropeptide receptors and adhesion molecules. Moreover, this first pool included 500 non-targeting controls for a total of 37 897 gRNAs. The second pool encompassed 4459 genes and 5336 TSS with on average 10 gRNAs per TSS. Targeted genes encoded 412 GPCRs (608 TSS) and other ion channels, amino acid transporters and olfactory receptors. This second pool included the same 500 non-targeting controls for a total of 53586 gRNAs. Each pool was synthesized separately and cloned under the control of a U6 promoter in a lentiviral vector.

[0448] In the CRISPRa screen underlying the current invention the above outlined libraries comprised multiple different gRNAs which individually induced genes encoding each of 6,538 membrane and secreted proteins. This allowed the unbiased identification of genes and pathways that increased AAV entry. That is, with the method according to the current invention the identification of surface exposed proteins that result in increased transduction of cells became possible, i.e. allowing the identification of target genes whose activation results in increased transduction of cells for those AAV serotypes that could not otherwise transduce those cells.

[0449] An adherent HEK293 cell line was engineered to express the components of a CRISPRa system based on the Synergistic Activation Mediator (SAM) concept (see, e.g., Heidersbach, A. J., et al., (Nat. Commun. 14 (2023) 902; Konermann, S., et al., Nature 517 (2014) 583-588). The SAM system consisted of a catalytically inactive form of Cas9 (dCas9) fused to the transcriptional activator domain VP64 and an MCP-(MS2 coat protein) p65-HSFl co-activator fusion protein (MPH). The transgene encoding MPH-dCas9-VP64 fusion protein under the control of a CAG promoter was stably integrated in the adherent HEK293 cells using a transposition-based system consisting of two plasmids: one encoding a transposon vector carrying the dCas9-VP64-MPH transgene flanked by two inverted / direct repeats IR / DR, and another one encoding a transposase. The transposon and the transposase vectors were co-transfected.

[0450] The adherent HEK293 cells stably expressing the CRISPRa transgene were isolated by single cell sorting (denoted as HEK293 A SAM cells). To assess gene activation potential, the isolated stable cell clones were transiently transfected with SAM-compatible guide RNAs (gRNAs) targeting thepromoter regions of two cell surface receptor genes (PD-L1 and CD2). Flow cytometry analysis showed higher levels of PD-L1 and CD2 in the gRNA condition compared to the non-targeting control providing proof of concept and enabling the selection of the most efficient clone for performing the screens.

[0451] The HEK293A SAM cells were seeded at a density of 5E5 cells per well and transduced with different lentiviral dilutions (1 / 10, 1 / 20, 1 / 30, 1 / 40 and 1 / 50 dilutions). Four days after transfection and following light-fixation of the cells, the fraction of transgene-positive cells was determined by flow cytometry. The percentage of transduced cells was calculated for each lentivirus dilution based on the number of transgene-positive cells 96 hours post transduction. An MOI of -0.4-0.5, equivalent to 30 % of transduced cells, was selected and used to perform the CRISPRa screen.

[0452] The HEK293A SAM cells were seeded at a density of 5E5 cells per well. The cells were transduced with an AAV9 carrying an mGreenLantern transgene at different MOIs. Two days after transduction, mGreenLantern fluorescence was evaluated by FACS and a titration curve was generated by plotting the % of transduced cells at each MOI. The MOI corresponding to the inflection point in the curve was used to perform the CRISPRa screen. Without being bound by this theory, it is assumed that the AAV should be used at an MOI at which cells were not transduced, i.e. <5 % transduced cells, but primed to be highly transduced with small changes in MOI or in receptor / co-receptor overexpression.

[0453] With the cells as described above and the conditions as described above, a pooled CRISPRa screen was performed. A 500x coverage of the gRNA library, which equals to 500 cells per gRNA in the library, was set. Therefore, 153 million HEK293A SAM cells were transduced with the lentiviral gRNA library at an MOI of -0.4-0.5, so that only 30 % of cells were infected. Without being bound by this theory, it is assumed that thereby the risk of having more than one gene activated in each cell is minimized. Therefore, the corresponding amount of virus was added to the cells in suspension, and then cells were seeded in cultivation dishes. Non-transduced cells were seeded at the same density in an extra dish for selection control. Fresh medium containing the selection agent was added 48 hours post transduction. Selection medium was renewed every 2 days. Eight days after transduction and six days after the start of selection, all cells were detached and re-seeded to maintain the 500x coverage for the library. Once the seeded cells were attached, AAV9 (mGreenLantern transgene) was added at an MOI of 25 000. Fluorescence-activated cell sorting (FACS) was performed 48 hours after transduction with AAV9-mGreenLantern and ten days after transduction with the lentiviral gRNA library, when all cells in the non-transduced control were dead. A fraction of the cells was separated as bulk control. The rest of cells were sorted according to their mGreenLantern fluorescence. About 11 % mGreenLantern-positive cells with highest

[0454] fluorescence intensity and about 11 % mGreenLantern-negative cells with lowest intensity were purified. The results are shown in Figures 8A-8C.

[0455] Sorted cells were pelleted and genomic DNA was extracted. gRNAs from bulk and sorted cell fractions were amplified using forward staggered primers and barcoded reverse primers with sequencing adapters. A PCR was performed and PCR products were purified. All samples were quantified, pooled to get even numbers of reads for all samples (-500 reads per gRNA in the library per sample) and sequenced.

[0456] Raw fastq files were mapped to the gRNA sequences in the CRISPRa library and gRNA read counts were normalized to the total number of reads. Enrichment and depletion of gRNAs in mGreenLantern-positive (transduced) cells compared to the bulk cell fraction was calculated. gRNAs with less than 20 read counts in all samples were excluded from further analyses to increase robustness. Log fold changes (LFC) of gRNA abundance at the gene level were calculated as the median LFC of gRNAs with an FDR <0.25. Results were plotted. Genes that were positively enriched in mGreenLantern-positive cells with an FDR<0.05 were defined as hits and selected for validations. With the method as outlined before, twenty-five hits were identified with a false discovery rate threshold of less than 0.10 (FDR<0.10). These included two previously published AAV9 receptors (Shay 2024; Pillay 2016), KIAA0319L (AAVR) and DPP4, which showed the working of the method according to the current invention (inherent positive controls), and twenty-four novel proteins enhancing AAV9 transduction were identified (Figure 5):

[0457] DPP4, AAVR, LPAR5, STIMATE, ITGB5, BRS3, IGF2R, FUT1, CH25H, SLC9A7, TMPRSS2, SUCO, PUM1, HTR4, KDELR3, CCR10, DNAJC13, SLC5A8, ADRA1A, SLC7A5, C19orf38, SLC10A1, CYB5D2, SLC7A11 and UGT2Bll.

[0458] AAVR, also known as KIAA0319L, has been reported as the primary adeno-associated virus receptor in mammalian cells. AAVR is a type I transmembrane protein. AAVR is crucial for AAV infection and binding, making it a key host factor for various AAV serotypes. Specific domains within AAVR, particularly PKD2 and PKD1, interact with the AAV capsid. It has the amino acid sequence denoted in SEQ ID NO: 1.

[0459] DPP4 is a multifunctional cell surface glycoprotein and serine exopeptidase expressed on many cell types, with both membrane-bound and soluble forms. It cleaves dipeptides from the N-terminus of peptides, particularly those with proline or alanine, regulating the activity of hormones, chemokines, and neuropeptides. DPP4 plays a crucial role in glucose metabolism by degrading incretins such as GLP-1. Beyond its enzymatic function, DPP4 is involved in immune regulation, T-cell activation, signal transduction, and has roles in inflammation, cancer, and viral entry. It has the amino acid sequence denoted in SEQ ID NO: 2.

[0460] HTR4 is a G protein-coupled receptor for serotonin, expressed in both the central and peripheral nervous systems. It stimulates cAMP production in response to serotonin, modulating the release of various neurotransmitters and hormones. It has the amino acid sequence denoted in SEQ ID NO: 3.

[0461] PUM1 is an RNA-binding protein that regulates the stability and translation of specific mRNAs. It acts as a negative regulator of innate immunity genes by repressing the expression of LGP2 and other immune-related transcripts, thus modulating immune responses and antiviral defense mechanisms. It has the amino acid sequence denoted in SEQ ID NO: 4.

[0462] SUCO is a protein-coding gene with limited functional characterization in the literature and major databases. Current knowledge suggests it may be involved in ossification and bone development, but its precise molecular function remains to be fully elucidated. It has the amino acid sequence denoted in SEQ ID NO: 5.

[0463] TMPRSS2 is a serine protease expressed in various tissues, most notably the prostate. It is best known for its role in viral entry, including SARS-CoV-2, by cleaving and activating viral spike proteins. It has the amino acid sequence denoted in SEQ ID NO: 6.

[0464] SLC9A7 encodes a sodium / potassium-proton antiporter of the solute carrier family 9. It is involved in maintaining pH homeostasis within intracellular organelles, particularly the Golgi apparatus, and plays a role in vesicular trafficking and cellular ion balance. It has the amino acid sequence denoted in SEQ ID NO: 7.

[0465] CH25H is an interferon-stimulated gene encoding an ER-associated enzyme that converts cholesterol to 25-hydroxycholesterol (25-HC). 25-HC regulates cholesterol biosynthesis, modulates immune responses, and exhibits antiviral activity by influencing lipid metabolism and inflammatory signaling. It has the amino acid sequence denoted in SEQ ID NO: 8.

[0466] FUT1 is a glycosyltransferase that catalyzes the addition of fucose to glycoproteins and glycolipids, essential for the synthesis of blood group antigens and cell surface glycan structures. It plays a role in cell-cell recognition, signaling, and immune response. It has the amino acid sequence denoted in SEQ ID NO: 9.

[0467] IGF2R, also known as the cation-independent mannose-6-phosphate receptor, binds IGF2 at the cell surface and M6P -tagged proteins in the Golgi. It regulates IGF2 signaling by clearing it from the cell surface and mediates lysosomal enzyme trafficking, thus influencing growth, development, and lysosomal function. It has the amino acid sequence denoted in SEQ ID NO: 10.

[0468] BRS3 is an orphan G protein-coupled receptor in the bombesin receptor family. It is expressed in the central nervous system and gastrointestinal tract, where it modulates smooth muscle contraction, metabolism, and behavior, but its natural ligand remains unidentified. It has the amino acid sequence denoted in SEQ ID NO: 11.

[0469] ITGB5 encodes a beta subunit of integrin receptors involved in cell adhesion, migration, and signaling. It contributes to extracellular matrix organization, angiogenesis, and cancer progression, notably promoting colorectal cancer development via the Wnt / p-catenin pathway and influencing immune cell infiltration. It has the amino acid sequence denoted in SEQ ID NO: 12.

[0470] STIMATE is an ER-resident multi-transmembrane protein that interacts with STIM1 to facilitate its conformational switch, promoting store-operated calcium entry at ER-plasma membrane junctions. It is essential for proper calcium signaling and downstream NF AT activation. It has the amino acid sequence denoted in SEQ ID NO: 13.

[0471] DNAJC13 is an endosome-associated protein involved in endosomal membrane trafficking, recycling, and cargo sorting. It has the amino acid sequence denoted in SEQ ID NO: 14.

[0472] SLC5A8 is a sodium-coupled transporter for monocarboxylates such as short-chain fatty acids and nicotinate. It has the amino acid sequence denoted in SEQ ID NO: 15.

[0473] LPAR5 is a G protein-coupled receptor for lysophosphatidic acid, mediating diverse cellular responses including cell proliferation, migration, and survival, among others. It has the amino acid sequence denoted in SEQ ID NO: 16.

[0474] SLC7A11 encodes the light chain of the system Xc-antiporter, which imports extracellular cystine in exchange for intracellular glutamate. This transport is vital for maintaining intracellular cysteine levels and glutathione synthesis, protecting cells from oxidative stress and ferroptosis. This protein has been identified as the predominant mediator of Kaposi sarcoma-associated herpesvirus fusion and entry permissiveness into cells. It has the amino acid sequence denoted in SEQ ID NO: 17.

[0475] Thus, the method according to the current invention can identify cell-surface proteins functioning as receptors, i.e. transduction enhancers, of AAV particles with unprecedented sensitivity.

[0476] With the cell-surface proteins identified by the method according to the current invention, cells that are not susceptible to AAV transduction can be made AAV responsive. Thereby the availability of cells for AAV transduction assays, such as potency assays, can be expanded.

[0477] For example, HEK cells can be transduced by AAV particles depending on the respective capsid, i.e. AAV particles with a capsid of the serotype or with an artificially made capsid as

[0478] AAV2HBKO, AAV-PHP B, AAVpo.l, AAV7, AAV8BP2, AAV2-ESGHGYF, AAV-PHP eB, AAV12, AAVrh.10 and many AAV9-based engineered capsids do not efficiently transduce HEK cells. Without being bound by this theory, it is assumed that HEK cells overexpressing a cellsurface or soluble protein identified with the method according to the current invention become amenable to transduction by the before non-transducing AAV particles and, thus, are thereafter amenable to be used in AAV transduction assays. Thereby the applicability of cells in AAV transduction assays is profoundly expanded.

[0479] With the method as outlined above, fifty-six hits were identified with a false discovery rate threshold of less than 0.10 (FDR<0.10). These constitute the first identified receptors for AAVrh74, and included some of the previously identified AAV9 receptors (Shay 2024; Pillay 2016), KIAA0319L (AAVR) and DPP4, along with other twelve shared receptors across both capsids. In addition, we identified forty-two novel receptors for AAVrh74 that were not shared with AAV9 (Figure 6 and Figure 11).

[0480] SLC10A1, also known as NTCP, is a sodium / bile acid cotransporter responsible for the cellular uptake of bile acids in the liver. Beyond its role in enterohepatic circulation and metabolic regulation, it functions as the primary cellular entry receptor for the hepatitis B and D viruses. It has the amino acid sequence denoted in SEQ ID NO: 18.

[0481] TMEM263 is a multi-pass transmembrane protein localized to cellular membranes. While its functional characterization is still emerging, recent evidence implicates it in the regulation of skeletal biology, bone mass, and systemic body weight homeostasis. It has the amino acid sequence denoted in SEQ ID NO: 19.

[0482] HTR2 is a G protein-coupled receptor for serotonin, heavily involved in central nervous system signaling. It modulates a wide variety of physiological and behavioral processes, including mood, appetite, and smooth muscle contraction, by signaling primarily through the phosphoinositide hydrolysis pathway. It has the amino acid sequence denoted in SEQ ID NO: 20.

[0483] SLC7A5, also known as LAT1, encodes a sodium-independent, high-affinity transmembrane transporter that mediates the uptake of large neutral amino acids. It is vital for cellular metabolism, particularly in rapidly dividing cells, and is essential for the transport of amino acids across the blood-brain barrier. It has the amino acid sequence denoted in SEQ ID NO: 21.

[0484] KDELR3 is an endoplasmic reticulum protein retention receptor. It retrieves proteins bearing the KDEL targeting motif from the Golgi apparatus and returns them to the ER, ensuring proper vesicular trafficking, protein localization, and secretory pathway homeostasis. It has the amino acid sequence denoted in SEQ ID NO: 22.

[0485] HTR6 is a G protein-coupled receptor for serotonin found almost exclusively in the central nervous system. It positively couples to adenylyl cyclase to stimulate cAMP production and heavily influences learning, memory, and cognitive function by modulating cholinergic and glutamatergic neurotransmission. It has the amino acid sequence denoted in SEQ ID NO: 23.

[0486] UGT3A1 is an enzyme of the UDP-glucuronosyltransferase family. It catalyzes the transfer of sugar residues to endogenous compounds and xenobiotics, facilitating their phase II metabolism, increasing their water solubility, and aiding in their subsequent bodily clearance. It has the amino acid sequence denoted in SEQ ID NO: 24.

[0487] TP53 encodes the tumor suppressor protein p53, a critical transcription factor that regulates the cell cycle, DNA repair, and apoptosis. It acts as a major cellular stress sensor, preventing the propagation of cells with unstable or damaged genomes. It has the amino acid sequence denoted in SEQ ID NO: 25.

[0488] ZC3HAV1, also known as zinc finger CCCH-type antiviral protein 1 (ZAP), is an antiviral host factor. It restricts viral infection by binding to specific CpG-rich viral transcripts and recruiting the RNA exosome complex to mediate their rapid degradation. It has the amino acid sequence denoted in SEQ ID NO: 26.

[0489] AD MIO is a disintegrin and metalloproteinase that acts as a membrane-anchored sheddase. It cleaves the extracellular domains of various cell surface proteins, including amyloid precursor protein and Notch, serving as a critical regulator of diverse developmental and neurological signaling pathways. It has the amino acid sequence denoted in SEQ ID NO: 27.

[0490] SUCO is a SUN domain-containing protein with emerging roles in skeletal biology. Current knowledge suggests it functions in the regulation of ossification and proper bone development, although its precise molecular mechanisms remain the subject of ongoing study. It has the amino acid sequence denoted in SEQ ID NO: 5.

[0491] SLC7A11 encodes the light chain of the system Xc- antiporter, which imports extracellular cystine in exchange for intracellular glutamate. This transport mechanism is vital for maintaining intracellular glutathione synthesis, protecting cells from oxidative stress, and preventing ferroptosis. It has the amino acid sequence denoted in SEQ ID NO: 17.

[0492] KIR3DL3 is a member of the killer cell immunoglobulin-like receptor family. It is expressed on natural killer cells and specific subsets of T cells, where it functions as an inhibitory receptor to regulate immune responses, cytotoxicity, and self-tolerance. It has the amino acid sequence denoted in SEQ ID NO: 28.

[0493] RABAC1, also known as PRA1, is a Rab acceptor protein prominently involved in vesicular trafficking. It participates in the docking and fusion of transport vesicles with their target membranes, facilitating communication between the Golgi network and the plasma membrane. It has the amino acid sequence denoted in SEQ ID NO: 29.

[0494] SLC2 A3 encodes a high-affinity facilitative glucose transporter, commonly known as GLUT3. It serves as the primary glucose transporter in neurons, ensuring an adequate and rapid energy supply to the brain under varying physiological conditions. It has the amino acid sequence denoted in SEQ ID NO: 30.

[0495] DNAJC13 is an endosome-associated protein involved in clathrin-mediated endocytosis. It regulates endosomal membrane trafficking, recycling, and cargo sorting, thereby assisting in the proper routing of internalized membrane receptors. It has the amino acid sequence denoted in SEQ ID NO: 14.

[0496] TNC encodes tenascin C, a large extracellular matrix glycoprotein. It is expressed heavily during embryogenesis, active tissue remodeling, wound healing, and tumorigenesis, where it interacts with integrins to regulate cell adhesion and migration. It has the amino acid sequence denoted in SEQ ID NO: 31.

[0497] CYB5D2 is a cytochrome b5 domain-containing protein implicated in heme binding. It plays a role in cellular survival pathways, promoting cell differentiation and offering protection against various apoptotic stimuli. It has the amino acid sequence denoted in SEQ ID NO: 32.

[0498] HTR7 is a G protein-coupled receptor for serotonin that stimulates cAMP production. It is expressed in various regions of the brain and peripheral tissues, playing a prominent role in the regulation of circadian rhythms, sleep-wake cycles, and mood. It has the amino acid sequence denoted in SEQ ID NO: 33.

[0499] LPAR5 is a G protein-coupled receptor for the bioactive lipid lysophosphatidic acid. It mediates diverse cellular responses, including profound alterations in the actin cytoskeleton, sensory nerve signaling, and immune cell migration. It has the amino acid sequence denoted in SEQ ID NO: 16.

[0500] STIMATE is an endoplasmic reticulum-resident transmembrane protein that interacts closely with STIM1. It facilitates the conformational switch of STIM1, thus promoting store-operated calcium entry at ER-plasma membrane junctions to maintain cellular calcium homeostasis. It has the amino acid sequence denoted in SEQ ID NO: 34.

[0501] FDCSP encodes the follicular dendritic cell secreted protein, a small secreted factor found predominantly in lymphoid tissues. It binds to B cells and plays an important immunomodulatoryrole in humoral immune responses and B cell activation. It has the amino acid sequence denoted in SEQ ID NO: 35.

[0502] DLK1 is a transmembrane protein of the epidermal growth factor-like family that acts as a non-canonical Notch ligand. It acts as an important regulator of cellular differentiation processes, most notably inhibiting adipogenesis. It has the amino acid sequence denoted in SEQ ID NO: 36.

[0503] GRM8 encodes a group III metabotropic glutamate receptor that operates primarily as an inhibitory presynaptic autoreceptor in the central nervous system. It suppresses neurotransmitter release by inhibiting adenylyl cyclase activity, thus regulating synaptic plasticity. It has the amino acid sequence denoted in SEQ ID NO: 37.

[0504] P2RY1 is a G protein-coupled receptor that binds extracellular ADP. It plays a central role in mediating platelet activation, shape change, and aggregation, functioning as a critical regulator of blood coagulation and thrombosis. It has the amino acid sequence denoted in SEQ ID NO: 38.

[0505] CCR10 is a G protein-coupled chemokine receptor that binds to the chemokines CCL27 and CCL28. It plays an essential role in the homing, migration, and survival of distinct T cell subsets to the skin and mucosal tissues. It has the amino acid sequence denoted in SEQ ID NO: 39.

[0506] YIF1B is a multi-pass membrane protein localized primarily to the endoplasmic reticulum and Golgi apparatus. It functions in intracellular vesicular trafficking, assisting in the forward transport and membrane targeting of specific cargo, including certain serotonin receptors. It has the amino acid sequence denoted in SEQ ID NO: 40.

[0507] KIAA0319L, also known as AAVR, is a type I transmembrane protein heavily recognized as the primary cellular receptor for multiple adeno-associated virus (AAV) serotypes. It mediates critical binding and entry processes, effectively facilitating viral transduction in host cells. It has the amino acid sequence denoted in SEQ ID NO: 1.

[0508] TMPRSS2 is a transmembrane serine protease expressed heavily in various epithelial tissues. It is widely known for its role in viral pathogenesis, particularly by cleaving and activating viral fusion glycoproteins, including the SARS-CoV-2 spike protein. It has the amino acid sequence denoted in SEQ ID NO: 6.

[0509] ITGB5 encodes a beta subunit of integrin receptors involved in cell adhesion and signaling. It interacts with the extracellular matrix to influence cellular migration, angiogenesis, and tumor progression, often signaling via focal adhesion pathways. It has the amino acid sequence denoted in SEQ ID NO: 12.

[0510] CELA3B is a chymotrypsin-like elastase functioning as a digestive serine protease. It is secreted by the pancreas to break down elastin and other structural proteins in the intestinal tract, ensuring proper nutrient digestion. It has the amino acid sequence denoted in SEQ ID NO: 41.

[0511] KCNIP3, also known as DREAM, is a multifaceted calcium-binding protein. It acts as an auxiliary subunit for voltage-gated potassium channels, functions as a transcriptional repressor, and regulates intracellular calcium signaling and neuronal pain sensation. It has the amino acid sequence denoted in SEQ ID NO: 42.

[0512] B3GNT5 is a glycosyltransferase located in the Golgi apparatus. It is involved in the biosynthesis of lacto- and neolacto-series glycosphingolipids, playing a crucial role in the formation of specific, biologically active cell surface glycan structures. It has the amino acid sequence denoted in SEQ ID NO: 43.

[0513] TMEM135 is a multi-pass transmembrane protein implicated in the regulation of mitochondrial dynamics. It participates in stress-induced mitochondrial fission, helping to maintain cellular metabolic homeostasis and protecting cells from structural damage. It has the amino acid sequence denoted in SEQ ID NO: 44.

[0514] MS4A8 is a member of the membrane-spanning 4-domains subfamily A, a group of structurally related cell surface proteins. While its exact molecular targets are not entirely mapped, it is implicated in immune cell regulation and downstream signal transduction processes. It has the amino acid sequence denoted in SEQ ID NO: 45.

[0515] TMEM253 is a transmembrane protein with limited functional characterization in current major databases. Structurally classified as a multi-pass membrane protein, its specific physiological roles and integration into defined metabolic pathways remain the subject of ongoing investigation. It has the amino acid sequence denoted in SEQ ID NO: 46.

[0516] TMEM72 is a relatively uncharacterized multi-pass transmembrane protein predominantly expressed in kidney tissue. Its exact molecular functions, transport capabilities, and signaling interactions remain largely elusive in the current literature. It has the amino acid sequence denoted in SEQ ID NO: 47.

[0517] GPR156 is an orphan G protein-coupled receptor belonging to the class C group. Structurally related to metabotropic glutamate and GABA-B receptors, it is implicated in central nervous system signal transduction, although its specific physiological ligand is uncharacterized. It has the amino acid sequence denoted in SEQ ID NO: 48.

[0518] LPAR4 is a G protein-coupled receptor for lysophosphatidic acid. It mediates diverse cellular responses, frequently linked to structural alterations in the actin cytoskeleton, cellular adhesion, and neurite retraction through multiple G-protein signaling cascades. It has the amino acid sequence denoted in SEQ ID NO: 49.

[0519] GPR12 is an orphan G protein-coupled receptor heavily expressed in the brain. It positively influences neurite outgrowth, neuronal development, and cellular survival pathways, exhibiting a high level of constitutive activity in the absence of a known ligand. It has the amino acid sequence denoted in SEQ ID NO: 50.

[0520] HTR2A is a widely expressed G protein-coupled receptor for serotonin that signals primarily through the phosphoinositide hydrolysis pathway. It mediates broad cognitive functions, mood regulation, perception, and learning. It has the amino acid sequence denoted in SEQ ID NO: 51.

[0521] SPRY1 is a member of the sprouty family of proteins that functions as a critical antagonist of receptor tyrosine kinase signaling pathways. It provides negative feedback regulation for cellular growth, differentiation, and branching morphogenesis. It has the amino acid sequence denoted in SEQ ID NO: 52.

[0522] SLC5A8 is a sodium-coupled cotransporter for short-chain fatty acids such as butyrate, pyruvate, and lactate. It plays important roles in colonocyte energy metabolism and functions physiologically as a tumor suppressor. It has the amino acid sequence denoted in SEQ ID NO: 15.

[0523] PCDHGA5 belongs to the protocadherin gamma gene cluster, encoding a neural cell adhesion molecule. It is critical for establishing and maintaining specific synaptic connections within the central nervous system, playing a role in neuronal network formation. It has the amino acid sequence denoted in SEQ ID NO: 53.

[0524] STEAP3 is a multipass membrane protein functioning as an endosomal ferrireductase. It is essential for cellular iron homeostasis, facilitating the reduction of iron(III) to iron(II) required for efficient transport across the endosomal membrane into the cytoplasm. It has the amino acid sequence denoted in SEQ ID NO: 54.

[0525] IGF2R, also known as the cation-independent mannose-6-phosphate receptor, binds insulin-like growth factor 2 at the cell surface to regulate growth signaling. Concurrently, it binds M6P -tagged proteins in the Golgi, mediating essential lysosomal enzyme trafficking. It has the amino acid sequence denoted in SEQ ID NO: 10.

[0526] KCNJ9, commonly known as GIRK3, encodes a G protein-activated inward rectifier potassium channel. It helps regulate resting membrane potential and modulates neuronal excitability bycontributing to slow inhibitory postsynaptic potentials. It has the amino acid sequence denoted in SEQ ID NO: 55.

[0527] DEFB126 is a member of the beta-defensin family of antimicrobial peptides. It is highly expressed in the epididymis, where it coats sperm cells to facilitate their movement through cervical mucus and protect them from female immune surveillance. It has the amino acid sequence denoted in SEQ ID NO: 56.

[0528] C19orf38 is an uncharacterized transmembrane protein. It exhibits poorly defined biological pathways and limited functional annotation in current major scientific literature, though its sequence suggests membrane-associated functions. It has the amino acid sequence denoted in SEQ ID NO: 57.

[0529] BICD1 is an adaptor protein that associates with the dynein-dynactin motor complex. It is essential for governing the intracellular, microtubule-based trafficking of various cargo, playing critical roles in nervous system development and vesicle localization. It has the amino acid sequence denoted in SEQ ID NO: 58.

[0530] MFSD14B is a transmembrane protein belonging to the major facilitator superfamily. It acts as a putative solute carrier predicted to transport specific, though currently uncharacterized, substrates across cellular membranes. It has the amino acid sequence denoted in SEQ ID NO: 59.

[0531] DPP4 is a multifunctional cell surface glycoprotein and serine exopeptidase. It regulates glucose metabolism by degrading incretins, and beyond its enzymatic function, participates in immune regulation, T-cell activation, and functions as an entry receptor for certain coronaviruses. It has the amino acid sequence denoted in SEQ ID NO: 2.

[0532] ADRA1A is an alpha-1 adrenergic receptor and G protein-coupled receptor that mediates the physiological action of catecholamines. It signals through the phosphoinositide pathway, primarily leading to smooth muscle contraction and cardiovascular regulation. It has the amino acid sequence denoted in SEQ ID NO: 60.

[0533] CALCR encodes the calcitonin receptor, a G protein-coupled receptor that binds the peptide hormone calcitonin. It plays a foundational role in maintaining calcium homeostasis by regulating bone resorption and influencing osteoclast activity. It has the amino acid sequence denoted in SEQ ID NO: 61.

[0534] PUM1 is an RNA-binding protein that binds to specific sequence motifs in the 3 '-untranslated regions of target mRNAs. It functions primarily as a repressor of translation and mRNA stability,playing secondary roles as an innate immune regulator. It has the amino acid sequence denoted in SEQ ID NO: 4.

[0535] S1PR2 is a G protein-coupled receptor for the bioactive lipid sphingosine- 1 -phosphate. It mediates various cellular responses, including alterations in cell proliferation, survival, migration, and endothelial barrier integrity within the cardiovascular and immune systems. It has the amino acid sequence denoted in SEQ ID NO: 62.

[0536] CH25H encodes an endoplasmic reticulum-associated enzyme that converts cholesterol to 25-hydroxy cholesterol. This product operates as a critical regulator of lipid metabolism and functions as an interferon-stimulated antiviral factor that inhibits viral entry. It has the amino acid sequence denoted in SEQ ID NO: 8.

[0537] SLC9A7 encodes a sodium / potassium-proton antiporter of the solute carrier family 9. It is vital for maintaining proper pH homeostasis within the trans-Golgi network, thus balancing cellular vesicular trafficking and post-translational modifications. It has the amino acid sequence denoted in SEQ ID NO: 7.

[0538] ZBTB33 also known as Kaiso, is a zinc finger-containing transcription factor. It binds to methylated DNA sequences to repress transcription, acting as a critical link between DNA methylation and epigenetic gene silencing. It has the amino acid sequence denoted in SEQ ID NO:

[0539] 63.

[0540] MUC21 is a heavily glycosylated, membrane-bound mucin found predominantly on the apical surfaces of epithelial cells. It offers structural protection to the epithelial barrier and dynamically influences cell-cell adhesion and signaling. It has the amino acid sequence denoted in SEQ ID NO:

[0541] 64.

[0542] HTR4 is a G protein-coupled receptor for serotonin that stimulates cAMP production. It modulates the release of various neurotransmitters in both the central and peripheral nervous systems, heavily influencing gastrointestinal motility. It has the amino acid sequence denoted in SEQ ID NO: 3.

[0543] BRS3 is an orphan G protein-coupled receptor of the bombesin receptor family. It is expressed in the central nervous system and gastrointestinal tract, where it modulates energy metabolism, body weight homeostasis, and smooth muscle dynamics. It has the amino acid sequence denoted in SEQ ID NO: 11.

[0544] UGT2B11 is a UDP-glucuronosyltransferase localizing to the endoplasmic reticulum. It functions in the phase II metabolic clearance of xenobiotics and endogenous steroids by transferring

[0545] glucuronic acid to increase substrate water solubility. It has the amino acid sequence denoted in SEQ ID NO: 65.

[0546] FUT1 is a glycosyltransferase responsible for catalyzing the addition of fucose to glycoproteins and glycolipids. This enzymatic step is vital for the synthesis of H blood group antigens and specific cellular recognition pathways. It has the amino acid sequence denoted in SEQ ID NO: 9.

[0547] CRB2 is a member of the Crumbs family of transmembrane proteins. It plays an important role in establishing and maintaining apical-basal cell polarity in epithelial tissues, and is critical for the proper morphogenesis of retinal photoreceptors. It has the amino acid sequence denoted in SEQ ID NO: 66.

[0548] GRM2 encodes a group II metabotropic glutamate receptor that acts primarily as an inhibitory presynaptic receptor. It suppresses synaptic transmission by negatively regulating adenylyl cyclase activity, thereby preventing excessive neurotransmitter release. It has the amino acid sequence denoted in SEQ ID NO: 67.

[0549] NAXD encodes an epimerase involved in fundamental metabolite repair. It specifically dehydrates and epimerizes aberrant NAD(P)H hydrates, preventing the accumulation of toxic metabolic byproducts that can impair cellular function. It has the amino acid sequence denoted in SEQ ID NO: 68.

[0550] All publications, patents, and patent applications cited herein are hereby incorporated by reference herein in their entirety for all purposes to the same extent as if each individual publication, patent, and patent application were specifically and individually indicated to be so incorporated by reference. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

[0551] The following examples and figures as well as the sequences are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

[0552] That is, although the disclosed teachings have been described with reference to various applications, methods, and compositions, it will be appreciated that various changes and

[0553] modifications can be made without departing from the teachings herein and the claimed invention below. The examples are provided to better illustrate the disclosed teachings and are not intended to limit the scope of the teachings presented herein. While the present teachings have been described in terms of these exemplary embodiments, the skilled artisan will readily understand that numerous variations and modifications of these exemplary embodiments are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.

[0554] -n -

[0555] Description of the Sequences

[0556] SEQ ID NO: 1 amino acid sequence of AAVR / KIAA0319L

[0557] MEKRLGVKPNPASWILSGYYWQTSAKWLRSLYLFYTCFCFSVLWLSTDASESRCQQGKTQFGVGLRSGGENHLWLLE GTPSLQSCWAACCQDSACHVFWWLEGMCIQADCSRPQSCRAFRTHSSNSMLVFLKKFQTADDLGFLPEDDVPHLLGL GWNWASWRQSPPRAALRPAVSSSDQQSLIRKLQKRGSPSDWTPIVTQHSKVNDSNELGGLTTSGSAEVHKAITISS PLTTDLTAELSGGPKNVSVQPEISEGLATTPSTQQVKSSEKTQIAVPQPVAPSYSYATPTPQASFQSTSAPYPVIKE LWSAGESVQITLPKNEVQLNAYVLQEPPKGETYTYDWQLITHPRDYSGEMEGKHSQILKLSKLTPGLYEFKVIVEG QNAHGEGYVNVTVKPEPRKNRPPIAIVSPQFQEISLPTTSTVIDGSQSTDDDKIVQYHWEELKGPLREEKISEDTAI LKLSKLVPGNYTFSLTWDSDGATNSTTANLTVNKAVDYPPVANAGPNQVITLPQNSITLFGNQSTDDHGITSYEWS LSPSSKGKWEMQGVRTPTLQLSAMQEGDYTYQLTVTDTIGQQATAQVTVIVQPENNKPPQADAGPDKELTLPVDST TLDGSKSSDDQKIISYLWEKTQGPDGVQLENANSSVATVTGLQVGTYVFTLTVKDERNLQSQSSVNVIVKEEINKPP IAKITGNWITLPTSTAELDGSKSSDDKGIVSYLWTRDEGSPAAGEVLNHSDHHPILFLSNLVEGTYTFHLKVTDAK GESDTDRTTVEVKPDPRKNNLVEIILDINVSQLTERLKGMFIRQIGVLLGVLDSDIIVQKIQPYTEQSTKMVFFVQN EPPHQIFKGHEVAAMLKSELRKQKADFLIFRALEVNTVTCQLNCSDHGHCDSFTKRCICDPFWMENFIKVQLRDGDS NCEWSVLYVIIATFVIWALGILSWTVICCCKRQKGKPKRKSKYKILDATDQESLELKPTSRAGIKQKGLLLSSSLM HSESELDSDDAI FTWPDREKGKLLHGQNGSVPNGQTPLKARSPREEIL

[0558] SEQ ID NO: 2 amino acid sequence of DPP4

[0559] MKTPWKVLLGLLGAAALVTIITVPWLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNIL VFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQW VTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDT EVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFWNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQ ERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHIC YFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFS KEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKK YPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKM GFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAE NFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP

[0560] SEQ ID NO: 3 amino acid sequence of HTR4

[0561] MDKLDANVSSEEGFGSVEKWLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVSVLVMPFG AIELVQDIWIYGEVFCLVRTSLDVLLTTASIFHLCCISLDRYYAICCQPLVYRNKMTPLRIALMLGGCWVIPTFISF LPIMQGWNNIGIIDLIEKRKFNQNSNSTYCVFMVNKPYAITCSWAFYIPFLLMVLAYYRIYVTAKEHAHQIQMLQR AGASSESRPQSADQHSTHRMRTETKAAKTLCIIMGCFCLCWAPFFVTNIVDPFIDYTVPGQVWTAFLWLGYINSGLN PFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTTINGSTHVLRDAVECGGQWESQCHPPATSPLVAAQP SDT

[0562] SEQ ID NO: 4 amino acid sequence of PUM1

[0563] MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPWLTSGTGSQAQPQPAANQALAAGTHSSPVPGSIGVAGRSQD DAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEHQVRSMDELNHDFQALALEGRAMGEQLLPGKKFWE TDESSKDGPKGIFLGDQWRDSAWGTSDHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPG DSCLRKGGFGPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPGNCQNSANE VDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQFDYSGTQVPVDSAAATVGLFDYNSQQ QLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLAPAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAWPHQYYG VTPWGVYPASLFQQQAAAAAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAF GQGLAAGMPGYPVLAPAAYYDQTGALWNAGARNGLGAPVRLVAPAPVI I S S SAAQAAVAAAAASANGAAGGLAGTT NGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSLFSQGSAQPANTSLGFGSSSSLGATLGSALGGFG TAVANSNTGSGSRRDSLTGSSDLYKRTSSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSS SLNLGGLTNGSGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNRYPNLQLR EIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGH VLSLALQMYGCRVIQKALEFIPSDQQVINEMVRELDGHVLKCVKDQNGNHWQKCIECVQPQSLQFIIDAFKGQVFA LSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHK FASNWEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYWQKMIDVAEPGQRKIVMHKIRPHIATLRK YTYGKHILAKLEKYYMKNGVDLGPICGPPNGII

[0564] SEQ ID NO: 5 amino acid sequence of SUCO

[0565] MKKHRRALALVSCLFLCSLVWLPSWRVCCKESSSASASSYYSQDDNCALENEDVQFQKKDEREGPINAESLGKSGSN LPISPKEHKLKDDSIVDVQNTESKKLSPPWETLPTVDLHEESSNAWDSETVENISSSSTSEITPISKLDEIEKSG TIPIAKPSETEQSETDCDVGEALDASAPIEQPSFVSPPDSLVGQHIENVSSSHGKGKITKSEFESKVSASEQGGGDP KSALNASDNLKNESSDYTKPGDIDPTSVASPKDPEDIPTFDEWKKKVMEVEKEKSQSMHASSNGGSHATKKVQKNRN NYASVECGAKILAANPEAKSTSAILIENMDLYMLNPCSTKIWFVIELCEPIQVKQLDIANYELFSSTPKDFLVSISD RYPTNKWIKLGTFHGRDERNVQSFPLDEQMYAKYVKMFIKYIKVELLSHFGSEHFCPLSLIRVFGTSMVEEYEEIAD SQYHSERQELFDEDYDYPLDYNTGEDKSSKNLLGSATNAILNMVNIAANILGAKTEDLTEGNKSISENATATAAPKM PESTPVSTPVPSPEYVTTEVHTHDMEPSTPDTPKESPIVQLVQEEEEEASPSTVTLLGSGEQEDESSPWFESETQIF CSELTTICCISSFSEYIYKWCSVRVALYRQRSRTALSKGKDYLVLAQPPLLLPAESVDVSVLQPLSGELENTNIERE AETWLGDLSSSMHQDDLVNHTVDAVELEPSHSQTLSQSLLLDITPEINPLPKIEVSESVEYEAGHIPSPVIPQESS VEIDNETEQKSESFSSIEKPSITYETNKVNELMDNIIKEDVNSMQIFTKLSETIVPPINTATVPDNEDGEAKMNIAD TAKQTLISWDSSSLPEVKEEEQSPEDALLRGLQRTATDFYAELQNSTDLGYANGNLVHGSNQKESVFMRLNNRIKA LEVNMSLSGRYLEELSQRYRKQMEEMQKAFNKTIVKLQNTSRIAEEQDQRQTEAIQLLQAQLTNMTQLVSNLSATVA ELKREVSDRQSYLVISLVLCWLGLMLCMQRCRNTSQFDGDYISKLPKSNQYPSPKRCFSSYDDMNLKRRTSFPLMR SKSLQLTGKEVDPNDLYIVEPLKFSPEKKKKRCKYKIEKIETIKPEEPLHPIANGDIKGRKPFTNQRDFSNMGEVYH SSYKGPPSEGSSETSSQSEESYFCGISACTSLCNGQSQKTKTEKRALKRRRSKVQDQGKLIKTLIQTKSGSLPSLHD

[0566] 11 KGNKE I T VGT FGVTAVS GH I

[0567] SEQ ID NO: 6 amino acid sequence of TMPRSS2

[0568] MALNSGSPPAIGPYYENHGYQPENPYPAQPTWPTVYEVHPAQYYPSPVPQYAPRVLTQASNPWCTQPKSPSGTVC TSKTKKALCITLTLGTFLVGAALAAGLLWKFMGSKCSNSGIECDSSGTCINPSNWCDGVSHCPGGEDENRCVRLYGP NFILQVYSSQRKSWHPVCQDDWNENYGRAACRDMGYKNNFYSSQGIVDDSGSTSFMKLNTSAGNVDIYKKLYHSDAC SSKAWSLRCIACGVNLNSSRQSRIVGGESALPGAWPWQVSLHVQNVHVCGGSIITPEWIVTAAHCVEKPLNNPWHW TAFAGILRQSFMFYGAGYQVEKVISHPNYDSKTKNNDIALMKLQKPLTFNDLVKPVCLPNPGMMLQPEQLCWISGWG ATEEKGKTSEVLNAAKVLLIETQRCNSRYVYDNLITPAMICAGFLQGNVDSCQGDSGGPLVTSKNNIWWLIGDTSWG SGCAKAYRPGVYGNVMVFTDWIYRQMRADG

[0569] SEQ ID NO: 7 amino acid sequence of SLC9A7

[0570] MEPGDAARPGSGRATGAPPPRLLLLPLLLGWGLRVAAAASASSSGAAAEDSSAMEELATEKEAEESHRQDSVSLLTF ILLLTLTILTIWLFKHRRVRFLHETGLAMIYGLIVGVILRYGTPATSGRDKSLSCTQEDRAFSTLLVNVSGKFFEYT LKGEISPGKINSVEQNDMLRKVTFDPEVFFNILLPPIIFHAGYSLKKRHFFRNLGSILAYAFLGTAVSCFIIGNLMY GWKLMKIMGQLSDKFYYTDCLFFGAIISATDPVTVLAI FNELHADVDLYALLFGESVLNDAVAIVLSSSIVAYQPA GLNTHAFDAAAFFKSVGIFLGIFSGSFTMGAVTGWTALVTKFTKLHCFPLLETALFFLMSWSTFLLAEACGFTGW AVLFCGITQAHYTYNNLSVESRSRTKQLFEVLHFLAENFIFSYMGLALFTFQKHVFSPIFIIGAFVAIFLGRAAHIY PLSFFLNLGRRHKIGWNFQHMMMFSGLRGAMAFALAIRDTASYARQMMFTTTLLIVFFTVWIIGGGTTPMLSWLNIR VGVEEPSEEDQNEHHWQYFRVGVDPDQDPPPNNDSFQVLQGDGPDSARGNRTKQESAWI FRLWYSFDHNYLKPILTH SGPPLTTTLPAWCGLLARCLTSPQVYDNQEPLREEDSDFILTEGDLTLTYGDSTVTANGSSSSHTASTSLEGSRRTK S S S EEVLERDLGMGDQKVS S RGTRLVFPLEDNA

[0571] SEQ ID NO: 8 amino acid sequence of CH25H

[0572] MSCHNCSDPQVLCSSGQLFLQPLWDHLRSWEALLQSPFFPVIFSITTYVGFCLPFWLDILCSWVPALRRYKIHPDF SPSAQQLLPCLGQTLYQHVMFVFPVTLLHWARSPALLPHEAPELLLLLHHILFCLLLFDMEFFVWHLLHHKVPWLYR TFHKVHHQNSSSFALATQYMSVWELFSLGFFDMMNVTLLGCHPLTTLTFHWNIWLSVEDHSGYNFPWSTHRLVPFG WYGGWHHDLHHSHFNCNFAPYFTHWDKILGTLRTASVPAR

[0573] SEQ ID NO: 9 amino acid sequence of FUT1

[0574] MWLRSHRQLCLAFLLVCVLSVIFFLHIHQDSFPHGLGLSILCPDRRLVTPPVAIFCLPGTAMGPNASSSCPQHPASL SGTWTVYPNGRFGNQMGQYATLLALAQLNGRRAFILPAMHAALAPVFRITLPVLAPEVDSRTPWRELQLHDWMSEEY ADLRDPFLKLSGFPCSWTFFHHLREQIRREFTLHDHLREEAQSVLGQLRLGRTGDRPRTFVGVHVRRGDYLQVMPQR WKGWGDSAYLRQAMDWFRARHEAPVFWTSNGMEWCKENIDTSQGDVTFAGDGQEATPWKDFALLTQCNHTIMTIG TFGFWAAYLAGGDTVYLANFTLPDSEFLKIFKPEAAFLPEWVGINADLSPLWTLAKP

[0575] SEQ ID NO: 10 amino acid sequence of IGF2R

[0576] MGAAAGRSPHLGPAPARRPQRSLLLLQLLLLVAAPGSTQAQAAPFPELCSYTWEAVDTKNNVLYKINICGSVDIVQC GPSSAVCMHDLKTRTYHSVGDSVLRSATRSLLEFNTTVSCDQQGTNHRVQSSIAFLCGKTLGTPEFVTATECVHYFE WRTTAACKKDIFKANKEVPCYVFDEELRKHDLNPLIKLSGAYLVDDSDPDTSLFINVCRDIDTLRDPGSQLRACPPG TAACLVRGHQAFDVGQPRDGLKLVRKDRLVLSYVREEAGKLDFCDGHSPAVTITFVCPSERREGTIPKLTAKSNCRY EIEWITEYACHRDYLESKTCSLSGEQQDVSIDLTPLAQSGGSSYISDGKEYLFYLNVCGETEIQFCNKKQAAVCQVKKSDTSQVKAAGRYHNQTLRYSDGDLTLIYFGGDECSSGFQRMSVINFECNKTAGNDGKGTPVFTGEVDCTYFFTWDT EYACVKEKEDLLCGATDGKKRYDLSALVRHAEPEQNWEAVDGSQTETEKKHFFINICHRVLQEGKARGCPEDAAVCA VDKNGSKNLGKFISSPMKEKGNIQLSYSDGDDCGHGKKIKTNITLVCKPGDLESAPVLRTSGEGGCFYEFEWHTAAA CVLSKTEGENCTVFDSQAGFSFDLSPLTKKNGAYKVETKKYDFYINVCGPVSVSPCQPDSGACQVAKSDEKTWNLGL SNAKLSYYDGMIQLNYRGGTPYNNERHTPRATLITFLCDRDAGVGFPEYQEEDNSTYNFRWYTSYACPEEPLECWT DPSTLEQYDLSSLAKSEGGLGGNWYAMDNSGEHVTWRKYYINVCRPLNPVPGCNRYASACQMKYEKDQGSFTEWSI SNLGMAKTGPWEDSGSLLLEYVNGSACTTSDGRQTTYTTRIHLVCSRGRLNSHPIFSLNWECWSFLWNTEAACPI QTTTDTDQACSIRDPNSGFVFNLNPLNSSQGYNVSGIGKIFMFNVCGTMPVCGTILGKPASGCEAETQTEELKNWKP ARPVGIEKSLQLSTEGFITLTYKGPLSAKGTADAFIVRFVCNDDVYSGPLKFLHQDIDSGQGIRNTYFEFETALACV PSPVDCQVTDLAGNEYDLTGLSTVRKPWTAVDTSVDGRKRTFYLSVCNPLPYIPGCQGSAVGSCLVSEGNSWNLGW QMSPQAAANGSLSIMYVNGDKCGNQRFSTRITFECAQISGSPAFQLQDGCEYVFIWRTVEACPWRVEGDNCEVKDP RHGNLYDLKPLGLNDTIVSAGEYTYYFRVCGKLSSDVCPTSDKSKWSSCQEKREPQGFHKVAGLLTQKLTYENGLL KMNFTGGDTCHKVYQRSTAIFFYCDRGTQRPVFLKETSDCSYLFEWRTQYACPPFDLTECSFKDGAGNSFDLSSLSR YSDNWEAITGTGDPEHYLINVCKSLAPQAGTEPCPPEAAACLLGGSKPVNLGRVRDGPQWRDGIIVLKYVDGDLCPD GIRKKSTTIRFTCSESQVNSRPMFISAVEDCEYTFAWPTATACPMKSNEHDDCQVTNPSTGHLFDLSSLSGRAGFTA AYSEKGLVYMSICGENENCPPGVGACFGQTRISVGKANKRLRYVDQVLQLVYKDGSPCPSKSGLSYKSVISFVCRPE ARPTNRPMLISLDKQTCTLFFSWHTPLACEQATECSVRNGSSIVDLSPLIHRTGGYEAYDESEDDASDTNPDFYINI CQPLNPMHGVPCPAGAAVCKVPIDGPPIDIGRVAGPPILNPIANEIYLNFESSTPCLADKHFNYTSLIAFHCKRGVS MGTPKLLRTSECDFVFEWETPWCPDEVRMDGCTLTDEQLLYSFNLSSLSTSTFKVTRDSRTYSVGVCTFAVGPEQG GCKDGGVCLLSGTKGASFGRLQSMKLDYRHQDEAWLSYVNGDRCPPETDDGVPCVFPFIFNGKSYEECIIESRAKL WCSTTADYDRDHEWGFCRHSNSYRTSSIIFKCDEDEDIGRPQVFSEVRGCDVTFEWKTKWCPPKKLECKFVQKHKT YDLRLLSSLTGSWSLVHNGVSYYINLCQKIYKGPLGCSERASICRRTTTGDVQVLGLVHTQKLGVIGDKVWTYSKG YPCGGNKTASSVIELTCTKTVGRPAFKRFDIDSCTYYFSWDSRAACAVKPQEVQMVNGTITNPINGKSFSLGDIYFK LFRASGDMRTNGDNYLYEIQLSSITSSRNPACSGANICQVKPNDQHFSRKVGTSDKTKYYLQDGDLDWFASSSKCG KDKTKSVSSTIFFHCDPLVEDGIPEFSHETADCQYLFSWYTSAVCPLGVGFDSENPGDDGQMHKGLSERSQAVGAVL SLLLVALTCCLLALLLYKKERRETVISKLTTCCRRSSNVSYKYSKVNKEEETDENETEWLMEEIQLPPPRQGKEGQE NGHITTKSVKALSSLHGDDQDSEDEVLTIPEVKVHSGRGAGAESSHPVRNAQSNALQEREDDRVGLVRGEKARKGKS SSAQQKTVSSTKLVSFHDDSDEDLLHI

[0577] SEQ ID NO: 11 amino acid sequence of BRS3

[0578] MAQRQPHSPNQTLISITNDTESSSSWSNDNTNKGWSGDNSPGIEALCAIYITYAVIISVGILGNAILIKVFFKTKS MQTVPNIFITSLAFGDLLLLLTCVPVDATHYLAEGWLFGRIGCKVLSFIRLTSVGVSVFTLTILSADRYKAWKPLE RQPSNAILKTCVKAGCVWIVSMIFALPEAIFSNVYTFRDPNKNMTFESCTSYPVSKKLLQEIHSLLCFLVFYIIPLS IISVYYSLIARTLYKSTLNIPTEEQSHARKQIESRKRIARTVLVLVALFALCWLPNHLLYLYHSFTSQTYVDPSAMH FIFTIFSRVLAFSNSCVNPFALYWLSKSFQKHFKAQLFCCKAERPEPPVADTSLTTLAVMGTVPGTGSIQMSEISVT SFTGCSVKQAEDRF

[0579] SEQ ID NO: 12 amino acid sequence of ITGB5

[0580] MPRAPAPLYACLLGLCALLPRLAGLNICTSGSATSCEECLLIHPKCAWCSKEDFGSPRSITSRCDLRANLVKNGCGG EIESPASSFHVLRSLPLSSKGSGSAGWDVIQMTPQEIAVNLRPGDKTTFQLQVRQVEDYPVDLYYLMDLSLSMKDDL DNIRSLGTKLAEEMRKLTSNFRLGFGSFVDKDISPFSYTAPRYQTNPCIGYKLFPNCVPSFGFRHLLPLTDRVDSFN EEVRKQRVSRNRDAPEGGFDAVLQAAVCKEKIGWRKDALHLLVFTTDDVPHIALDGKLGGLVQPHDGQCHLNEANEY TASNQMDYPSLALLGEKLAENNINLIFAVTKNHYMLYKNFTALIPGTTVEILDGDSKNIIQLIINAYNSIRSKVELS VWDQPEDLNLFFTATCQDGVSYPGQRKCEGLKIGDTASFEVSLEARSCPSRHTEHVFALRPVGFRDSLEVGVTYNCT CGCSVGLEPNSARCNGSGTYVCGLCECSPGYLGTRCECQDGENQSVYQNLCREAEGKPLCSGRGDCSCNQCSCFESE FGKIYGPFCECDNFSCARNKGVLCSGHGECHCGECKCHAGYIGDNCNCSTDISTCRGRDGQICSERGHCLCGQCQCT EPGAFGEMCEKCPTCPDACSTKRDCVECLLLHSGKPDNQTCHSLCRDEVITWVDTIVKDDQEAVLCFYKTAKDCVMM FTYVELPSGKSNLTVLREPECGNTPNAMTILLAWGSILLVGLALLAIWKLLVTIHDRREFAKFQSERSRARYEMAS NPLYRKPISTHTVDFTFNKFNKSYNGTVD

[0581] SEQ ID NO: 13 amino acid sequence of STIMATE

[0582] MQGPAGNASRGLPGGPPSTVASGAGRCESGALMHSFGIFLQGLLGWAFSTLMLKRFREPKHERRPWRIWFLDTSKQ AIGMLFIHFANVYLADLTEEDPCSLYLINFLLDATVGMLLIYVGVRAVSVLVEWQQWESLRFGEYGDPLQCGAWVGQ CALYIVIMIFEKSWFIVLLILQWKKVALLNPIENPDLKLAIVMLIVPFFVNALMFWWDNFLMRKGKTKAKLEERG ANQDSRNGSKVRYRRAASHEESESEILISADDEMEESDVEEDLRRLTPLKPVKKKKHRFGLPV

[0583] SEQ ID NO: 14 amino acid sequence of DNAJC13

[0584] MNIIRENKDLACFYTTKHSWRGKYKRVFSVGTHAITTYNPNTLEVTNQWPYGDICSISPVGKGQGTEFNLTFRKGSG KKSETLKFSTEHRTELLTEALRFRTDFSEGKITGRRYNCYKHHWSDSRKPVILEVTPGGFDQINPATNRVLCSYDYR NIEGFVDLSDYQGGFCILYGGFSRLHLFASEQREEIIKSAIDHAGNYIGISLRIRKEPLEFEQYLNLRFGKYSTDES ITSLAEFWQKISPRHSEPVKRVLALTETCLVERDPATYNIATLKPLGEVFALVCDSENPQLFTIEFIKGQVRKYSS TERDSLLASLLDGVRASGNRDVCVKMTPTHKGQRWGLLSMPVDEEVESLHLRFLATPPNGNFADAVFRFNANISYSG VLHAVTQDGLFSENKEKLINNAITALLSQEGDWASNAELESQFQAVRRLVASKAGFLAFTQLPKFRERLGVKWKA LKRSNNGIIHAAVDMLCALMCPMHDDYDLRQEQLNKASLLSSKKFLENLLEKFNSHVDHGTGALVISSLLDFLTFAL CAPYSETTEGQQFDMLLEMVASNGRTLFKLFQHPSMAIIKGAGLVMKAIIEEGDKEIATKMQELALSEGALPRHLHT AMFTISSDQRMLTNRQLSRHLVGLWTADNATATNLLKRILPPGLLAYLESSDLVPEKDADRMHVRDNVKIAMDQYGK FNKVPEWQRLAGKAAKEVEKFAKEKVDLVLMHWRDRMGIAQKENINQKPWLRKRRQRIKIEANWDLFYYRFGQDHA RSNLIWNFKTREELKDTLESEMRAFNIDRELGSANVISWNHHEFEVKYECLAEEIKIGDYYLRLLLEEDENEESGSI KRSYEFFNELYHRFLLTPKVNMKCLCLQALAIVYGRCHEEIGPFTDTRYIIGMLERCTDKLERDRLILFLNKLILNK KNVKDLMDSNGIRILVDLLTLAHLHVSRATVPLQSNVIEAAPDMKRESEKEWYFGNADKERSGPYGFHEMQELWTKG MLNAKTRCWAQGMDGWRPLQSIPQLKWCLLASGQAVLNETDLATLILNMLITMCGYFPSRDQDNAIIRPLPKVKRLL SDSTCLPHIIQLLLTFDPILVEKVAILLYHIMQDNPQLPRLYLSGVFFFIMMYTGSNVLPVARFLKYTHTKQAFKSE ETKGQDIFQRSILGHILPEAMVCYLENYEPEKFSEIFLGEFDTPEAIWSSEMRRLMIEKIAAHLADFTPRLQSNTRA LYQYCPIPIINYPQLENELFCNIYYLKQLCDTLRFPDWPIKDPVKLLKDTLDAWKKEVEKKPPMMSIDDAYEVLNLP QGQGPHDESKIRKAYFRLAQKYHPDKNPEGRDMFEKVNKAYEFLCTKSAKIVDGPDPENIILILKTQSILFNRHKED LQPYKYAGYPMLIRTITMETSDDLLFSKESPLLPAATELAFHTVNCSALNAEELRRENGLEVLQEAFSRCVAVLTRA SKPSDMSVQVCGYISKCYSVAAQFEECREKITEMPSIIKDLCRVLYFGKSIPRVAALGVECVSSFAVDFWLQTHLFQ AGILWYLLGFLFNYDYTLEESGIQKSEETNQQEVANSLAKLSVHALSRLGGYLAEEQATPENPTIRKSLAGMLTPYV ARKLAVASVTEILKMLNSNTESPYLIWNNSTRAELLEFLESQQENMIKKGDCDKTYGSEFVYSDHAKELIVGEIFVR VYNEVPTFQLEVPKAFAASLLDYIGSQAQYLHTFMAITHAAKVESEQHGDRLPRVEMALEALRNVIKYNPGSESECI GHFKLIFSLLRVHGAGQVQQLALEWNIVTSNQDCVNNIAESMVLSSLLALLHSLPSSRQLVLETLYALTSSTKIIK EAMAKGALIYLLDMFCNSTHPQVRAQTAELFAKMTADKLIGPKVRITLMKFLPSVFMDAMRDNPEAAVHIFEGTHEN PELIWNDNSRDKVSTTVREMMLEHFKNQQDNPEANWKLPEDFAWFGEAEGELAVGGVFLRIFIAQPAWVLRKPREF LIALLEKLTELLEKNNPHGETLETLTMATVCLFSAQPQLADQVPPLGHLPKVIQAMNHRNNAIPKSAIRVIHALSEN ELCVRAMASLETIGPLMNGMKKRADTVGLACEAINRMFQKEQSELVAQALKADLVPYLLKLLEGIGLENLDSPAATK AQIVKALKAMTRSLQYGEQVNEILCRSSVWSAFKDQKHDLFISESQTAGYLTGPGVAGYLTAGTSTSVMSNLPPPVD HEAGDLGYQT

[0585] SEQ ID NO: 15 amino acid sequence of SLC5A8

[0586] MDT P RGI GT FWWD YWFAGMLVI S AAI GI YYAFAGGGQQT S KD FLMGGRRMTAVP VAL S LTAS FMS AVT VLGT P S E VYRFGAIFSIFAFTYFFVWI SAEVFLPVFYKLGITSTYEYLELRFNKCVRLCGTVLFIVQTILYTGIVIYAPALAL NQVTGFDLWGAWATGWCTFYCTLGGLKAVIWTDVFQVGIMVAGFASVIIQAWMQGGISTILNDAYDGGRLNFWN FNPNPLQRHTFWTIIIGGTFTWTSIYGVNQSQVQRYISCKSRFQAKLSLYINLVGLWAILTCSVFCGLALYSRYHDC DPWTAKKVSAPDQLMPYLVLDILQDYPGLPGLFVACAYSGTLSTVSSSINALAAVTVEDLIKPYFRSLSERSLSWIS QGMS WYGALCI GMAALASLMGALLQAALSVFGMVGGPLMGLFALGI LVPFANS I GALVGLMAGFAI SLWVGI GAQI YPPLPERTLPLHLDIQGCNSTYNETNLMTTTEMPFTTSVFQIYNVQRTPLMDNWYSLSYLYFSTVGTLVTLLVGILV SLSTGGRKQNLDPRYILTKEDFLSNFDIFKKKKHVLSYKSHPVEDGGTDNPAFNHIELNSDQSGKSNGTRL

[0587] SEQ ID NO: 16 amino acid sequence of LPAR5

[0588] MLANSSSTNSSVLPCPDYRPTHRLHLWYSLVLAAGLPLNALALWVFLRALRVHSWSVYMCNLAASDLLFTLSLPV RLSYYALHHWPFPDLLCQTTGAI FQMNMYGSCIFLMLINVDRYAAIVHPLRLRHLRRPRVARLLCLGVWALILVFAV PAARVHRPSRCRYRDLEVRLCFESFSDELWKGRLLPLVLLAEALGFLLPLAAWYSSGRVFWTLARPDATQSQRRRK TVRLLLANLVIFLLCFVPYNSTLAVYGLLRSKLVAASVPARDRVRGVLMVMVLLAGANCVLDPLVYYFSAEGFRNTL RGLGTPHRARTSATNGTRAALAQSERSAVTTDATRPDAASQGLLRPSDSHSLSSFTQCPQDSAL

[0589] SEQ ID NO: 17 amino acid sequence of SLC7A11

[0590] MVRKPWSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIIIGTIIGAGIFISPKGVLQNTGSVG MSLTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYILEVFGPLPAFVRVWVELLIIRPAATAVISLAFGRYILEPF FIQCEIPELAIKLITAVGITWMVLNSMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFKDAFSGRDSS ITRLPLAFYYGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTTINAEELLLSNAVAVTFS ERLLGNFSLAVPIFVALSCFGSMNGGVFAVSRLFYVASREGHLPEILSMIHVRKHTPLPAVIVLHPLTMIMLFSGDL DSLLNFLSFARWLFIGLAVAGLIYLRYKCPDMHRPFKVPLFIPALFSFTCLFMVALSLYSDPFSTGIGFVITLTGVP AYYLFIIWDKKPRWFRIMSEKITRTLQIILEWPEEDKL

[0591] SEQ ID NO: 18 amino acid sequence of SLC10A1

[0592] MEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSKIKAHLWKPKGLAIALVAQYGIMPLTAF VLGKVFRLKNIEALAILVCGCSPGGNLSNVFSLAMKGDMNLSIVMTTCSTFCALGMMPLLLYIYSRGIYDGDLKDKV PYKGIVISLVLVLIPCTIGIVLKSKRPQYMRYVIKGGMIIILLCSVAVTVLSAINVGKSIMFAMTPLLIATSSLMPF IGFLLGYVLSALFCLNGRCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPLLYMIFQLGEGLLLIAIFWCYE KFKTPKDKTKMIYTAATTEETIPGALGNGTYKGEDCSPCTA

[0593] SEQ ID NO: 19 amino acid sequence of TMEM263

[0594] MNQTDKNQQEIPSYLNDEPPEGSMKDHPQQQPGMLSRVTGGIFSVTKGAVGATIGGVAWIGGKSLEVTKTAVTTVPS MGIGLVKGGVSAVAGGVTAVGSAWNKVPLTGKKKDKSD

[0595] SEQ ID NO: 20 amino acid sequence of HTR2

[0596] CMVNLRNAVHSFLVHLIGLLVWQSDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSIVIIIIMTIGGNILVIM AVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVWPLPRYLCPVWISLDVLFSTASIMHLCAISLDRY VAIRNPIEHSRFNSRTKAIMKIAIVWAISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIM VITYCLTIYVLRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTMQAINNER KASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVCSGINPLVYTLFNKIYRRAFSNYLR CNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTNEPVIEKASDNEPGIEMQVENLELPVNPSSWSERISSV

[0597] SEQ ID NO: 21 amino acid sequence of SLC7A5

[0598] MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNITLLNGVAIIVGTIIGSGIFVTPTGVLK EAGSPGLALWWAACGVFSIVGALCYAELGTTISKSGGDYAYMLEVYGSLPAFLKLWIELLIIRPSSQYIVALVFAT YLLKPLFPTCPVPEEAAKLVACLCVLLLTAVNCYSVKAATRVQDAFAAAKLLALALIILLGFVQIGKGDVSNLDPNF SFEGTKLDVGNIVLALYSGLFAYGGWNYLNFVTEEMINPYRNLPLAIIISLPIVTLVYVLTNLAYFTTLSTEQMLSS EAVAVDFGNYHLGVMSWIIPVFVGLSCFGSVNGSLFTSSRLFFVGSREGHLPSILSMIHPQLLTPVPSLVFTCVMTL LYAFSKDIFSVINFFSFFNWLCVALAIIGMIWLRHRKPELERPIKVNLALPVFFILACLFLIAVSFWKTPVECGIGF TIILSGLPVYFFGVWWKNKPKWLLQGIFSTTVLCQKLMQWPQET

[0599] SEQ ID NO: 22 amino acid sequence of KDELR3

[0600] MNVFRILGDLSHLLAMILLLGKIWRSKCCKGISGKSQILFALVFTTRYLDLFTNFISIYNTVMKWFLLCAYVTVYM IYGKFRKTFDSENDTFRLEFLLVPVIGLSFLENYSFTLLEILWTFSIYLESVAILPQLFMISKTGEAETITTHYLFF LGLYRALYLANWIRRYQTENFYDQIAWSGWQTIFYCDFFYLYVTKVLKGKKLSLPMPI

[0601] SEQ ID NO: 23 amino acid sequence of HTR6

[0602] MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCWIALTAAANSLLIALICTQPALRNTSNFFLVSLFTSDLMVGL WMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLISLDRYLLILSPLRYKLRMTPLRALALVLGAWSLA ALASFLPLLLGWHELGHARPPVPGQCRLLASLPFVLVASGLTFFLPSGAICFTYCRILLAARKQAVQVASLTTGMAS QASETLQVPRTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVTWLPFFVANIVQAVCDCISPGLFDVLTWL GYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGPRPGLSLQQVLPLPLPPDSDSDSDAG SGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNFFNIDPAEPELRPHPLGIPTN

[0603] SEQ ID NO: 24 amino acid sequence of UGT3A1

[0604] MVGQRVLLLVAFLLSGVLLSEAAKILTISTLGGSHYLLLDRVSQILQEHGHNVTMLHQSGKFLIPDIKEEEKSYQVI RWFSPEDHQKRIKKHFDSYIETALDGRKESEALVKLMEIFGTQCSYLLSRKDIMDSLKNENYDLVFVEAFDFCSFLI AEKLVKPFVAILPTTFGSLDFGLPSPLSYVPVFPSLLTDHMDFWGRVKNFLMFFSFSRSQWDMQSTFDNTIKEHFPE GSRPVLSHLLLKAELWFVNSDFAFDFARPLLPNTVYIGGLMEKPIKPVPQDLDNFIANFGDAGFVLVAFGSMLNTHQ SQEVLKKMHNAFAHLPQGVIWTCQSSHWPRDVHLATNVKIVDWLPQSDLLAHPSIRLFVTHGGQNSVMEAIRHGVPM VGLPVNGDQHGNMVRWAKNYGVSIRLNQVTADTLTLTMKQVIEDKRYKSAWAASVILHSQPLSPAQRLVGWIDHI LQTGGATHLKPYAFQQPWHEQYLIDVFVFLLGLTLGTMWLCGKLLGWARWLRGARKVKKT

[0605] SEQ ID NO: 25 amino acid sequence of TP53

[0606] MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAP AAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPG TRVRAMAIYKQSQHMTEWRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVWPYEPPEVGSDCTT IHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRAL PNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMF KTEGPDSD

[0607] SEQ ID NO: 26 amino acid sequence of ZC3HAV1

[0608] MADPEVCCFITKILCAHGGRMALDALLQEIALSEPQLCEVLQVAGPDRFWLETGGEAGITRSWATTRARVCRRKY CQRPCDNLHLCKLNLLGRCNYSQSERNLCKYSHEVLSEENFKVLKNHELSGLNKEELAVLLLQSDPFFMPEICKSYK GEGRQQICNQQPPCSRLHICDHFTRGNCRFPNCLRSHNLMDRKVLAIMREHGLNPDWQNIQDICNSKHMQKNPPGP RAPSSHRRNMAYRARSKSRDRFFQGSQEFLASASASAERSCTPSPDQISHRASLEDAPVDDLTRKFTYLGSQDRARP PSGSSKATDLGGTSQAGTSQRFLENGSQEDLLHGNPGSTYLASNSTSAPNWKSLTSWTNDQGARRKTVFSPTLPAAR SSLGSLQTPEAVTTRKGTGLLSSDYRIINGKSGTQDIQPGPLFNNNADGVATDITSTRSLNYKSTSSGHREISSPRI QDAGPASRDVQATGRIADDADPRVALVNDSLSDVTSTTSSRVDDHDSEEICLDHLCKGCPLNGSCSKVHFHLPYRWQ MLIGKTWTDFEHMETIEKGYCNPGIHLCSVGSYTINFRVMSCDSFPIRRLSTPSSVTKPANSVFTTKWIWYWKNESG TWIQYGEEKDKRKNSNVDSSYLESLYQSCPRGWPFQAGSRNYELSFQGMIQTNIASKTQKDVIRRPTFVPQWYVQQ MKRGPDHQPAKTSSVSLTATFRPQEDFCFLSSKKYKLSEIHHLHPEYVRVSEHFKASMKNFKIEKIKKIENSELLDK FTWKKSQMKEEGKLLFYATSRAYVESICSNNFDSFLHETHENKYGKGIYFAKDAIYSHKNCPYDAKNWMFVAQVLV GKFTEGNITYTSPPPQFDSCVDTRSNPSVFVI FQKDQVYPQYVIEYTEDKACVIS

[0609] SEQ ID NO: 27 amino acid sequence of ADAM10

[0610] MVLLRVLILLLSWAAGMGGQYGNPLNKYIRHYEGLSYNVDSLHQKHQRAKRAVSHEDQFLRLDFHAHGRHFNLRMKR DTSLFSDEFKVETSNKVLDYDTSHIYTGHIYGEEGSFSHGSVIDGRFEGFIQTRGGTFYVEPAERYIKDRTLPFHSV IYHEDDINYPHKYGPQGGCADHSVFERMRKYQMTGVEEVTQIPQEEHAANGPELLRKKRTTSAEKNTCQLYIQTDHL FFKYYGTREAVIAQISSHVKAIDTIYQTTDFSGIRNISFMVKRIRINTTADEKDPTNPFRFPNIGVEKFLELNSEQN HDDYCLAYVFTDRDFDDGVLGLAWVGAPSGSSGGICEKSKLYSDGKKKSLNTGIITVQNYGSHVPPKVSHITFAHEV GHNFGSPHDSGTECTPGESKNLGQKENGNYIMYARATSGDKLNNNKFSLCSIRNISQVLEKKRNNCFVESGQPICGN GMVEQGEECDCGYSDQCKDECCFDANQPEGRKCKLKPGKQCSPSQGPCCTAQCAFKSKSEKCRDDSDCAREGICNGF TALCPASDPKPNFTDCNRHTQVCINGQCAGSICEKYGLEECTCASSDGKDDKELCHVCCMKKMDPSTCASTGSVQWS RHFSGRTITLQPGSPCNDFRGYCDVFMRCRLVDADGPLARLKKAIFSPELYENIAEWIVAHWWAVLLMGIALIMLMA GFIKICSVHTPSSNPKLPPPKPLPGTLKRRRPPQPIQQPQRQRPRESYQMGHMRR

[0611] SEQ ID NO: 28 amino acid sequence of KIR3DL3

[0612] MSLMWSMACVGFFLLEGPWPHVGGQDKPFLSAWPGTWSEGQHVTLQCRSRLGFNEFSLSKEDGMPVPELYNRIFR NSFLMGPVTPAHAGTYRCCSSHPHSPTGWSAPSNPWIMVTGVHRKPSLLAHPGPLVKSGETVILQCWSDVRFERFL LHREGITEDPLRLVGQLHDAGSQVNYSMGPMTPALAGTYRCFGSVTHLPYELSAPSDPLDIVWGLYGKPSLSAQPG PTVQAGENVTLSCSSRSLFDIYHLSREAEAGELRLTAVLRVNGTFQANFPLGPVTHGGNYRCFGSFRALPHAWSDPS DPLPVSVTGNSRNLHVLIGTSWIIPFAILLFFLLHRWCANKKNAWMDQEPAGNRTVNREDSDEQDPQEVTYAQLN HCVFTQRKITRPSQRPKTPPTDTSV

[0613] SEQ ID NO: 29 amino acid sequence of RABAC1

[0614] MAAQKDQQKDAEAEGLSGTTLLPKLIPSGAGREWLERRRATIRPWSTFVDQQRFSRPRNLGELCQRLVRNVEYYQSN YVFVFLGLILYCWTSPMLLVALAVFFGACYILYLRTLESKLVLFGREVSPAHQYALAGGISFPFFWLAGAGSAVFW VLGATLWIGSHAAFHQIEAVDGEELQMEPV

[0615] SEQ ID NO: 30 amino acid sequence of SLC2A3

[0616] MGTQKVTPALIFAITVATIGSFQFGYNTGVINAPEKIIKEFINKTLTDKGNAPPSEVLLTSLWSLSVAIFSVGGMIG SFSVGLFVNRFGRRNSMLIVNLLAVTGGCFMGLCKVAKSVEMLILGRLVIGLFCGLCTGFVPMYIGEISPTALRGAF GTLNQLGIWGILVAQIFGLEFILGSEELWPLLLGFTILPAILQSAALPFCPESPRFLLINRKEEENAKQILQRLWG TQDVSQDIQEMKDESARMSQEKQVTVLELFRVSSYRQPIIISIVLQLSQQLSGINAVFYYSTGIFKDAGVQEPIYAT IGAGWNTIFTWSLFLVERAGRRTLHMIGLGGMAFCSTLMTVSLLLKDNYNGMSFVCIGAILVFVAFFEIGPGPIP WFIVAELFSQGPRPAAMAVAGCSNWTSNFLVGLLFPSAAHYLGAYVFIIFTGFLITFLAFTFFKVPETRGRTFEDIT RAFEGQAHGADRSGKDGVMEMNSIEPAKETTTNV

[0617] SEQ ID NO: 31 amino acid sequence of TNC

[0618] MGAMTQLLAGVFLAFLALATEGGVLKKVIRHKRQSGVNATLPEENQPWFNHVYNIKLPVGSQCSVDLESASGEKDL APPSEPSESFQEHTVDGENQIVFTHRINIPRRACGCAAAPDVKELLSRLEELENLVSSLREQCTAGAGCCLQPATGR LDTRPFCSGRGNFSTEGCGCVCEPGWKGPNCSEPECPGNCHLRGRCIDGQCICDDGFTGEDCSQLACPSDCNDQGKC VNGVCICFEGYAGADCSREICPVPCSEEHGTCVDGLCVCHDGFAGDDCNKPLCLNNCYNRGRCVENECVCDEGFTGE DCSELICPNDCFDRGRCINGTCYCEEGFTGEDCGKPTCPHACHTQGRCEEGQCVCDEGFAGVDCSEKRCPADCHNRG RCVDGRCECDDGFTGADCGELKCPNGCSGHGRCVNGQCVCDEGYTGEDCSQLRCPNDCHSRGRCVEGKCVCEQGFKG YDCSDMSCPNDCHQHGRCVNGMCVCDDGYTGEDCRDRQCPRDCSNRGLCVDGQCVCEDGFTGPDCAELSCPNDCHGQ GRCVNGQCVCHEGFMGKDCKEQRCPSDCHGQGRCVDGQCICHEGFTGLDCGQHSCPSDCNNLGQCVSGRCICNEGYS GEDCSEVSPPKDLWTEVTEETVNLAWDNEMRVTEYLWYTPTHEGGLEMQFRVPGDQTSTIIQELEPGVEYFIRVF AILENKKSIPVSARVATYLPAPEGLKFKSIKETSVEVEWDPLDIAFETWEIIFRNMNKEDEGEITKSLRRPETSYRQ

[0619] TGLAPGQEYEISLHIVKNNTRGPGLKRVTTTRLDAPSQIEVKDVTDTTALITWFKPLAEIDGIELTYGIKDVPGDRT TIDLTEDENQYSIGNLKPDTEYEVSLISRRGDMSSNPAKETFTTGLDAPRNLRRVSQTDNSITLEWRNGKAAIDSYR IKYAPISGGDHAEVDVPKSQQATTKTTLTGLRPGTEYGIGVSAVKEDKESNPATINAATELDTPKDLQVSETAETSL TLLWKTPLAKFDRYRLNYSLPTGQWVGVQLPRNTTSYVLRGLEPGQEYNVLLTAEKGRHKSKPARVKASTEQAPELE NLTVTEVGWDGLRLNWTAADQAYEHFIIQVQEANKVEAARNLTVPGSLRAVDIPGLKAATPYTVSIYGVIQGYRTPV LSAEASTGETPNLGEVWAEVGWDALKLNWTAPEGAYEYFFIQVQEADTVEAAQNLTVPGGLRSTDLPGLKAATHYT ITIRGVTQDFSTTPLSVEVLTEEVPDMGNLTVTEVSWDALRLNWTTPDGTYDQFTIQVQEADQVEEAHNLTVPGSLR SMEIPGLRAGTPYTVTLHGEVRGHSTRPLAVEWTEDLPQLGDLAVSEVGWDGLRLNWTAADNAYEHFVIQVQEVNK VEAAQNLTLPGSLRAVDIPGLEAATPYRVSIYGVIRGYRTPVLSAEASTAKEPEIGNLNVSDITPESFNLSWMATDG IFETFTIEIIDSNRLLETVEYNISGAERTAHISGLPPSTDFIVYLSGLAPSIRTKTISATATTEALPLLENLTISDI NPYGFTVSWMASENAFDSFLVTWDSGKLLDPQEFTLSGTQRKLELRGLITGIGYEVMVSGFTQGHQTKPLRAEIVT EAEPEVDNLLVSDATPDGFRLSWTADEGVFDNFVLKIRDTKKQSEPLEITLLAPERTRDITGLREATEYEIELYGIS KGRRSQTVSAIATTAMGSPKEVIFSDITENSATVSWRAPTAQVESFRITYVPITGGTPSMVTVDGTKTQTRLVKLIP GVEYLVSIIAMKGFEESEPVSGSFTTALDGPSGLVTANITDSEALARWQPAIATVDSYVISYTGEKVPEITRTVSGN TVEYALTDLEPATEYTLRIFAEKGPQKSSTITAKFTTDLDSPRDLTATEVQSETALLTWRPPRASVTGYLLVYESVD GTVKEVIVGPDTTSYSLADLSPSTHYTAKIQALNGPLRSNMIQTIFTTIGLLYPFPKDCSQAMLNGDTTSGLYTIYL NGDKAEALEVFCDMTSDGGGWIVFLRRKNGRENFYQNWKAYAAGFGDRREEFWLGLDNLNKITAQGQYELRVDLRDH GETAFAVYDKFSVGDAKTRYKLKVEGYSGTAGDSMAYHNGRSFSTFDKDTDSAITNCALSYKGAFWYRNCHRVNLMG RYGDNNHSQGVNWFHWKGHEHSIQFAEMKLRPSNFRNLEGRRKRA

[0620] SEQ ID NO: 32 amino acid sequence of CYB5D2

[0621] MLRCGGRGLLLGLAVAAAAVMAARLMGWWGPRAGFRLFIPEELSRYRGGPGDPGLYLALLGRVYDVSSGRRHYEPGS HYSGFAGRDASRAFVTGDCSEAGLVDDVSDLSAAEMLTLHNWLSFYEKNYVCVGRVTGRFYGEDGLPTPALTQVEAA ITRGLEANKLQLQEKQTFPPCNAEWSSARGSRLWCSQKSGGVSRDWIGVPRKLYKPGAKEPRCVCVRTTGPPSGQMP DNPPHRNRGDLDHPNLAEYTGCPPLAITCSFPL

[0622] SEQ ID NO: 33 amino acid sequence of HTR7

[0623] MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTWDAPPDNASGCGEQINYG RVEKWIGSILTLITLLTIAGNCLWISVCFVKKLRQPSNYLIVSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFF CNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVC LISQDFGYTIYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVEECANLSRL LKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSCIPLWVERTFLWLGYANSLINPFIYA FFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNW LADKMLTTVEKKVMIHD

[0624] SEQ ID NO: 34 amino acid sequence of STIMATE

[0625] MKRSLQALYCQLLSFLLILALTEALAFAIQEPSPRESLQVLPSGTPPGTMVTAPHSSTRHTSWMLTPNPDGPPSQA

[0626] AAPMATPTPRAEGHPPTHTISTIAATVTAPHSESSLSTGPAPAAMATTSSKPEGRPRGQAAPTILLTKPPGATSRPT TAPPRTTTRRPPRPPGSSRKGAGNSSRPVPPAPGGHSRSKEGQRGRNPSSTPLGQKRPLGKIFQIYKGNFTGSVEPE PSTLTPRTPLWGYSSSPQPQTVAATTVPSNTSWAPTTTSLGPAKDKPGLRRAAQGGGSTFTSQGGTPDATAASGAPV SPQAAPVPSQRPHHGDPQDGPSHSDSWLTVTPGTSRPLSTSSGVFTAATGPTPAAFDTSVSAPSQGIPQGASTTPQA PTHPSRVSESTISGAKEETVATLTMTDRVPSPLSTWSTATGNFLNRLVPAGTWKPGTAGNISHVAEGDKPQHRATI CLSKMDIAWVILAISVPISSCSVLLTVCCMKRKKKTANPENNLSYWNNTITMDYFNRHAVELPREIQSLETSEDQLS EPRSPANGDYRDTGMVLVNPFCQETLFVGNDQVSEI

[0627] SEQ ID NO: 35 amino acid sequence of FDCSP

[0628] MKKVLLLITAILAVAVGFPVSQDQEREKRSISDSDELASGFFVFPYPYPFRPLPPIPFPRFPWFRRNFPI PIPESAP TTPLPSEK

[0629] SEQ ID NO: 36 amino acid sequence of DLK1

[0630] MTATEALLRVLLLLLAFGHSTYGAECFPACNPQNGFCEDDNVCRCQPGWQGPLCDQCVTSPGCLHGLCGEPGQCICT DGWDGELCDRDVRACSSAPCANNRTCVSLDDGLYECSCAPGYSGKDCQKKDGPCVINGSPCQHGGTCVDDEGRASHA SCLCPPGFSGNFCEIVANSCTPNPCENDGVCTDIGGDFRCRCPAGFIDKTCSRPVTNCASSPCQNGGTCLQHTQVSY ECLCKPEFTGLTCVKKRALSPQQVTRLPSGYGLAYRLTPGVHELPVQQPEHRILKVSMKELNKKTPLLTEGQAICFT ILGVLTSLWLGTVGIVFLNKCETWVSNLRYNHMLRKKKNLLLQYNSGEDLAVNIIFPEKIDMTTFSKEAGDEEI

[0631] SEQ ID NO: 37 amino acid sequence of GRM8

[0632] MVCEGKRSASCPCFFLLTAKFYWILTMMQRTHSQEYAHSIRVDGDIILGGLFPVHAKGERGVPCGELKKEKGIHRLEAMLYAIDQINKDPDLLSNITLGVRILDTCSRDTYALEQSLTFVQALIEKDASDVKCANGDPPIFTKPDKISGVIGAA ASSVSIMVANILRLFKIPQISYASTAPELSDNTRYDFFSRWPPDSYQAQAMVDIVTALGWNYVSTLASEGNYGESG VEAFTQISREIGGVCIAQSQKIPREPRPGEFEKIIKRLLETPNARAVIMFANEDDIRRILEAAKKLNQSGHFLWIGS DSWGSKIAPVYQQEEIAEGAVTILPKRASIDGFDRYFRSRTLANNRRNVWFAEFWEENFGCKLGSHGKRNSHIKKCT GLERIARDSSYEQEGKVQFVIDAVYSMAYALHNMHKDLCPGYIGLCPRMSTIDGKELLGYIRAVNFNGSAGTPVTFN ENGDAPGRYDIFQYQITNKSTEYKVIGHWTNQLHLKVEDMQWAHREHTHPASVCSLPCKPGERKKTVKGVPCCWHCE

[0633] RCEGYNYQVDELSCELCPLDQRPNMNRTGCQLIPIIKLEWHSPWAWPVFVAILGIIATTFVIVTFVRYNDTPIVRA SGRELSYVLLTGIFLCYSITFLMIAAPDTIICSFRRVFLGLGMCFSYAALLTKTNRIHRIFEQGKKSVTAPKFISPA SQLVITFSLISVQLLGVFVWFWDPPHIIIDYGEQRTLDPEKARGVLKCDISDLSLICSLGYSILLMVTCTVYAIKT RGVPETFNEAKPIGFTMYTTCIIWLAFIPIFFGTAQSAEKMYIQTTTLTVSMSLSASVSLGMLYMPKVYIIIFHPEQ NVQKRKRSFKAWTAATMQSKLIQKGNDRPNGEVKSELCESLETNTSSTKTTYISYSNHSI

[0634] SEQ ID NO: 38 amino acid sequence of P2RY1

[0635] MTEVLWPAVPNGTDAAFLAGPGSSWGNSTVASTAAVSSSFKCALTKTGFQFYYLPAVYILVFIIGFLGNSVAIWMFV FHMKPWSGI SVYMFNLALADFLYVLTLPALI FYYFNKTDWI FGDAMCKLQRFI FHVNLYGS I LFLTCI SAHRYSGW YPLKSLGRLKKKNAICISVLVWLIVWAISPILFYSGTGVRKNKTITCYDTTSDEYLRSYFIYSMCTTVAMFCVPLV LILGCYGLIVRALIYKDLDNSPLRRKSIYLVIIVLTVFAVSYIPFHVMKTMNLRARLDFQTPAMCAFNDRVYATYQV TRGLASLNSCVDPILYFLAGDTFRRRLSRATRKASRRSEANLQSKSEDMTLNILPEFKQNGDTSL

[0636] SEQ ID NO: 39 amino acid sequence of CCR10

[0637] MGTEATEQVSWGHYSGDEEDAYSAEPLPELCYKADVQAFSRAFQPSVSLTVAALGLAGNGLVLATHLAARRAARSPT SAHLLQLALADLLLALTLPFAAAGALQGWSLGSATCRTISGLYSASFHAGFLFLACISADRYVAIARALPAGPRPST PGRAHLVSVIVWLLSLLLALPALLFSQDGQREGQRRCRLIFPEGLTQTVKGASAVAQVALGFALPLGVMVACYALLG RTLLAARGPERRRALRVWALVAAFWLQLPYSLALLLDTADLLAARERSCPASKRKDVALLVTSGLALARCGLNPV LYAFLGLRFRQDLRRLLRGGSCPSGPQPRRGCPRRPRLSSCSAPTETHSLSWDN

[0638] SEQ ID NO: 40 amino acid sequence of YIF1B

[0639] MHPAGLAAAAAGTPRLRKWPSKRRIPVSQPGMADPHQLFDDTSSAQSRGYGAQRAPGGLSYPAASPTPHAAFLADPV SNMAMAYGSSLAAQGKELVDKNIDRFIPITKLKYYFAVDTMYVGRKLGLLFFPYLHQDWEVQYQQDTPVAPRFDVNA PDLYIPAMAFITYVLVAGLALGTQDRFSPDLLGLQASSALAWLTLEVLAILLSLYLVTVNTDLTTIDLVAFLGYKYV GMI GGVLMGLLFGKI GYYLVLGWCCVAI FVFMI RTLRLKI LADAAAEGVPVRGARNQLRMYLTMAVAAAQPMLMYWL TFHLVR

[0640] SEQ ID NO: 41 amino acid sequence of CELA3B

[0641] MMLRLLSSLLLVAVASGYGPPSSRPSSRWNGEDAVPYSWPWQVSLQYEKSGSFYHTCGGSLIAPDWWTAGHCISS SRTYQWLGEYDRAVKEGPEQVIPINSGDLFVHPLWNRSCVACGNDIALIKLSRSAQLGDAVQLASLPPAGDILPNE TPCYITGWGRLYTNGPLPDKLQEALLPWDYEHCSRWNWWGSSVKKTMVCAGGDIRSGCNGDSGGPLNCPTEDGGWQ VHGVTSFVSAFGCNTRRKPTVFTRVSAFIDWIEETIASH

[0642] SEQ ID NO: 42 amino acid sequence of KCNIP3

[0643] MQPAKEVTKASDGSLLGDLGHTPLSKKEGIKWQRPRLSRQALMRCCLVKWILSSTAPQGSDSSDSELELSTVRHQPE GLDQLQAQTKFTKKELQSLYRGFKNECPTGLVDEDTFKLIYAQFFPQGDATTYAHFLFNAFDADGNGAIHFEDFWG LSILLRGTVHEKLKWAFNLYDINKDGYITKEEMLAIMKSIYDMMGRHTYPILREDAPAEHVERFFEKMDRNQDGWT IEEFLEACQKDENIMSSMQLFENVI

[0644] SEQ ID NO: 43 amino acid sequence of B3GNT5

[0645] MRMLVSGRRVKKWQLIIQLFATCFLASLMFFWEPIDNHIVSHMKSYSYRYLINSYDFVNDTLSLKHTSAGPRYQYLI NHKEKCQAQDVLLLLFVKTAPENYDRRSGIRRTWGNENYVRSQLNANIKTLFALGTPNPLEGEELQRKLAWEDQRYN DIIQQDFVDSFYNLTLKLLMQFSWANTYCPHAKFLMTADDDIFIHMPNLIEYLQSLEQIGVQDFWIGRVHRGAPPIR DKSSKYYVSYEMYQWPAYPDYTAGAAYVISGDVAAKVYEASQTLNSSLYIDDVFMGLCANKIGIVPQDHVFFSGEGK TPYHPCIYEKMMTSHGHLEDLQDLWKNATDPKVKTISKGFFGQIYCRLMKIILLCKISYVDTYPCRAAFI

[0646] SEQ ID NO: 44 amino acid sequence of TMEM135

[0647] MAALSKSIPHNCYEIGHTWHPSCRVSFLQITGGALEESLKIYAPLYLIAAILRKRKLDYYLHKLLPEILQSASFLTA NGALYMAFFCILRKILGKFYSWTPGFGAALPASYVAILIERKSRRGLLTIYMANLATETLFRMGVARGTITTLRNGE VLLFCITAAMYMFFFRCKDGLKGFTFSALRFIVGKEEIPTHSFSPEAAYAKVEQKREQHEEKPGRMNMIGLVRKFVD SICKHGPRHRCCKHYEDNCISYCIKGFIRMFSVGYLIQCCLRIPSAFRHLFTQPSRLLSLFYNKENFQLGAFLGSFV SIYKGTSCFLRWIRNLDDELHAIIAGFLAGISMMFYKSTTISMYLASKLVETMYFKGIEAGKVPYFPHADTIIYSIS

[0648] TAICFQAAVMEVQTLRPSYWKFLLRLTKGKFAVMNRKVLDVFGTGASKHFQDFIPRLDPRYTTVTPELPTEFS

[0649] SEQ ID NO: 45 amino acid sequence of MS4A8

[0650] MNSMTSAVPVANSVLWAPHNGYPVTPGIMSHVPLYPNSQPQVHLVPGNPPSLVSNVNGQPVQKALKEGKTLGAIQI IIGLAHIGLGSIMATVLVGEYLSISFYGGFPFWGGLWFIISGSLSVAAENQPYSYCLLSGSLGLNIVSAICSAVGVI LFITDLSIPHPYAYPDYYPYAWGVNPGMAISGVLLVFCLLEFGIACASSHFGCQLVCCQSSNVSVIYPNIYAANPVI TPEPVTSPPSYSSEIQANK

[0651] SEQ ID NO: 46 amino acid sequence of TMEM253

[0652] MEDRAGEQEQERHSLRLEKLQHWARHRQSGHLLVLAVSQLWLAWWPLAVSVACLNSDCHMATALPLGPGASGLLT GTVTLELRRAPRLWKVRAMMIFNTFNLILGFIWWEVMKTALGPAPTASSQHAGLLVLELSAEAFTLGGVLVSVHA LFLLSQRKPGCCRSQSLHYQELQEGFSELEEVPGLENGPTVASTGANERVGQREQTRAALLPP

[0653] SEQ ID NO: 47 amino acid sequence of TMEM72

[0654] MQLQVFWTGLEYTCRLLGITTAAVLIGVGTETFLQGQFKSLAFYLLFTGAAVSICEGAYFVAQLLAICFQCQPGSLA DRVREKAHWLGCFQKFLAYLLLSVACFLHPVLVWHVTIPGSMLIITGLAYFLLSKRKKRKAAPEVLASPEQYTDPSS SAVSTTGSGDTEQTYTFHGALKEGPSSLFIHMKSILKGTKKPSALQPPNTLMELSLEPADSLAKKKQVHFEDNLVRI VPSLAEGLDDGDSEPEETTSDTTPIIPPPQAPLFLSSLTATGLF

[0655] SEQ ID NO: 48 amino acid sequence of GPR156

[0656] MEPEINCSELCDSFPGQELDRRPLHDLCKTTITSSHHSSKTISSLSPVLLGIVWTFLSCGLLLILFFLAFTIHCRKN RIVKMSSPNLNIVTLLGSCLTYSSAYLFGIQDVLVGSSMETLIQTRLSMLCIGTSLVFGPILGKSWRLYKVFTQRVP DKRVIIKDLQLLGLVAALLMADVILLMTWVLTDPIQCLQILSVSMTVTGKDVSCTSTSTHFCASRYSDVWIALIWGC KGLLLLYGAYLAGLTGHVSSPPVNQSLTIMVGVNLLVLAAGLLFWTRYLHSWPNLVFGLTSGGIFVCTTTINCFIF IPQLKQWKAFEEENQTIRRMAKYFSTPNKSFHTQYGEEENCHPRGEKSSMERLLTEKNAVIESLQEQVNNAKEKIVR LMSAECTYDLPEGAAPPASSPNKDVQAVASVHTLAAAQGPSGHLSDFQNDPGMAARDSQCTSGPSSYAQSLEGPGKD SSFSPGKEEKISDSKDFSDHLDSGCSQKPWTEQSLGPERGDQVPMNPSQSLLPERGGSDPQRQRHLENSEEPPERRS RVSSVIREKLQEVLQDLGLGPEASLSTAPSCHQQTWKNSAAFSPQKMPLSKELGFSPYMVRRRRAAQRARSHFPGSA PSSVGHRANRTVPGAHSRLHVQNGDSPSLAPQTTDSRVRRPSSRKPSLPSDPQDRPGTLEGSKQSQTEPEGARGSKA AFLRQPSGSGRAPSPAAPCLSKASPDLPEQWQLWPPVPSGCASLSSQHSYFDTESSSSDEFFCRCHRPYCEICFQSS SDSSDSGTSDTDPEPTGGLASWEKLWARSKPIVNFKDDLKPTLV

[0657] SEQ ID NO: 49 amino acid sequence of LPAR4

[0658] MGDRRFIDFQFQDSNSSLRPRLGNATANNTCIVDDSFKYNLNGAVYSWFILGLITNSVSLFVFCFRMKMRSETAIF ITNLAVSDLLFVCTLPFKIFYNFNRHWPFGDTLCKISGTAFLTNIYGSMLFLTCISVDRFLAIVYPFRSRTIRTRRN SAIVCAGVWILVLSGGISASLFSTTNVNNATTTCFEGFSKRVWKTYLSKITIFIEWGFIIPLILNVSCSSWLRTL RKPATLSQIGTNKKKVLKMITVHMAVFWCFVPYNSVLFLYALVRSQAITNCFLERFAKIMYPITLCLATLNCCFDP FIYYFTLESFQKSFYINAHIRMESLFKTETPLTTKPSLPAIQEEVSDQTTNNGGELMLESTF

[0659] SEQ ID NO: 50 amino acid sequence of GPR12

[0660] MNEDLKVNLSGLPRDYLDAAAAENISAAVSSRVPAVEPEPELWNPWDIVLCTSGTLISCENAIWLIIFHNPSLRA PMFLLIGSLALADLLAGIGLITNFVFAYLLQSEATKLVTIGLIVASFSASVCSLLAITVDRYLSLYYALTYHSERTV TFTYVMLVMLWGTSICLGLLPVMGWNCLRDESTCSWRPLTKNNAAILSVSFLFMFALMLQLYIQICKIVMRHAHQI ALQHHFLATSHYVTTRKGVSTLAIILGTFAACWMPFTLYSLIADYTYPSIYTYATLLPATYNSIINPVIYAFRNQEI QKALCLICCGCIPSSLAQRARSPSDV

[0661] SEQ ID NO: 51 amino acid sequence of HTR2A

[0662] MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGCLSPSCLSLLHLQEKNWS ALLTAWIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIADMLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYL DVLFSTASIMHLCAISLDRYVAIQNPIHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLAD DNFVLIGSFVSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIHREPGSYTG RRTMQSISNEQKACKVLGIVFFLFWMWCPFFITNIMAVICKESCNEDVIGALLNVFVWIGYLSSAVNPLVYTLFNK TYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYKSSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSD GVNEKVSCV

[0663] SEQ ID NO: 52 amino acid sequence of SPRY1

[0664] MDPQNQHGSGSSLWIQQPSLDSRQRLDYEREIQPTAILSLDQIKAIRGSNEYTEGPSWKRPAPRTAPRQEKHERT HEIIPINVNNNYEHRHTSHLGHAVLPSNARGPILSRSTSTGSAASSGSNSSASSEQGLLGRSPPTRPVPGHRSERAIRTQPKQLIVDDLKGSLKEDLTQHKFICEQCGKCKCGECTAPRTLPSCLACNRQCLCSAESMVEYGTCMCLVKGIFYH

[0665] CSNDDEGDSYSDNPCSCSQSHCCSRYLCMGAMSLFLPCLLCYPPAKGCLKLCRRCYDWIHRPGCRCKNSNTVYCKLE

[0666] SCPSRGQGKPS

[0667] SEQ ID NO: 53 amino acid sequence of PCDHGA5

[0668] MASPPRGWGCGELLLPFMLLGTLCEPGSGQIRYSMPEELDKGSFVGNIAKDLGLEPQELAERGVRIVSRGRTQLFAL NPRSGSLVTAGRIDREELCAQSPLCWNFNILVENKMKIYGVEVEIIDINDNFPRFRDEELKVKVNENAAAGTRLVL PFARDADVGVNSLRSYQLSSNLHFSLDWSGTDGQKYPELVLEQPLDREKETVHDLLLTALDGGDPVLSGTTHIRVT VLDANDNAPLFTPSEYSVSVPENIPVGTRLLMLTATDPDEGINGKLTYSFRNEEEKISETFQLDSNLGEISTLQSLD YEESRFYLMEWAQDGGALVASAKVWTVQDVNDNAPEVILTSLTSSISEDCLPGTVIALFSVHDGDSGENGEIACS IPRNLPFKLEKSVDNYYHLLTTRDLDREETSDYNITLTVMDHGTPPLSTESHIPLKVADVNDNPPNFPQASYSTSVT ENNPRGVSIFSVTAHDPDSGDNARVTYSLAEDTFQGAPLSSYVSINSDTGVLYALRSFDYEQLRDLQLWVTASDSGN PPLSSNVSLSLFVLDQNDNTPEILYPALPTDGSTGVELAPRSAEPGYLVTKWAVDKDSGQNAWLSYRLLKASEPGL FAVGLHTGEVRTARALLDRDALKQSLWAVEDHGQPPLSATFTVTVAVADRIPDILADLGSIKTPIDPEDLDLTLYL WAVAAVSCVFLAFVIVLLVLRLRRWHKSRLLQAEGSRLAGVPASHFVGVDGVRAFLQTYSHEVSLTADSRKSHLIF PQPNYADTLLSEESCEKSEPLLMSDKVDANKEERRVQQAPPNTDWRFSQAQRPGTSGSQNGDDTGTWPNNQFDTEML QAMILASASEAADGSSTLGGGAGTMGLSARYGPQFTLQHVPDYRQNVYIPGSNATLTNAAGKRDGKAPAGGNGNKKK SGKKEKK

[0669] SEQ ID NO: 54 amino acid sequence of STEAP3

[0670] MSHQPAVATKMPEEMDKPLISLHLVDSDSSLAKVPDEAPKVGILGSGDFARSLATRLVGSGFKVWGSRNPKRTARL FPSAAQVTFQEEAVSSPEVIFVAVFREHYSSLCSLSDQLAGKILVDVSNPTEQEHLQHRESNAEYLASLFPTCTWK AFNVI SAWTLQAGPRDGNRQVPICGDQPEAKRAVSEMALAMGFMPVDMGSLASAWEVEAMPLRLLPAWKVPTLLALG LFVCFYAYNFVRDVLQPYVQESQNKFFKLPVSWNTTLPCVAYVLLSLVYLPGVLAAALQLRRGTKYQRFPDWLDHW LQHRKQIGLLSFFCAALHALYSFCLPLRRAHRYDLVNLAVKQVLANKSHLWVEEEVWRMEIYLSLGVLALGTLSLLA VTSLPSIANSLNWREFSFVQSSLGFVALVLSTLHTLTYGWTRAFEESRYKFYLPPTFTLTLLVPCWILAKALFLLP CIS RRLARI RRGWE RE S T I K FT L P T DHALAE KT S H V

[0671] SEQ ID NO: 55 amino acid sequence of KCNJ9

[0672] MAQENAAFSPGQEEPPRRRGRQRYVEKDGRCNVQQGNVRETYRYLTDLFTTLVDLQWRLSLLFFVLAYALTWLFFGA IWWLIAYGRGDLEHLEDTAWTPCVNNLNGFVAAFLFSIETETTIGYGHRVITDQCPEGIVLLLLQAILGSMVNAFMV GCMFVKISQPNKRAATLVFSSHAWSLRDGRLCLMFRVGDLRSSHIVEASIRAKLIRSRQTLEGEFIPLHQTDLSVG FDTGDDRLFLVSPLVISHEIDAASPFWEASRRALERDDFEIWILEGMVEATGMTCQARSSYLVDEVLWGHRFTSVL TLEDGFYEVDYASFHETFEVPTPSCSARELAEAAARLDAHLYWSIPSRLDEKVEEEGAGEGAGGEAGADKEQNGCLP PPESESKV

[0673] SEQ ID NO: 56 amino acid sequence of DEFB126

[0674] MKSLLFTLAVFMLLAQLVSGNWYVKKCLNDVGICKKKCKPEEMHVKNGWAMCGKQRDCCVPADRRANYPVFCVQTKT TRISTVTATTATTTLMMTTASMSSMAPTPVSPTG

[0675] SEQ ID NO: 57 amino acid sequence of C19orf38

[0676] MPWTILLFAAGSLAI PAPSIRLVPPYPSSQEDPIHIACMAPGNFPGANFTLYRGGQWQLLQAPTDQRGVTFNLSGG SSKAPGGPFHCQYGVLGELNQSQLSDLSEPVNVSFPVPTWILVLSLSLAGALFLLAGLVAVALWRKVKLRNLQKKR DRESCWAQINFDSTDMSFDNSLFTVSAKTMPEEDPATLDDHSGTTATPSNSRTRKRPTSTSSSPETPEFSTFRACQ

[0677] SEQ ID NO: 58 amino acid sequence of BICD 1

[0678] MAAEEVLQTVDHYKTEIERLTKELTETTHEKIQAAEYGLWLEEKLTLKQQYDELEAEYDSLKQELEQLKEAFGQSF SIHRKVAEDGETREETLLQESASKEAYYLGKILEMQNELKQSRAWTNVQAENERLTAWQDLKENNEMVELQRIRM KDEIREYKFREARLLQDYTELEEENITLQKLVSTLKQNQVEYEGLKHEIKRFEEETVLLNSQLEDAIRLKEIAEHQL EEALETLKNEREQKNNLRKELSQYISLNDNHISISVDGLKFAEDGSEPNNDDKMNGHIHGPLVKLNGDYRTPTLRKG ESLNPVSDLFSELNISEIQKLKQQLMQVEREKAILLANLQESQTQLEHTKGALTEQHERVHRLTEHVNAMRGLQSSK ELKAELDGEKGRDSGEEAHDYEVDINGLEILECKYRVAVTEVIDLKAEIKALKEKYNKSVENYTDEKAKYESKIQMY DEQVTSLEKTTKESGEKMAHMEKELQKMTSIANENHSTLNTAQDELVTFSEELAQLYHHVCLCNNETPNRVMLDYYR QSRVTRSGSLKGPDDPRGLLSPRLARRGVSSPVETRTSSEPVAKESTEASKEPSPTKTPTISPVITAPPSSPVLDTS DIRKEPMNIYNLNAIIRDQIKHLQKAVDRSLQLSRQRAAARELAPMIDKDKEALMEEILKLKSLLSTKREQIATLRA VLKANKQTAEVALANLKNKYENEKAMVTETMTKLRNELKALKEDAATFSSLRAMFATRCDEYVTQLDEMQRQLAAAE DEKKTLNTLLRMAIQQKLALTQRLEDLEFDHEQSRRSKGKLGKSKIGSPKVSGEASVTVPTIDTYLLHSQGPQTPNI RVSSGTQRKRQFSPSLCDQSRPRTSGASYLQNLLRVPPDPTSTESFLLKGPPSMSEFIQGHRLSKEKRLTVAPPDCQQPAASVPPQCSQLAGRQDCPTVSPDTALPEEQPHSSSQCAPLHCLSKPPHP

[0679] SEQ ID NO: 59 amino acid sequence of MFSD14B

[0680] MSVEPPPELEEKAASEPEAGAMPEKRAGAQAAGSTWLQGFGRPSVYHAAIVIFLEFFAWGLLTTPMLTVLHETFSQH TFLMNGLIQGVKGLLSFLSAPLIGALSDVWGRKPFLLGTVFFTCFPIPLMRISPWWYFAMISVSGVFSVTFSVIFAY VADVTQEHERSTAYGWVSATFAASLVSSPAIGAYLSASYGDSLWLVATWALLDICFILVAVPESLPEKMRPVSWG AQISWKQADPFASLKKVGKDSTVLLICITVFLSYLPEAGQYSSFFLYLRQVIGFGSVKIAAFIAMVGILSIVAQTAF LSILMRSLGNKNTVLLGLGFQMLQLAWYGFGSQAWMMWAAGTVAAMSSITFPAI SALVSRNAESDQQGVAQGIITGI RGLCNGLGPALYGFIFYMFHVELTELGPKLNSNNVPLQGAVIPGPPFLFGACIVLMSFLVALFIPEYSKASGVQKHS NSSSGSLTNTPERGSDEDIEPLLQDSSIWELSSFEEPGNQCTEL

[0681] SEQ ID NO: 60 amino acid sequence of ADRA1 A

[0682] MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTS TVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALS LVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYWAKRESRGLKSGLKTDKSDSEQ VTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIWGCFVLCWLPFFLVMPIGSFFPDFKPSETVF KIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETF YRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSEN GEEV

[0683] SEQ ID NO: 61 amino acid sequence of CALCR

[0684] MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYWGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWD GWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIV GHSLSIFTLVISLGIFVFFRSLGCQRVTLHKNMFLTYILNSMIIIIHLVEWPNGELVRRDPVSCKILHFFHQYMMA CNYFWMLCEGIYLHTLIWAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAA LWNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKATMILVPLLGIQFWFPWRPSNKMLGKIYDYVMHSLIHFQGF FVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQELRNEPANNQGEESAEI IPLNIIEQESSA

[0685] SEQ ID NO: 62 amino acid sequence of S1PR2

[0686] MGSLYSEYLNPNKVQEHYNYTKETLETQETTSRQVASAFIVILCCAIWENLLVLIAVARNSKFHSAMYLFLGNLAA SDLLAGVAFVANTLLSGSVTLRLTPVQWFAREGSAFITLSASVFSLLAIAIERHVAIAKVKLYGSDKSCRMLLLIGA SWLISLVLGGLPILGWNCLGHLEACSTVLPLYAKHYVLCWTIFSIILLAIVALYVRIYCWRSSHADMAAPQTLAL LKTVTIVLGVFIVCWLPAFSILLLDYACPVHSCPILYKAHYFFAVSTLNSLLNPVIYTWRSRDLRREVLRPLQCWRP GVGVQGRRRGGTPGHHLLPLRSSSSLERGMHMPTSPTFLEGNTW

[0687] SEQ ID NO: 63 amino acid sequence of ZBTB33

[0688] MESRKLISATDIQYSGSLLNSLNEQRGHGLFCDVTVIVEDRKFRAHKNILSASSTYFHQLFSVAGQWELSFIRAEI FAEILNYIYSSKIVRVRSDLLDELIKSGQLLGVKFIAELGVPLSQVKSISGTAQDGNTEPLPPDSGDKNLVIQKSKD EAQDNGATIMPIITESFSLSAEDYEMKKIIVTDSDDDDDDVIFCSEILPTKETLPSNNTVAQVQSNPGPVAISDVAP SASNNSPPLTNITPTQKLPTPVNQATLSQTQGSEKLLVSSAPTHLTPNIILLNQTPLSTPPNVSSSLPNHMPSSINL LVQNQQTPNSAILTGNKANEEEEEEIIDDDDDTISSSPDSAVSNTSLVPQADTSQNTSFDGSLIQKMQIPTLLQEPL SNSLKISDIITRNTNDPGVGSKHLMEGQKIITLDTATEIEGLSTGCKVYANIGEDTYDIVI PVKDDPDEGEARLENE IPKTSGSEMANKRMKVKHDDHYELIVDGRVYYICIVCKRSYVCLTSLRRHFNIHSWEKKYPCRYCEKVFPLAEYRTK HEIHHTGERRYQCLACGKSFINYQFMSSHIKSVHSQDPSGDSKLYRLHPCRSLQIRQYAYLSDRSSTIPAMKDDGIG YKVDTGKEPPVGTTTSTQNKPMTWEDIFIQQENDSIFKQNVTDGSTEFEFIIPESY

[0689] SEQ ID NO: 64 amino acid sequence of MUC21

[0690] MKMQKGNVLLMFGLLLHLEAATNSNETSTSANTGSSVISSGASTATNSGSSVTSSGVSTATISGSSVTSNGVSIVTN SEFHTTSSGISTATNSEFSTVSSGISIATNSESSTTSSGASTATNSESSTPSSGASTATNSDSSTTSSGASTATNSD SSTTSSEASTATNSESSTTSSGASTATNSESSTVSSRASTATNSESSTTSSGASTATNSESRTTSNGAGTATNSESS TTSSGASTATNSESSTPSSGAGTATNSESSTTSSGAGTATNSESSTVSSGISTVTNSESSTPSSGANTATNSESSTT SSGANTATNSDSSTTSSGASTATNSESSTTSSGASTATNSESSTTSSGASTATNSGSSTTSSGTSTATNSESSTVSS GASTATTSESSTTSSGASTATNSESSTVSSGASTATNSESSTTSSGANTATNSGSSVTSAGSGTAALTGMHTTSHSA STAVSEAKPGGSLVPWEIFLITLVSWAAVGLFAGLFFCVRNSLSLRNTFNTAVYHPHGLNHGLGPGPGGNHGAPHR PRWS PNWFWRRPVS S I AMEMS GRNS GP

[0691] SEQ ID NO: 65 amino acid sequence of UGT2B11

[0692] MTLKWTSVLLLIHLSCYFSSGSCGKVLVWAAEYSHWMNMKTILKELVQRGHEVTVLASSASILFDPNDASTLKFEVY PTSLTKTEFENIIMQQVKRWSDIRKDSFWLYFSQEQEILWELYDIFRNFCKDWSNKKVMKKLQESRFDIVFADAVF PCGELLAALLNIRFVYSLRFTPGYTIERHSGGLIFPPSYIPIVMSKLSDQMTFMERVKNMIYVLYFDFWFQMSDMKK WDQFYSEVLGRPTTLFETMGKADIWLMRNSWSFQFPHPFLPNVDFVGGFHCKPAKPLPKEMEEFVQSSGENGVWFS LGSVISNMTAERANVIATALAKIPQKVLWRFDGNKPDALGLNTRLYKWIPQNDLLGHPKTRAFITHGGANGIYEAIY HGIPMVGIPLFFDQPDNIAHMKAKGAAVRLDFNTMSSTDLLNALKTVINDPLYKENIMKLSRIQHDQPVKPLDRAVF WIEFVMPHKGAKHLRVAAHDLTWFQYHSLDVIGFLLACVATVIFIITKFCLFCFWKFARKGKKGKRD

[0693] SEQ ID NO: 66 amino acid sequence of CRB2

[0694] MALARPGTPDPQALASVLLLLLWAPALSLLAGTVPSEPPSACASDPCAPGTECQATESGGYTCGPMEPRGCATQPCH HGALCVPQGPDPTGFRCYCVPGFQGPRCELDIDECASRPCHHGATCRNLADRYECHCPLGYAGVTCEMEVDECASAP CLHGGSCLDGVGSFRCVCAPGYGGTRCQLDLDECQSQPCAHGGTCHDLVNGFRCDCAGTGYEGTHCEREVLECASAP CEHNASCLEGLGSFRCLCWPGYSGELCEVDEDECASSPCQHGGRCLQRSDPALYGGVQAAFPGAFSFRHAAGFLCHC PPGFEGADCGVEVDECASRPCLNGGHCQDLPNGFQCHCPDGYAGPTCEEDVDECLSDPCLHGGTCSDTVAGYICRCP ETWGGRDCSVQLTGCQGHTCPLAATCIPIFESGVHSYVCHCPPGTHGPFCGQNTTFSVMAGSPIQASVPAGGPLGLA LRFRTTLPAGTLATRNDTKESLELALVAATLQATLWSYSTTVLVLRLPDLALNDGHWHQVEWLHLATLELRLWHEG CPARLCVASGPVALASTASATPLPAGISSAQLGDATFAGCLQDVRVDGHLLLPEDLGENVLLGCERREQCRPLPCVH GGSCVDLWTHFRCDCARPHRGPTCADEIPAATFGLGGAPSSASFLLQELPGPNLTVSFLLRTRESAGLLLQFANDSA AGLTVFLSEGRIRAEVPGSPAWLPGRWDDGLRHLVMLSFGPDQLQDLGQHVHVGGRLLAADSQPWGGPFRGCLQDL RLDGCHLPFFPLPLDNSSQPSELGGRQSWNLTAGCVSEDMCSPDPCFNGGTCLVTWNDFHCTCPANFTGPTCAQQLW CPGQPCLPPATCEEVPDGFVCVAEATFREGPPAAFSGHNASSGRLLGGLSLAFRTRDSEAWLLRAAAGALEGVWLAV RNGSLAGGVRGGHGLPGAVLPIPGPRVADGAWHRVRLAMERPAATTSRWLLWLDGAATPVALRGLASDLGFLQGPGA VRILLAENFTGCLGRVALGGLPLPLARPRPGAAPGAREHFASWPGTPAPILGCRGAPVCAPSPCLHDGACRDLFDAF ACACGPGWEGPRCEAHVDPCHSAPCARGRCHTHPDGRFECRCPPGFGGPRCRLPVPSKECSLNVTCLDGSPCEGGSP AANCSCLEGLAGQRCQVPTLPCEANPCLNGGTCRAAGGVSECICNARFSGQFCEVAKGLPLPLPFPLLEVAVPAACA CLLLLLLGLLSGILAARKRRQSEGTYSPSQQEVAGARLEMDSVLKVPPEERLI

[0695] SEQ ID NO: 67 amino acid sequence of GRM2

[0696] MGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQRLEAMLFALDRINRDPH LLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHICPDGSYATHGDAPTAITGVIGGSYSDVSIQVANL LRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARAR NICVATSEKVGRAMSRAAFEGWRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGALESWAGSE GAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLRAVPFEQESKIMFWNAV YAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAG SGRYRYQKVGYWAEGLTLDTSLIPWASPSAGPLPASRCSEPCLQNEVKSVQPGEVCCWLCIPCQPYEYRLDEFTCAD CGLGYWPNASLTGCFELPQEYIRWGDAWAVGPVTIACLGALATLFVLGVFVRHNATPWKASGRELCYILLGGVFLC YCMTFI FIAKPSTAVCTLRRLGLGTAFSVCYSALLTKTNRIARI FGGAREGAQRPRFI S PASQVAI CLALI SGQLLI WAWLWEAPGTGKETAPERREWTLRCNHRDASMLGSLAYNVLLIALCTLYAFKTRKCPENFNEAKFIGFTMYTTC IIWLAFLPIFYVTSSDYRVQTTTMCVSVSLSGSWLGCLFAPKLHIILFQPQKNWSHRAPTSRFGSAAARASSSLG QGSGSQFVPTVCNGREWDSTTSSL

[0697] SEQ ID NO: 68 amino acid sequence of NAXD

[0698] MALGPRCGAIRACRRVLERAFSLRKAHSIKDMENTLQLVRNIIPPLSSTKHKGQDGRIGWGGCQEYTGAPYFAAIS ALKVGADLSHVFCASAAAPVIKAYSPELIVHPVLDSPNAVHEVEKWLPRLHALWGPGLGRDDALLRNVQGILEVSK ARDIPWIDADGLWLVAQQPALIHGYRKAVLTPNHVEFSRLYDAVLRGPMDSDDSHGSVLRLSQALGNVTWQKGER DILSNGQQVLVCSQEGSSRRCGGQGDLLSGSLGVLVHWALLAGPQKTNGSSPLLVAAFGACSLTRQCNHQAFQKHGR STTTSDMIAEVGAAFSKLFET

[0699] References

[0700] Dudek, A. M., et al., Mol. Ther. 28 (2020) 367-381.

[0701] Freeth, J. and Soden, J., SLAS Discov. 25 (2019) 223-230.

[0702] Hao, S., et al., J. Virol. 97 (2023) e01330-23.

[0703] Joung, J., et al., Nat. Prot. 12 (2017) 828-863.

[0704] Pillay, S., et al., Nature 530 (2016) 108-112.

[0705] Shay, T. F., et al., Nat. Commun. 15 (2024) 7853.

[0706] General Cell Culture Method

[0707] An adherent human embryonic kidney cell line 293 (HEK293) was cultured in Dulbecco's Modified Eagle Medium (DMEM) High Glucose medium (PAN-Biotech, #P04-01597), supplemented with 10 % fetal bovine serum (FBS) (Gibco, #A5670801), 1 % L-Glutamine (Life Technologies, #35050-038) and 1 % Penicillin-Streptomycin. The cells were passaged using Trypsin 0.05 % - EDTA 0.02 % (PAN-Biotech, #P10-023100), and cultured at 37 °C and 5 % CO2 in a humidified incubator.

[0708] Gibco™ Viral Production Cells (Gibco, #A35347) for lentivirus production were cultured in LV-MAX™ Production Medium (Gibco, #A3583401) according to the manufacturer's instructions. These cells were cultured at about 95 rpm, 37 °C and 8 % CO2 on an orbital shaker platform with >80 % humidity.

[0709]

[0710] Generation of adherent HEK293 stable clones for CRISPR-mediated gene activation

[0711] An adherent HEK293 cell line was engineered to express the components of a CRISPR-mediated transcriptional activator (CRISPRa) system based on the Synergistic Activation Mediator (SAM) concept. These cells will be referred to as HEK293A SAM cells hereafter. The SAM system consists of a catalytically inactive form of Cas9 (dCas9) fused to the transcriptional activator domain VP64 and an MCP-(MS2 coat protein) p65-HSFl co-activator fusion protein (MPH). The gene encoding MPH-dCas9-VP64 fusion protein under the control of a CAG promoter was stably integrated in HEK293 A cells using a transposition-based system consisting of two plasmids: one encoding a transposon vector carrying a puromycin resistance in which the MPH-dCas9-VP64 transgene under the control of a CAG promoter was flanked by two inverted terminal repeats / and another one encoding a transposase. The transposon and the transposase vectors were cotransfected into adherent HEK293A cells using Lipofectamine 3000 reagent (Invitrogen, #L3000008) according to the manufacturer’s protocol. Genetically-engineered adherent HEK293A cells were maintained in the media described above supplemented with 2.5 pg / mL puromycin (Gibco, #A1113803).

[0712] Adherent HEK293A cells stably expressing the CRISPRa transgene were isolated by single cell sorting with a BD FACSAria III cell sorter (BD Biosciences) and cultured to establish stable cell clones. To assess gene activation potential, stable cell clones were transiently transfected withSAM-compatible guide RNAs (gRNAs) targeting the promoter regions of two cell surface receptor genes (PD-L1 and CD2) using Lipofectamine 3000. Flow cytometry analysis using anti-human APC PD-L1 and anti-human APC CD2 antibodies (Miltenyi Biotec, #130-127-907 and #130-116-253, respectively) was performed 72 h post-transfection. The clone showing higher levels of PD-L1 and CD2 in the gRNA condition compared to the non-targeting control was expanded and used to perform the screens and further experiments.

[0713]

[0714] and cloning of a targeted CRISPRa library

[0715] The gRNA library was designed as two separate pools. The first pool targeted 2079 genes and a total of 2517 transcription start sites (TSS) with 15 gRNAs per TSS on average. Targeted genes included 400 GPCR genes (458 TSS), 1679 STM (single-pass transmembrane) genes (2059 TSS) and other genes encoding tyrosine-kinase, cytokine and neuropeptide receptors and adhesion molecules. Moreover, the first pool included 500 non-targeting controls for a total of 37 897 gRNAs. The second pool targeted 4459 genes and 5336 TSS with on average 10 gRNAs per TSS. Targeted genes encoded 412 GPCRs (608 TSS) and other ion channels, amino acid transporters and olfactory receptors. This second pool included the same 500 non-targeting controls for a total of 53586 gRNAs.

[0716] Each pool was synthesized separately and cloned under the control of a U6 promoter in a lentiviral vector containing a blue fluorescent protein reporter (mTagBFP2) and a bleomycin resistance (BleoR) marker driven by the human PGK promoter. Both pools were amplified separately in 400 mL Luria-Bertani (LB) medium supplemented with Ampicillin (100 pg / mL) for 16 h before harvesting and plasmid extraction using the NucleoBond Xtra Maxi Kit for Plasmid DNA (74014.50). Each pool was PCR-amplified using staggered forward primers binding to the U6 promoter and a different barcoded reverse primer binding to the tracrRNA compatible with Illumina Next Generation Sequencing as previously described (Joung et al., 2017). Single-end 75 bp sequencing of this product revealed a good representation of both library pools, with the second and largest pool being a bit less even.

[0717]

[0718] Production of lentiviruses carrying the targeted CRISPRa library

[0719] Lentivirus production was done using the LV-MAX™ Lentiviral Production System (Gibco, # A35684) according to the manufacturer's instructions. Briefly, LV-MAX Production Cells (#A35347) were seeded at a density of 3.5E6 cells / mL in five 125 mL Erlenmeyer flasks with 20 mL of cell suspension each. On the next day, cells were diluted to a density of 4.7E6 cells / mL with fresh LV-MAX™ Production Medium (#A3583401) followed by the addition of LV-MAX™

[0720] Supplement in the LV-MAX™ Transfection Kit (# A35346). The cells were transfected with three packaging plasmids from the ViraSafe Lentiviral Packaging System (Cell Biolabs, #VPK-206) at a 1:1:1 ratio and the two plasmids containing gRNA library pools 1 and 2. A total of 1.5 pg of packaging plasmids per mL and 1 pg of library plasmids per mL were diluted in Opti-MEM, and 6 pL / mL of LV-MAX™ transfection reagent from the kit was diluted in Opti-MEM. The DNA and transfection mixes were incubated together for 10 min. at room temperature before transferring the DNA-Transfection Reagent complexes to the flasks. Five to six hours post transfection, 4 % of the total volume of LV-MAX™ Enhancer was added to the flasks. About 48-55 h post transfection, the medium was collected, centrifuged to pellet cells, filtered through a 0.45 m filter and concentrated using % of the volume of Lenti-X Concentrator (Takara, #631232) following manufacturer’s instructions. The final virus pellet was resuspended in 1 / 100 of the original volume of PBS and stored in aliquots at -80 °C

[0721] Example 4

[0722] Functional titration of lentiviruses carrying the targeted CRISPRa library

[0723] HEK293 A SAM cells were seeded in 12-well plates at a density of 5E5 cells per well. Immediately after seeding, five pL of different lentiviral dilutions were added in duplicate to the cells (1 / 10, 1 / 20, 1 / 30, 1 / 40 and 1 / 50 dilutions). Fresh medium was added 48 hours post-transfection. Four days after transfection and following light-fixation of the cells with 2.5 % PF A, blue fluorescent protein (BFP)-positive cells were determined by flow cytometry in a BD FACSCelesta Cell Analyzer (BD Biosciences). A dilution that resulted in 30 % of BFP+ transduced cells (MOI ~0.5) was selected and scaled up to the cell numbers used in the screen.

[0724] Example 5

[0725] Production of rAAV by triple transfection

[0726] Recombinant AAVs were produced by triple transfection in Expi293F (Thermo Fisher Scientific) cells using PEI MAX (Polysciences) as a transfection reagent according to the manufacturers’ recommendation. In brief, Expi293F cells were grown in shake flasks with a culture volume of 125 mL to a density of 3E6 cells / mL. For transfection, equimolar amounts of a first plasmid carrying the rep-cap gene of AAV2 (pAAV2_rep / cap), a second plasmid carrying the adenoviral helper genes E4, E2a and VA (pHelper) and a third plasmid carrying the reporter gene of interest flanked by AAV2 ITRs (pTransgene) were combined and diluted in 2.5 mL Expi293 expression medium. In total 0.6 pg DNA per 1E6 cells was used. PEI MAX was separately mixed with 2.5 mL Expi293 expression medium and combined with the DNA mix at a ratio of 1:2.5 (DNA: PEI). After incubation the DNA-PEI complexes were added dropwise to the cells. Finally, transfected cell cultures were incubated at 37 °C, 125 rpm and 8% CO2 for 72 h.

[0727] To harvest recombinant AAVs, cells were centrifuged at 300 g for 5 min. and chemically lysed using a Triton CG-110-based lysis buffer containing 50 U / mL DENARASE (c-LEcta). For complete lysis, the cells were incubated and agitated for 1.5 h at 37 °C and 180 rpm. To remove cell debris, the suspension was centrifuged at 4,000 x g for 60 min. At last, the supernatant was passed through a 0.8 / 0.2 pm dual filter unit and collected. The sterile and clarified cell lysates were stored at -80 °C until the iodixanol gradient purification was performed.

[0728] This process can be up-scaled to 500 L.

[0729]

[0730] Purification of rAAV by iodixanol gradient ultracentrifugation

[0731] For purification and separation of full rAAV particles, iodixanol density-gradient ultracentrifugation was applied, using layers of 60 %, 40 %, 25 % and 15 % iodixanol. Filtered virus lysates were thawed and transferred to an ultracentrifugation tube. Subsequently, the differently concentrated iodixanol solutions were added on top, tubes were mass balanced, sealed and centrifuged at 230,000 x g for 2 hours at 4 °C in a Beckman 50.2 Ti Rotor. Upon centrifugation, tubes were fixed well and punctured on the top with a 21G needle to allow air inflow. After centrifugation, a second 21G needle attached to a syringe was carefully inserted below the 60-40 % interface and 1.0 to 2.5 mL were collected from the 40 % phase. The resulting vector stocks were either stored at -80 °C or further processed to exchange the iodixanol against PBS and increase the virus particle concentration. This was achieved by ultrafiltration using Amicon Ultra- 15 centrifugal filter units. Concentrated samples were stored at -80 °C.

[0732]

[0733] Functional titration of rAAV

[0734] HEK293 A SAM cells were seeded in 12-well plates at a density of 5E5 cells per well. On the next day, cells were transduced in triplicates with different MOIs of AAV9 carrying an mGreenLantem transgene. Two days after transduction, mGreenLantem fluorescence was evaluated in a BD FACSCelesta Cell Analyzer (BD Biosciences). A titration curve was generated by plotting the % of transduced cells at each MOI. The MOI corresponding to the inflection point in the curve was used to perform the CRISPRa screen. The rationale behind this approach was to use an MOI at which cells were not transduced (<5 % mGreenLantern+ cells) but primed to be highly transduced with small changes in MOI (or in receptor / co-receptor overexpression).

[0735]

[0736] Pooled CRISPRa screen of membrane

[0737] Three independent replicates of transduction were performed on independent days. For each of these screen replicates, a 500x coverage was aimed at, which equals to 500 cells per gRNA in the library. Therefore, 153 million HEK293A SAM cells were transduced with the lentiviral gRNA library at an MOI of -0.4-0.5, so that only 30 % of cells were infected, thereby minimizing the risk of having more than one gene activated in each cell. The corresponding amount of concentrated virus was added to the cells in suspension, and then cells were seeded in 25 Pl 50 mm dishes (Sarstedt, #83.3903) with 6.4 million cells per dish. Non-transduced cells were seeded at the same density in an extra dish for selection control. Fresh media containing 300 pg / mL zeocin (Invitrogen, #R25001) was added 48 h post transduction. The selection medium was renewed every 2 days. Eight days after transduction and six days after the start of selection, cells were detached, and 180 million cells were seeded again in 14 Pl 50 mm dishes to maintain the 500x coverage for the library, taking into account that half of the cells would be lost during the sorting and that a bulk control population should be separated before the sorting. After verifying that cells were free from lentivirus using the Takara Lenti-X p24 Rapid Titer kit, the rest of transduced cells were frozen at a density of 10 million cells per vial. 5-6 h after seeding, once the cells were attached, AAV9 was added at an MOI of 25 000. In the case of the AAVrh74 screen, 100 million frozen cells were thawed and expanded for one week for each screen replicate. These cells were detached on day 8 after thawing and seeded at a density of 12 million cells per Pl 50 mm dish in a minimum of 12 dishes per replicate. AAVrh74 was added at an MOI of 13 0005-6 h after seeding. For both screens, 0.5 million cells were seeded in one 6-well and not transduced with the AAV as a control to set the gates during the sorting.

[0738] Fluorescence-activated cell sorting (FACS) was performed 48 h after transduction with AAV9 and ten days after transduction with the lentiviral gRNA library, when all cells in the non-transduced control were dead. A fraction of approximately 40 million cells was separated as a bulk control. The rest of cells were sorted according to their mGreenLantern fluorescence. Briefly, cells were collected and resuspended in FACS buffer (5% FBS in PBS), filtered using polystyrene tubes with 35 pm cell strainer snap caps (Falcon, #352235), and kept on ice prior to sorting using BD FACSAria II cell sorter (BD Biosciences). For each replicate, about 11 % mGreenLantem-positive cells with highest fluorescence intensity and aboutl 1 % mGreenLantern-negative cells with lowest intensity were purified.

[0739] Sorted cells were pelleted and genomic DNA was extracted using Quick-DNA Midiprep Plus Kit (Zymo Research #D4075). gRNAs from bulk and sorted cell fractions from all three screen replicates were amplified with NEBNext Ultrall Q5 Master mix (New England Biolabs, #M0544L) using forward staggered primers and barcoded reverse primers with sequencing adapters. PCR was performed with 2 pg of DNA and a final primer concentration of 0.5 pM as described earlier (Joung et al., 2017). Cycling conditions were 98 °C for 3 min., 23 cycles of (98 °C10 sec., 65 °C 75 sec.) and 65 °C for 5 min. PCR products were purified using 1.8X SPRISelect beads (Beckman Coulter GmbH, #B23318) following the manufacturer’s instructions and ran on a 4200 TapeStation system (Agilent) using a DI 000 tape and reagents (Agilent Technologies, #5067-5582 and #5067-5583, respectively). All samples were quantified using the KAPA Library Quantification Kit optimized for LightCycler® 480 (Roche Diagnostics GmbH, #KK4854), pooled to get even numbers of reads for all samples (-500 reads per gRNA in the library per sample) and sequenced using a NovaSeq 6000 instrument with 100 cycles per flowcell.

[0740]

[0741] analysis of CRISPRa screen results

[0742] Raw fastq files were mapped to the gRNA sequences in the CRISPRa library using the MAGeCK algorithm (version = 0.5.9.5 with Python 3.12.4) (Li 2014). gRNA read counts were normalized to the total number of reads. Quality control visualization was performed in R 4.4.1 as described using the MAGeCKFlute package (2.9.0) as described previously (Wang 2019).

[0743] Enrichment and depletion of gRNAs in mGreenLantem-positive (transduced) cells compared to the bulk cell fraction was calculated using the robust rank aggregation (RRA) statistical method from the MAGeCK algorithm (0.5.9.5) with pairwise comparisons across screen replicates. gRNAs with less than 20 read counts in all samples were excluded from further analyses to increase robustness. Log fold changes (LFC) of gRNA abundance at the gene level were calculated as the median LFC of gRNAs with a false discovery rate (FDR) <0.25. Results were plotted using ggplot2 in R 4.4.1. Genes that were positively enriched in mGreenLantern-positive cells with an FDR<0.05 were defined as hits and selected for validations.

[0744] Example 10

[0745] Validation of CRISPRa screen hits by cDNA delivery

[0746] HEK293 wild type cells were seeded in 48-well plates at a density of 12,500 cells per well. The day after seeding, cells were transfected using Lipofectamine 3000 with individual plasmids containing each of the cDNAs encoding the most prevalent isoform of the 14 top-ranked genes from the CRISPRa screen. Thirty hours post transfection, AAV9-mGreenLantern was added to each of the wells at an MOI of 25,000. Forty-eight hours after the addition of AAV9 and seventy-two hours post-transfection, cells were imaged and the percentage of transduced cells (mGreenLantem positive) was quantified using a BD FACSCelesta Cell Analyzer (BD Biosciences).

[0747]

[0748] Statistical analysis

[0749] Statistical analyses of experimental data were conducted using R 4.4.1 and GraphPad Prism (GraphPad Software, version 10.4.1). Statistically significant differences were tested as reported in figure legends.

[0750]

[0751] for the validation of CRISPRa screen hits

[0752] HEK293 wild type cells were seeded in 12-well plates at a density of 70,000 cells per well. The day after seeding, cells were co-transfected with individual plasmids containing each of the cDNAs encoding the most prevalent isoform of top-ranked genes from the CRISPRa screens and a plasmid encoding the Sleeping Beauty transposase in a 2:1 ratio. Transfections were performed in OptiMEM reduced-serum media (Gibco, #31985062) using Lipofectamine 3000 (ThermoFisher, #L30000I5) with a 3:1 ratio of Lipofectamine: DNA and a 2:1 ratio of P3000: DNA. The total amount of DNA per well was 1 ug. Cells from each well were split 48-72 h post-transfection, and Puromycin (Gibco, #A1113803) selection was added 96 h post-transfection at 2.5 ug / mL. Cells were kept under that selection pressure for all subsequent experiments.

[0753] For the validation of screen hits, each of the generated cell lines were seeded in triplicates in a 96-well plate at a density of 7,000 cells per well. The day after seeding, cells were transduced with the appropriate AAV carrying a fluorescent protein transgene at different MOIs: 25K, 50K, 75K, 100K and 200K for AAV9; 25K, 100K and 200K for AAVrh74. Fluorescence was measured 48 h post transfection using an Incucyte Live-Cell Analysis System (Sartorius) and a BD FACSCelesta Cell Analyzer (BD Biosciences).

[0754] Example 14

[0755] Design, amplification and cloning of a whole-genome CRISPRa library

[0756] While sgRNA targeting schemes for CRISPRa have advanced in recent years, the ability to predict a function for each guide remains low compared to gene knock-out / suppression methods. Proper targeting of the transcriptional start site (TSS) is believed to be key to achieving robust gene upregulation. This examples describes a method for generating a human CRISPRa whole genome sgRNA library using some of the most up-to-date TSS information. Human proteincoding genes were first identified using GENCODE Human Release 29 (GRCh38 genome build). Candidate TSSs were identified using the FANTOM5 dataset, with a specific focus on identifying those FANTOM5 CAGE robust peaks representing TSSs located in a [-500 bp, 500 bp] window around the start of GENCODE-annotated isoforms. Other databases which could be used to identify TSSs will be apparent from the disclosure herein to one of ordinary skill in theart and may include EPDnew, ENCODE, and RefTSS (which combines datasets including FANTOM5, EPDnew, and ENCODE). From these data, a primary promoter (Pl; selected as the reference TSS with the highest CAGE peak) was nominated for each gene, as well as up to six additional promoters per gene (P2-P5), for a total of 21,423 promoter regions (Pl = 19,104; P2 = 1778; P3 = 369; P4 = 118; P5 = 54). Finally, also included were an additional 1372 promoters taken from the leading human CRISPRa whole-genome sgRNA libraries: Calabrese and Weissman v2, provided that they were at least 1 kb removed from the already selected promoters. In total, 22,795 TSSs were included in the annotation.

[0757] Using this annotation as a foundation, about 10 sgRNAs per TSS were designed. The sgRNAs with spacer sequences containing either EcoRI or Kpnl restriction enzyme recognition sites were filtered out (to eliminate complications with library synthesis / cloning methods). As the distance between corresponding sgRNAs and TSSs has been shown to be a major determinant of guide efficacy, the selection of sgRNAs located within a projected optimal activation window of [-150 bp, -75 bp] was prioritized, while also placing guides within an additional six regions of decreasing priority (and increasing size) to ensure 10 sgRNAs per promoter were obtained if possible (Figure 14). Within each of these regions, sgRNAs were further filtered to remove those with a poly-T termination signal and extreme GC content, followed by ranking prospective sequences based on Azimuth on-target activity score. The collection of sgRNA sequences were then cloned as described herein. In total, 222,225 sgRNAs were included in the final whole-genome library, collectively named “Sonata”.

[0758] The substantial volume of sgRNAs comprising the full Sonata library could be restrictive for some screening applications. Therefore, five non-overlapping sub-libraries (each with 1000 NTC sgRNAs) is created: sub-library 1 contains sgRNAs targeting genes involved in DNA repair, ubiquitination, and epigenetic mechanisms, G protein-coupled receptor genes, kinase genes, phosphatase genes, and protease genes; sub-library 2 contains ion channel -related genes and genes implicated as encoding druggable targets; sub-library 3 contains genes encoding the secretome, and sub-libraries 4 and 5 contain all other remaining genes. The sub-library concept described herein is believed to enable both unbiased genome-wide screening using all libraries, or targeted screening of select genes / gene families with maximized TSS coverage. Each pool is synthesized separately and cloned as described in Example 2.

Claims

1. Patent Claims1. A method for identifying a cell-surface or secreted protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles comprising the steps of- generating a library of cells wherein in each cell a different cell-surface or secreted protein is overexpressed,- identifying and selecting cells of the library which show increased transduction efficiency compared to a cell not overexpressing said cell-surface protein / compared to the parent cell used for the generation of the library,- amplifying the nucleic acid sequence from the genome of the selected cells encoding the overexpressed cell-surface protein,and thereby identifying a cell-surface protein in a mammalian cell that increases the transduction efficiency of adeno-associated viral particles.

2. The method according to claim 1, wherein the generation of the library is by introducing a library of guide RNAs (gRNAs) directed to the genomic region surrounding the transcription start site (TSS) of genes encoding cell-surface proteins of the cell and the identifying is by CRISPR-mediated transcriptional activation (CRISPRa) screening.

3. The method according to claim 2, wherein the library of gRNAs comprises about 10-15 gRNAs per TSS.

4. The method according to any one of claims 2 to 3, wherein the library is generated by the introduction of the gRNAs as lentiviral vectors.

5. The method according to any one of claims 1 to 4, wherein the method comprises before the identifying step the step of- transducing the cells of the library with an adeno-associated virus (AAV) preparation at an MOI that results in about 30 % of the cells in the library being transduced.

6. The method according to any one of claims 4 to 5, wherein the MOI is in the range of about 0.3 to about 0.5.

7. The method according to any one of claims 5 to 6, wherein the AAV comprises a transgene encoding a fluorescent protein.

8. The method according to any one of claims 2 to 7, wherein the cell library has as size so that about 500-1000 cells per gRNA are employed.

9. The method according to any one of claims 5 to 8, wherein the method comprises after the transduction step and before the identifying step the step of- cultivating the transduced cells.

10. The method according to claim 9, wherein the cultivation is splitted after about 6 days into a first fraction of unsorted cells and a second fraction of transduced cells.

11. The method according to claim 10, wherein the fraction of transduced cells is generated by subjecting the second fraction to FACS sorting based on the expression of the fluorescent protein.

12. A method for increasing the transduction efficiency of AAV particles or of a preparation comprising AAV particles of a cell comprising the steps of- transfecting the cell with a nucleic acid encoding / overexpressing at least one protein selected from the group of proteins consisting of LPAR5, BRS3, FUT1, CH25H, PUM1, SLC5A8 and SLC7A11 in the cell.

13. An assay for determining the transduction efficiency of an AAV preparation or an AAV particle comprising the steps of- incubating cells overexpressing at least one protein selected from the group of proteins consisting of LPAR5, BRS3, FUT1, CH25H, PUM1, SLC5A8 and SLC7A11 with the AAV preparation or particle,- determining the fraction of the cells transduced by the AAV preparation or AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV preparation or particle),and thereby determining the transduction efficiency of an AAV preparation or AAV particle.

14. An assay for selecting an AAV particle comprising the steps of- separately incubating cells overexpressing at least one protein selected from the group of proteins consisting of LPAR5, BRS3, FUT1, CH25H, PUM1, SLC5A8 and SLC7A11 with AAV particles differing in their capsid amino acid sequence,- determining for each AAV particle the fraction of the cells transduced by the AAV particle (by determining the fraction of cells expressing the transgene contained in the AAV particle) andthereby determining the transduction efficiency of each AAV particle differing in their capsid amino acid sequence,- ranking the AAV particles differing in their capsid amino acid sequence according to their transduction efficiency,and- selecting one or more AAV particles.

15. Use of a protein selected from the list of proteins consisting of LPAR5, BRS3, FUT1, CH25H, PUM1, SLC5A8 and SLC7A11 for increasing the transduction efficiency of an AAV preparation or AAV particle of a cell.

16. A human CRISPR-mediated transcriptional activation (CRISPRa) guide RNA library comprising:- a plurality of single guide RNAs (sgRNAs), each sgRNA comprising:- a DNA-targeting segment having a spacer sequence which targets a promoter region of a targeted gene, the promoter region comprising a genomic region surrounding a transcriptional start site (TSS); and- a backbone capable of binding to a dCas fusion protein;wherein the plurality of sgRNAs comprise 10 or more sgRNA per promoter region such that the plurality of sgRNAs comprise at least 10 sgRNA per targeted gene.